THE UROLOGY FOUNDATION

England & Wales · Charity number 1128683

Details

Status	Registered
Legal form	Charitable company
Company number	06817868
Registered	2009-03-19
Register	View on the Charity Commission register

Contact

Address	1-2 St Andrew's Hill London EC4V 5BY
Phone	02077139538
Email	info@theurologyfoundation.org
Website	www.theurologyfoundation.org

Activities

Objects: TO ADVANCE, PROMOTE, ENCOURAGE, DEVELOP AND IMPROVE THE STUDY AND KNOWLEDGE OFUROLOGY, UROLOGICAL SURGERY AND THE GENERAL KNOWLEDGE OF SCIENCE AND MEDICINE ANDALL MATTERS RELATING TO THE PROGRESS AND DEVELOPMENT OF THAT BRANCH OF SCIENCE ANDMEDICINE AND FOR THAT PURPOSE TO FUND, AID, MAINTAIN AND ENDOW SCHOLARSHIPS,FELLOWSHIPS, CHAIRS AND BURSARIES AND GENERALLY TO ASSIST IN THE FUNDING, INSTRUCTIONAND SUPPORT OF PERSONS AND INSTITUTIONS ENGAGED OR INVOLVED IN UROLOGICAL RESEARCHWORK.

Activities: The Foundation uses its funds to raise the standard of treatment and management of urological diseases and of research in UK and Ireland by funding educational, training programmes and research posts.The Foundation aims to improve the diagnosis, treatment and management of urological disease through the development and support of medical education, training, and sponsorship of scientific research.

Downloaded from opencharities.uk/ew/1128683

Classification

- **How:** Makes Grants To Individuals, Makes Grants To Organisations, Provides Advocacy/advice/information, Sponsors Or Undertakes Research
- **What:** Education/training, The Advancement Of Health Or Saving Of Lives
- **Who:** Other Charities Or Voluntary Bodies, The General Public/mankind

Geography

- **Area of benefit:** UNDEFINED. IN PRACTICE, NATIONAL
- Ireland
- Northern Ireland
- Scotland
- Throughout England And Wales

Finances

Period end	Income	Expenditure	Assets	Employees
2024-12-31	£2,090,290	£1,605,960	£3,762,840	7
2023-12-31	£1,470,272	£1,288,459	£3,111,987	4
2022-12-31	£1,355,713	£907,359	£2,640,341	3
2021-12-31	£810,931	£899,197	£2,447,884	3
2020-12-31	£1,431,539	£1,232,002	£2,158,423	4

Downloaded from opencharities.uk/ew/1128683

Trustees

Name	Role	Appointed
Mary Garthwaite	Chair	2021-01-23
Angela Daniel		2018-10-19
Ben Challacombe		2016-11-07
Hannah Warren		2021-01-23
Hilary Baker		2024-03-21
Juliana Taylor		2024-03-21
Kieran O'Flynn		2023-12-08
Mark Becker		2016-11-07
Michael Griggs		2023-01-01
Mohammed Belal		2024-03-21

Downloaded from opencharities.uk/ew/1128683

THE UROLOGY FOUNDATION

England & Wales - Charity number 1128683

Accounts

THE UROLOGY FOUNDATION

TRUSTEES' REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2024

CONTENTS

STATEMENT FROM THE CHAIR AND CHIEF EXECUTIVE....3
OBJECTIVES AND ACTIVITIES 5
A YEAR IN VIEW....7
ACHIEVEMENTS AND PERFORMANCE IN 2024 7
FINANCIAL REVIEW 23
STRUCTURE, GOVERNANCE & MANAGEMENT 28
REFERENCE AND ADMINISTRATIVE DETAILS 30
TRUSTEES' & DIRECTORS' RESPONSIBILITIES IN THE PREPARATION OF FINANCIAL STATEMENTS 31
REPORT OF THE INDEPENDENT AUDITORS 32
STATEMENT OF FINANCIAL ACTIVITIES 35
BALANCE SHEET 37
CASHFLOW STATEMENT 38
NOTES TO THE FINANCIAL STATEMENTS 39

STATEMENT FROM THE CHAIR AND CHIEF EXECUTIVE

People diagnosed and living with urological cancers and conditions seek information, support and interventions that enable them to get the help, support and care they need to navigate the challenges of everyday life. The Urology Foundation is the only charity in the UK representing the entire spectrum of urology health and disease through our investment in world class research, training and education programmes for our urology community and allied healthcare professionals, campaigns to raise public awareness and commitment to driving policy change.

Building on the many achievements of 2023 we set out an ambitious and exciting programme for 2024. Thanks to the support and commitment of our stakeholders, including the scientific and clinical community, nurses and allied health professionals, patients and their families, volunteers, decision makers and influencers, charity and industry partners and our generous supporters, we have achieved so much. Highlights include:

- The launch of our new five-year Research Strategy '**Improving urology health: transforming lives through research'** which aims to significantly accelerate the progress of urological research, to advance knowledge, to invest in our scientific and medical communities and, guided by research outcomes, to drive change.
- The expansion of our research portfolio, training and education programme, study and travel awards and career development opportunities to support our urology community and allied healthcare professionals. We were pleased to appoint our first Grants Executive & PPIE (Patient and Public Involvement and Engagement) Lead to support this busy programme.
- A three-year grant to the TUF Trials Unit (TTU) - our partnership with the Centre for Healthcare Randomised Trials (CHaRT) at Aberdeen University. The TTU aims to identify and support promising research ideas in urology, mentoring and developing the next generation of urological surgeon trialists, and promoting best practices within the urological community.
- A commitment to driving change in Urinary Tract Infections (UTIs) which has seen the launch of a dedicated UTI Research Grant call totalling £250,000, a Nurse-led UTI Information Service and Helpline, training and resources for healthcare professionals. TUF was invited to become a partner on the James Lind Alliance (JLA) Chronic and recurrent urinary tract infection Priority Setting Partnership (PSP).
- The launch of a new Communications Strategy to raise awareness of urology health and the work of The Urology Foundation, drive change in urology care and practice through our policy work, campaigning and health awareness initiatives and strengthen our partnerships. This has seen the launch of a new website, engagement with parliamentarians and decision makers including our "Urology Pledges" manifesto to coincide with the General Election, expanded media relations and campaigns.
- Ensuring people affected by or at risk of urological disease have the opportunity to be heard, to influence and drive change through our PPIE Programme, campaigning and advocacy, media engagement, services and resources.
- Our campaigning and advocacy work particularly in the areas of prostate cancer, UTIs and bladder health.
- Investment in our fundraising programme: dedicated resourcing, an enhanced events programme and the development of a Fundraising Appeal to support the delivery of our new Research Strategy.

Our success and achievements would not have been possible were it not for the efforts and commitment of so many people and the generosity of our wonderful supporters. Sincere thanks to all those who have supported us and contributed to the many achievements of 2024.



Mary Garthwaite, Chair



Rebecca Porta, CEO

OBJECTIVES AND ACTIVITIES

The Urology Foundation's objectives are to:

"Advance, promote, encourage, develop and improve the study and knowledge of urology, urological surgery and the general knowledge of science and medicine and all matters relating to the progress and development of that branch of science and medicine and for that purpose to fund, aid, maintain and endow scholarships, fellowships, chairs and bursaries and generally to assist in the funding, instruction and support of persons and institutions engaged or involved in urological research work."

OUR VISION AND MISSION

We see a world where people will not die early from urological cancers and diseases, and where people with problems of the bladder, kidneys, prostate and male reproductive organs can still lead full, active and productive lives.

Our mission is to improve survival and quality of life for urology patients through research, training, and education, campaigning, policy change, support and information, ensuring patients receive the best possible treatment and care and fewer lives are devastated.

OUR AIMS

The Urology Foundation is committed to reducing the burden caused by urological diseases. We work with researchers, urology and healthcare professionals to improve the diagnosis, treatment and management of urological disease and the nation's urology care.

We rely on donations from individuals, trusts and foundations, and from companies to help fund our work. The money we raise is invested directly into research to find better treatments and cures, and in training for urology professionals to care for and help people affected by urology conditions.

The Foundation is governed by the rules and regulations set down in its company memorandum and articles of association originally dated 12 February 2009 and last updated by a special resolution on 29 June 2009.

OUR VALUES

In undertaking our remit, we are:

- ***Ambitious*** to see UK urology care, treatment and practice are the best in the world.
- ***Dedicated*** to beating all urology diseases through research and training.
- ***Proud*** of working in urology and committed to transforming the lives of people with a urology condition.
- ***Collaborative*****;** working with researchers, urologists, nurses and healthcare professionals, influencers and decision makers, charity partners, patients and their families, we are improving the nation's urology care.

WHAT WE DO

We seek to improve patient treatment and care through investing in world class research, education and training programmes, raising public awareness and driving change in policy. We fund research that increases our understanding of urological cancers and conditions, and that can bring about change in urology practice and guidelines for the benefit of patients and their families. We are also looking for ways that can make treatments more effective and kinder. We are driving improvement

in standards in urology practice through training and we are developing the next generation of urological experts who can meet the challenge of the increased burden of disease and who put excellence of care at their core.

Awareness campaigns such as Urology Awareness Month in September bring urological cancers and conditions to the public eye, breaking the stigma and taboos associated with these diseases and conditions and encouraging people to seek an early diagnosis where they may be concerned about potential early warning signs and symptoms.

PUBLIC BENEFIT

The Trustees have taken The Charity Commission's general guidance on public benefit into consideration in preparing their statements on public benefit contained within this annual report. In accordance with its charitable objectives, The Foundation gives grants to individuals and not-for-profit organisations to:

- Promote the study of urological cancers and conditions by supporting and carrying out research into the causes, prevention, diagnosis and method of treatment of this disease and by publishing the useful results of such research;
- Provide opportunities for training and education of health professionals working in urology, in order to advance practice and improve patient treatment and care;
- Such other purposes for the benefit of the community as shall be exclusively charitable as the Trustees from time to time shall decide.

In addition, the charity provides information on urological cancers and conditions, raises awareness, campaigns and drives policy change.

GRANTS POLICY

The Foundation advertises its programmes and awards on its website, through its professional e-newsletter and networks. Applications for research are assessed by an independent Scientific and Education Committee (SEC) and Review Panel.

The charity is a member of the Association of Medical Research Charities (AMRC) and abides by its standards and guidelines for peer review and funding. It is also a National Institute for Health Research (NIHR) non-commercial partner. Research studies funded through our NIHR approved funding streams are automatically eligible for consideration for NIHR Research Delivery Network (RDN) support subject to meeting the standard study eligibility criteria.

A YEAR IN VIEW

ACHIEVEMENTS AND PERFORMANCE IN 2024

OUR RESEARCH STRATEGY

The Urology Foundation (TUF) was delighted to launch a new Research Strategy, **'Improving urology health: transforming lives through research. Research Strategy 2024-2028'** in July. The Strategy was developed in consultation with a wide range of stakeholders – urology healthcare professionals and researchers, patients and their families, policy makers and wider stakeholders - to understand priorities for TUF's work moving forward. Some clear messages came through regarding disease priority areas and types of research and programmes we should fund, and it was gratifying to see that there was significant agreement among our stakeholders on these areas. The Research Strategy is built on four key pillars, each with clearly defined objectives:

- Pillar 1 – Lead a transformation in urology health
- Pillar 2 – Understand the factors driving urological cancers and conditions
- Pillar 3 – Build and invest in our research community
- Pillar 4 – Improve outcomes for patients and their families

The strategy is a bold, exciting, and ambitious vision. Building on our achievements and informed by the knowledge and expertise of a range of stakeholders – the scientific and clinical community, nurses and allied health professionals, patients and their families, volunteers, decision makers and influencers, charity and industry partners and supporters - our aim is to significantly accelerate the progress of urological research, to advance knowledge, to invest in our scientific and medical communities and, guided by research outcomes, to drive change. At the heart of our strategy are patients and their families: involving and working with people affected by urological disease, embedding patient integration and engagement in research, and ensuring they have a "voice" in shaping future research agendas and priority areas.

OUR RESEARCH PROGRAMMES

Innovation & Research Awards

Our Innovation & Research Awards fund projects up to a value of £60,000 that seek to use new, exciting, innovative approaches to address urological diseases and disorders. The projects must either (a) aim to create innovative treatments or devices, (b) aim to deliver innovative care pathways or (c) aim to use innovative research techniques or methods.

We are pleased to report that eight awards totalling £499,532 were made in 2024 (in 2023 there were eight awards totalling £431,592). The eight projects were:

Multi-modal cfDNA surveillance following radical treatment for high-risk penile cancer
Penile cancer is a rare but impactful disease often diagnosed late due to limited awareness, leading to severe consequences for patients and their families. Current treatments are invasive and can leave lasting side effects, with no reliable blood tests or scans to monitor progress effectively. This project aims to revolutionise penile cancer care by developing a non-invasive blood test using "liquid biomarkers," which are DNA fragments shed from tumours or the associated HPV virus.

The study, conducted at The Christie NHS Foundation Trust and the Cancer Research UK National Biomarker Centre, will analyse blood samples from 100 patients to detect these biomarkers. Success could mean earlier cancer detection, fewer surgeries, and better-tailored treatments, ultimately improving patient outcomes and reducing the burden on healthcare systems. This innovative

approach promises to enhance the quality of life for men with penile cancer by allowing remote monitoring and more precise treatment strategies.

Malignant ureteric obstruction in prostate cancer: a national population-based study
Over 50,000 men are diagnosed with prostate cancer every year across England and Wales. Half of these men have advanced cancer that spreads outside of the prostate and may cause complications to the whole body. Cancerous prostate growth may obstruct the urinary system and more specifically the tubes that drain the kidney, this is called malignant ureteric obstruction and may lead to pain, infections, kidney damage, and death. The true numbers and consequences of malignant ureteric obstruction in prostate cancer are unknown. Currently, patients and clinicians are not well-informed on who is at most risk and how best to manage this problem.

This study will use population-based data to answer key questions surrounding malignant ureteric obstruction including which patients are at the highest risk of developing the problem, the best treatments to prevent the problem and the best method of managing the problem.

Characterising lymphatics in bladders affected by posterior urethral valves using advanced 3D imaging techniques
Posterior Urethral Valves (PUV) are a condition that only occurs in boys and is characterised by abnormal tiny flaps of tissues at the level of the urethra, the final channel that carries urine outside the body. These tissue membranes, so called PUV, can partly block normal urine flow, which can cause problems at the level of the bladder and kidneys. In fact, around half of the boys with PUV will end up having major kidney issues requiring dialysis or transplantation. A big reason for the kidney problems is that PUV block the passage of urine, the bladder fills too much and stops functioning properly over time, which causes the kidney to become swollen and damaged.

Preserving bladder health and function is paramount to prevent kidney problems in boys with this disease. This project will determine how bladder lymphatics are laid out in health and how these change in PUV. They will conduct 3D imaging experiments utilising human bladder samples from boys undergoing surgery for PUV and will also apply this technique to a new mouse model that their lab has developed, which mimics the human disease.

Ward Admission of Symptomatic Haematuria: an Observational mUlticentre sTudy (WASHOUT)
Around 25,000 patients require emergency admission for blood in the urine each year in the UK. Patients often stay in hospital for several days, experiencing painful retention of urine, and may need blood transfusions or emergency interventions. Clinicians are not sure what the best management strategy is because there are no guidelines or evidence on how to best manage these patients. The care provided to patients in hospital may vary with the hospital they are in, the consultant on call, and other considerations such as the time of the week.

The WASHOUT study aims to observe how these patients are managed in hospital and assess important outcomes such as length of hospital stay, timing of operations, cost of scans and operations, and the frequency of re-admissions. Study findings may show which types of management have better outcomes. Findings from WASHOUT will also help clinicians to produce guideline documents and carry out clinical trials in this field.

Gene therapy for early-onset genetic bladder disease
This project will focus on an inherited condition that affects nerves in the bladder and can lead to kidney infections and even failure in children. The researchers have developed a gene therapy strategy to treat mice with this condition, and excitingly, were able to completely restore the function of the bladder nerves, showing the gene therapy is successful. To bring this therapy closer to the clinic the study will address two key questions:

1. What is the oldest we can effectively deliver the treatment? To inform whether the therapy is likely to be successful in babies, children, or adults.

2. Is therapy effective and safe in the longer term?

A nested case-control study of BK and JC polyomaviruses as risk factors for urothelial carcinoma in Malmö Diet and Cancer Study (MDCS) serum samples.
The DNA of nearly all bladder cancers carry the fingerprints of damage caused by some of the cell's own proteins called 'APOBECs'. The APOBECs are enzymes which defend against infections, like BK virus, by damaging viral DNA. During BK virus infection, we have evidence that APOBECs can cause collateral damage to a cell's own DNA, potentially leading to the development of bladder cancer.

This research will look at blood samples from the Swedish Malmö Diet and Cancer Study for antibody proteins targeting BK virus. An abundance of antibodies shows that a person's immune system has recently fought BK virus. It will investigate if individuals with more BK antibodies in their blood were at increased risk of developing bladder cancer. If BK virus is shown to be a risk factor, this research could lead to many cases of bladder cancer being seen as preventable through the development of new antiviral drugs and vaccinations.

We are grateful to the Charles Reynolds Foundation for their funding towards the above six research projects.

Investigating combination BH3-mimetics and identifying accompanying biomarkers as a new therapeutic strategy for prostate cancer
Prostate cancers often have increased levels of certain proteins of a family called 'BCL-2 family'. The increase in these proteins can prevent cancer therapies from successfully eliminating prostate cancer cells. A new class of drugs, called BH3-mimetics, can improve cancer cell elimination, and counteract disease recurrence by blocking BCL-2 proteins. The use of these drugs has been shown to be effective in cancers of the blood but have not been explored in depth in prostate cancer. This project will generate data on how BH3-mimetics can be used to eradicate prostate cancer cells. The ability of therapies to effectively eliminate cancer cells will be influenced by the neighbourhood in which the cancer is growing. Thus, the research aims to better understand the changes that the prostate cancer neighbourhood experiences when using BH3-mimetics and help identify which patients will benefit most from these new treatments.

The role of PSMA related metabolites in the progression and treatment of Prostate Cancer
Radiotherapy is often used in conjunction with hormone therapy to treat prostate cancer. There is a set regimen which is the same for each patient. Some men may respond better or worse to radiation and the biology behind this is an active area of research. Other than PSA blood test monitoring over the longer term (months to years) there is no short term, rapid, measure of response to radiation in the prostate. Such a measure could be used to further adjust radiation for each patient, downscaling treatment to avoid side effects. This project aims to develop a convenient rapid test to monitor radiation treatment response by measuring the metabolites in the urine within existing radiation treatment appointments.

We are grateful to the John Black Charitable Foundation for their funding of the above two prostate cancer projects.

Smaller Research Projects Fund

The Smaller Research Projects Fund is focused on improving treatment and care and supports projects up to the value of £10,000. The Fund is aimed at projects that can be delivered quickly (within two years) and are focused on supporting vital research that seeks to improve the quality of clinical services and patient treatments and care.

We are pleased to report that six awards totalling £53,500 were made in 2024 (in 2023 there were five awards totalling £50,000). The projects were:

- *Understanding the impact of Out-of-Pocket Costs for Patients Receiving Stone Treatment in a Rural Region.*
- *Does invasive supervised Pelvic Floor muscle training increase membranous urethral length?*
- *Identifying the relationship between brain centre/s involved in cerebrovascular accidents and likelihood of detrusor sphincter dyssynergia in patients with suspected prostatic obstruction.*
- *Self-Targeted Relaxation Efforts for Surgical Situations (STRESS) study.*
- *Surgical outcomes for CAVAL THROMBus involved Renal Cell Cancer (IR1 – CAVALThromb): a prospective, multicentre registry.*
- *Ex vivo real-time analysis of detrusor muscle status at time of primary transurethral resection of bladder tumour (TURBT) using fluorescence confocal microscopy: IB1-LASERComplete, prospective, feasibility study.*

We are grateful to the charity Penguins Against Cancer for their co-funding of the above bladder cancer project.

Our work in Urinary Tract Infections (UTIs)

Urinary Tract Infections (UTIs) are a major health concern affecting millions globally each year. These infections not only cause pain and discomfort but all too often affect overall well-being, with many experiencing either repeated or chronic infections that significantly impact on quality of life. UTIs can also lead to more serious complications such as kidney infections, sepsis, and kidney damage if left untreated. UTIs are the second most common reason for prescribed antibiotics and have been identified by the World Health Organisation (WHO) as a significant factor in antimicrobial resistance. In 2024, The Champniss Foundation generously pledged £250,000 to be used specifically for a new research programme into UTIs.

TUF convened two Roundtable Meetings involving clinicians and researchers working in UTIs, and people with lived experience of recurrent and chronic UTIs. These meetings were to help indentify:

- the challenges around UTIs and research questions that are difficult to address; and
- scope the type of research we should be funding with the donation.

The discussion on pertinent research questions and the current challenges in UTI research was focused on five areas:

- Diagnostics: the challenges around the poor performance of current testing methods and the fact that none of the current diagnostics listed by NICE can be recommended as effective.
- Etiopathology (how and why people get UTIs): this is still largely unknown with multiple factors such as genetics, hormones, diet, and use of devices such as catheters.
- Therapeutics: what sort of treatments might be effective, particularly thinking about reducing reliance on antibiotics.
- Prevention: this would feed into the above three areas as more becomes known about UTIs and their progression.
- Types of Research and Implementation: where research (bearing in mind the current level of research funding) might have most impact, and how to implement what is already known to be good practice.

The information from these Roundtables was used to scope the call for UTI research applications. The call was opened in September and awards are expected to be made in Spring 2025, following a robust review process with an initial Expressions of Interest round before progress to the full application round.

In addition to the above work, TUF was invited to become a partner on a James Lind Alliance, UTI Priority Setting Partnership with Antibiotic Research UK and Bladder Health UK. The TUF Director of Research sits as a charity partner member of the steering group, which includes representation from healthcare professionals working in UTIs, experts in antimicrobial infection and patients with lived experience. This piece of work will last approximately 18 months and is expected to prioritise the most important areas of research to patients and researchers.

The TUF Trials Unit

Following our successful partnership with The Centre for Healthcare Randomised Trials (CHaRT) at the University of Aberdeen to create the TUF Trials Unit (TTU), we renewed our relationship for a further three years in 2024, at funding of £60,000 per annum. During the year, the TTU managed to lever in just under £1 million of funding (£953,000) in support of the following research:

- DIETRICH: Dietary fibre supplement, inulin, given before and during radical radiotherapy to the prostate, to reduce radiotherapy side effects.
- Digital Camera-based Uroflowmetry for Early Diagnosis and Monitoring of Lower Urinary Tract Symptoms

This was in addition to the previous £6.1 million funding from the National Institute of Health and Social Care (NIHR) to conduct three large-scale, multi-centre trials across the United Kingdom:

- PARTIAL – comparing two types of surgery for kidney cancer; complete removal of the kidney or partial removal where the tumour is.
- ELIPSE – comparing surgery where the prostate and lymph glands are removed, with surgery where the prostate alone is removed.
- FOLLOW UP - a natural experiment estimating the clinical and cost-effectiveness of follow up strategies after curative treatment for prostate cancer.

CHaRT has committed to increasing capacity and proactive engagement with unit by committing more named methodologists and statisticians to support the TTU. Their work includes:

- Mentoring future urology research leaders in grant writing.
- Contributing to new methodologist and clinical research investigator collaborations.
- Providing administrative support for clinical investigators.
- Co-ordinating Patient and Public Involvement activities for specific grant requirements.
- Providing methods of support for unfunded work to underpin future grant applications.
- Delivering project support for successful funding applications before contracts are signed and funding begins.

TUF GRANTS MANAGEMENT SYSTEM

During 2024 TUF implemented a bespoke grants management system, TUF Grant Tracker. The system has proven to be a comprehensive way of recording applications, recipients, reviewers, timelines, deliverable outputs, payments, sponsors, and liabilities for each grant. Through using the TUF Grant Tracker for over a year, monitoring the status of the grants has been significantly streamlined. The Tracker flags ‘late outputs’ which helps to ensure we receive reports from grant awardees and can therefore make timely payments. It is possible to generate records of grant awards across the four nations, regions, disease areas etc. using the system. The Tracker also provides historical data for

comparison. Both aspects have been utilised when the team needs to compile information on grants, and the Tracker enables this to be done quickly and efficiently. It has also enabled efficient collection and recall of information on research results and impact. The charity currently has over 80 active grants and awards.

PATIENT AND PUBLIC INVOLVEMENT AND ENGAGEMENT (PPIE) PROGRAMME

In 2023 the charity launched its Patient and Public Involvement and Engagement (PPIE) programme. The PPIE Programme brings together researchers, people affected by urological cancers and conditions, their carers and the public, to help drive research forward. It is an opportunity to get involved in helping to plan, design, manage, evaluate, and communicate about research and leads to research that is relevant, appropriate, and better-designed with clearer outcomes, and is therefore well placed to have an impact. The key aims of the PPIE Programme are:

- To bring together researchers and people affected by or interested in urological cancers and conditions to drive research forward.
- To provide a source of expertise for activities within TUF.
- To ensure that the patient's voice remains central to TUF's work by providing feedback and comment on activities within the charity.

In 2024 we established the programme's workflows and developed the associated documents required to ensure a smooth process for patients and members of the public joining the programme. We also secured our place providing PPIE support for two new research projects at the Freeman Hospital and University of Nottingham. 2025 will see the charity carrying out targeted recruitment drives for these projects and meetings for patients and public to input into the projects as well as developing resources for professionals to explain the support we can offer.

In 2024 Rosie Cockroft was appointed as Grants Executive and PPIE Lead to support the growing programmes and grants portfolio and the development of our PPIE Programme. The Programme is overseen by a PPIE Development Board - members include Imran Ahmed (Professor of Urological Oncology / Urological & Robotic Surgeon at the University of Glasgow), Hannah Warren (Research Fellow, Urology Registrar), Helen Lake (Urology Nurse), Lesley Booth (specialist in public engagement within medical research) and Susannah La-Touche (Urology Consultant at St George's University Hospital).

IMPROVING KNOWLEDGE AND SKILLS THROUGH EDUCATION AND TRAINING

FELLOWSHIPS

Fellowships enhance urological training, education, knowledge transfer, and collaboration. They are an important stage in professional and career development, and in building and supporting outstanding surgical leaders in their field. Fellows go to study a particular specialism or technique, so they can provide that service in their own hospitals on return. Through the acquisition of new skills and knowledge, Fellows make an important contribution to the advancement of science and practice thereby ensuring better outcomes for patients. TUF offers a variety of different Fellowship opportunities.

David Thompson Fellowship

The David Thompson Fellowships are worth up to £35,000 per Fellow. The grant supports attending a centre or centres of excellence for up to one year to enable candidates to gain invaluable experience and skills in urology care and best practice, and to make contributions to research in their area of

specialty. Successful candidates will act as ambassadors promoting best practice and sharing knowledge amongst their own team, hospital, and wider urology community.

In 2024 we were again delighted to receive a number of strong applications. Thanks to the generosity of the Thompson Family Charitable Trust, which sponsors the Fellowships, we were able to make the following awards:

- Daniel McNicholas, a urology ST7 registrar at the Liverpool University Hospital Trust. He will visit the Austin Hospital in Melbourne, Australia, to gain further training in reconstruction of the urinary tract.
- Adrian Fuentes, a urology ST8 registrar at the Mater Misericordiae University Hospital, Dublin, Ireland. He will visit Princess Alexandra Hospital, Brisbane, Australia, where he will gain extensive exposure to open abdomino-pelvic oncological surgery, minimally invasive robotic techniques, and transplant surgery.
- Andy Kozan, a senior post-CCT (Certificate of Completion of Training) Teaching Fellow at Leeds University Hospitals. Andy will visit the Tenon Sorbonne University Hospital in Paris, France, where he will gain experience in robotic surgery techniques in female, functional and reconstructive urology.
- Muheilan Muheilan, a post-CST Urology Registrar at The Mater Misericordiae University Hospital, Dublin, Ireland. Muheilan will start a senior clinical fellowship in robotic pelvic surgery at the Lister hospital in Stevenage, which will expose him to a wide range of oncological cases and the possibilities of complex surgery.

We are grateful to the Thompson Family Charitable Trust for enabling these Fellowships.

Malcolm Coptcoat Travelling Fellowship

The Malcolm Coptcoat Fellowship, worth £5,000, enables trainees to travel to international centres of excellence for a period of four to six weeks to gain invaluable experience and skills in urology care and best practice. In 2024 the Fellowship was awarded to Miss Elizabeth Day, a post-CCT Fellow based at UCL, London. Miss Day chose to visit two European Centres – the Rijnstate Hospital in Arnhem, The Netherlands, and the Martini Klinik in Hamburg, Germany. At both centres she had the opportunity to observe surgery and understand the variations in techniques to prostate and bladder cancer surgery and the rationale for these, in order to expand her understanding of the different approaches. She was also able to gain an insight into the non-technical aspects such as organisational and systems cultures, including ways of assessing continual improvement of care.

TUF/Urolink Fellowships

The TUF/Urolink Fellowships, worth up to £1,500, are open to those senior level trainees who have completed their FRCS (Urol), enabling them to experience working in Low or Middle Income (LMIC) countries. The Fellowships help develop urological services in these countries, as well as enabling the cross-fertilisation of knowledge and skills, benefiting the professional development of both the Fellow and those working in healthcare systems where the annual per capita income is less than $1,135 a year. In 2024 four awards were made to:

- Ravi Banthia, a Senior Clinical Urology Fellow at NHS Tayside, Dundee
- Brendon Berry, a Urology ST6 Registrar at University College Hospital, London
- Johann Boaz, a Senior Clinical Urology Fellow at Charing Cross Hospital, Imperial College
- Mike Ng, a Urology ST4 Registrar at University Hospital, Plymouth

Visits will take place in 2025 across a number of hospitals in Ghana, Malawi and Tanzania.

SUPPORT FOR UROLOGY TRAINEES AND UROLOGY NURSES

Keith Yeates Medal/Ralph Shackman Prize

The Medal and Prize are conferred when candidates achieve over 90% in their Intercollegiate Specialty Examination in Urology. In 2024 there were three winners of the medal and the Shackman travelling fellowship worth £2,000.

- Clare O'Connell, who put her prize towards her Society of Uro-Oncology Fellowship at the University of Toronto, Canada.
- Killian Daly, who visited the Department of Uro-Oncology at the University of British Columbia, Canada.
- Nicholas Simson, who attended robotic urology surgery training courses at Aalborg University in Denmark and Guy's Hospital, London.

Nurse Education and Training

TUF is committed to ensuring urology nurses and allied healthcare professionals have opportunities to enhance their skills and practice and increase their specialist knowledge. We also believe career advancement goals should be supported, and that further education may open up specialist urology nursing positions in oncology or stones, or roles such as advanced nurse practitioner and urology nurse clinician. We received significant take up of TUF's Nurse Bursary awards in 2024, worth up to £5,000 each. Successful applicants were:

- Julie Lavilla, a Deputy Sister at Urology Outpatients, Nottingham University Hospitals NHS Trust, who is doing a Postgraduate Certificate at Ulster University.
- Esther Tarowera, a urology nurse at Dartford & Gravesham NHS Trust, who is doing a BSc at the University of Sunderland.
- Cyrus Solano, a Prostate Nurse Specialist at the Torbay & South Devon NHS Trust who is doing a Postgraduate Certificate at Edge Hill University.
- Claire Evans, a urology nurse at Cheshire & Wirral Community Partnership Continence & Urology Service, who is doing a Postgraduate Certificate at Edge Hill University.

In addition, we funded a further nine nurses with travel grants worth up to £500 each to attend study days and nursing conferences in the UK and Europe.

We are grateful to the Charles Reynolds Foundation for their ongoing support of these awards and opportunities for urology nurses.

Regional Trainee Awards and Best of the Regions

In 2024, continuing our support for urology trainees, TUF provided £500 prizes to the Best Trainee Presentation or Paper given at a regional meeting of the British Association of Urological Surgeons (BAUS). There are 16 regions throughout the British Isles and Republic of Ireland. The winners of each region were then invited to present their papers at the annual BAUS Conference, at which the overall 'Best of the Regions' would be selected and win a further £500 prize. The overall winner in 2024 was Sorcha O'Meara, a trainee from the Republic of Ireland, for her paper on *Holmium Yag Laser Injury in Human Ureter*.

Support for Robotic Surgery Training

Once again, TUF provided support to two of our TUF Centres of Robotic Training, to run cadaveric courses for trainees. The courses are designed for surgeons, urologists, and multi-disciplinary teams to gain system knowledge and develop a working understanding of the robot and learn technical skills useful in the operating theatre. The Freeman Hospital in Newcastle, and Guy's Hospital in London were each given £10,000 to provide the training courses over 2 days. The courses mixed lectures and videos with hands-on robotic surgery practice.

Supporting Advanced Consultant Training

TUF funded the Advanced Urology Simulation Boot Camp course with a £12,000 grant. The course is aimed at senior urology trainees and new consultants, supporting the transition to a consultant role, and provides training in often overlooked areas such as dealing with stress, effective leadership, and the day-to-day challenges of consultant practice. The course was extremely well attended and received excellent feedback.

Support for Travel, Conferences and Educational Programmes

During the year, a number of small grants were made to urologists and allied healthcare professionals to travel to, or attend, training courses, or conferences.

TRAINING AND EDUCATION

As part of our commitment to training and supporting our urology community and those with an interest in urological cancers and conditions, the charity delivered training sessions and attended conferences. Highlights include:

- In May we attended the Association for Continence Professionals (ACP) annual conference in Liverpool. The ACP is a multi-professional association open to healthcare professionals working within, or who have an interest in bladder and bowel care. This was the first time TUF attended the conference, and we were delighted that TUF Chair, Mary Garthwaite, was invited to speak at the Welcome Reception. The 2024 Conference entitled "Advancing Continence Priorities" included sessions on the pharmacy role in the promotion of continence, continence research and working with the third sector.
- In June we attended the British Association of Urological Surgeons (BAUS) Annual Conference in Birmingham. TUF presence at the Conference included an exhibition stand, the TUF Session, Best of the Regions, the BSoT Run and Guest Lecture. We were delighted to welcome Patient Advocate, Alfred Samuels, who delivered the TUF Guest Lecture and who gave an insightful and moving account of his experience of prostate cancer. Alfred is an author, award winning documentary filmmaker (A Survivor Amongst Survivors, 2021), mentor and inspirational speaker. He has won 27 international awards, including at the London Cine Week and the Tokyo Short Film Fest.
- In November we attended the British Association of Urological Nurses (BAUN) Annual Conference in Liverpool. The conference theme was "educate, inspire, innovate, improve" and alongside hearing from keynote speakers it offered an opportunity to meet with urology colleagues and industry.

During the year TUF CEO was invited to join the Advisory Board of Knowlex. Knowlex provide a wide range of educational resources and activities for the healthcare community and commissioning organisations including conferences, panel debates, webinars, and an excellent online resource centre. The Advisory Board provides advice and insight to Knowlex and its work.

SUPPORTING PATIENTS AND THEIR FAMILIES

LAUNCH OF THE UTI INFORMATION SERVICE

Urinary tract infections (UTIs) are the second most common kind of infection (after chest infections). The National Institute for Health Research (NIHR 2016) report that UTIs are among the most common types of infections within excess of 92 million people affected worldwide. Around 50% of all women develop a UTI at some stage. An estimated one million women in the UK live with chronic UTIs and experience debilitating, consistent pain.

UTIs are a significant cause of mortality, especially amongst the elderly population, with UTI related symptoms accounting for between 1-3% of all primary care consultations and being the main reason for 13.7% of community antibiotic prescriptions. There is a higher-than-expected number of patients being admitted to hospital with a UTI or a UTI associated condition compared to trips, falls etc. UTIs can cause severe confusion which develops quickly over a couple of days, especially in older people.

There was a considerable body of evidence which showed people affected by UTIs would welcome information and support in understanding and managing the condition. With the generous support of The Champniss Charitable Trust and The Champniss Foundation this year saw the launch of a dedicated Nurse led UTI Information Service.

The aim of the Information Service is to provide up-to-date, quality information, support and a "listening ear" to anyone affected by or interested in UTIs including patients, their families, carers, healthcare professionals including those with an interest in UTIs, care home staff, GPs, and pharmacists. The Service responds to the needs of patients and carers for information, advice and support in understanding and managing the condition via a freephone Helpline, email and UTI Hub featuring a range of resources. The Service is open two days per week to support anyone with a concern about UTIs. This includes chronic and recurrent UTIs, symptoms and risk factors, UTIs in men, treatment options, when to request a referral to a urologist and the latest research. The dedicated email service launched on the 20 March 2024 - nurse@theurologufoundation.org and the freephone Helpline launched on the 30 July 20204 - 0808 801 1108.

The following resources were developed during the year:

- Understanding UTIs Factsheet - full guide
- UTI Essentials – for those new to UTIs
- UTIs in Older People
- Self-Care Strategies for Relief and Prevention of UTIs
- Understanding and managing recurrent UTIs
- How to talk to your GP about recurring UTIs
- Urinary Tract Infections in Men: Challenges and contemporary management - a guide for healthcare professionals

Information and training for health and social care professionals is a key part of the Service. Alongside developing dedicated resources, the Service was promoted at conferences, training sessions, and UTI clinics and via industry partners, pharmacy networks, and the media.

The Service is led by Helen Lake. A Urology Specialist Nurse with over 35 years of experience in both the NHS and the private sector, Helen is exceptionally qualified to deliver this new Service. Her expertise spans a wide range of urology conditions, including Bladder Dysfunction, Urinary Tract Infections, Bladder Pain, Prostate conditions (Prostatitis, Benign Prostatic Enlargement), Prostate

Cancer, other Urology Cancers, Erectile Dysfunction, and Male Infertility. Her career highlights include Ward Sister and a Clinical Nurse Specialist in Urology Stoma and Continence, running Nurse-Led Clinics, Lead Urology Specialist Nurse and Clinical Educator at B. Braun Medical Limited, Honorary Urology Specialist Nurse at The Newcastle upon Tyne Hospitals NHS Foundation Trust, and Specialist Urology Nurse at Convatec. Before joining the charity Helen was Director of Men's Health at Peppy Health. She is a former Trustee for the British Association of Urology Nurses (BAUN) and Nurse Advisor for The Urostomy Association. She has contributed significantly to the field through published peer-reviewed articles and as a contributing author to the RCN Guidelines on Male Infertility. Helen is affiliated with the Royal College of Nursing.

FEEDBACK FROM USERS OF THE UTI INFORMATION SERVICE

'Information given and resources on the website brilliant'

'Thank you for being kind and welcoming'

'Thank you for kindly taking the time to ring me back. It was very helpful and left me feeling more positive than I have for a long time'.

'I am so glad to hear that there is planned research to look at future testing for UTIs that are not always picked up by current testing'

'Thank you so much for listening, believe me it helps. I myself have worked in the NHS for many years and it is good to see that there are people striving to help people with these conditions, and that research is ongoing'

Thanks for everything u have done (young enquirer)

Thank you so much for speaking with me, and providing a helpful summary below. After sharing the information with my GP, I have been referred to a specialist UTI clinic!

'I am so glad I have found you'

IMPROVING PUBLIC AWARENESS OF UROLOGICAL CANCERS AND CONDITIONS

TUF is committed to improving public awareness of urological cancers and conditions, to promoting research progress and highlighting research developments, to commenting on topical issues and sharing patient experience.

OUR WORK IN WESTMINSTER

In February, we attended a Parliamentary Roundtable **'Driving service innovation: preparing for the future of prostate cancer care'**. The Roundtable was an opportunity to examine how current and future challenges facing prostate cancer services can be addressed through innovation in service delivery and new models of care. The event was supported by Astellas

In April we hosted a Parliamentary Reception together with the Urology Trade Association (UTA) titled: **'Putting patients first: promoting best practice in the continence sector'**. This was our third Reception with the UTA and over 80 stakeholders attended the event including policy makers, medical technology companies, researchers, clinicians, specialist nurses, funders, patients and charities. Over 14 Parliamentarians were in attendance. The reception was an opportunity to discuss continence issues and to identify what best practice in continence care should look like.

In November we attended Prostate Cancer Research's Parliamentary reception, **'Prostate Cancer Research: Cost Benefit Analysis Report'** at the House of Commons. The event saw the launch of a new report **'*Socio-economic Impact of Prostate Cancer Screening*'** and attracted excellent cross-party support.

In December we attended a Parliamentary drop-in event organised by Johnson & Johnson and hosted by Sadik Al-Hassan MP. TUF and Prostate Cancer Research were given the opportunity to raise key issues on cancer care with Members of Parliament. Seventeen MPs attended the event.

CAMPAIGNS

Throughout the year we took part and supported a number of campaigns including World Cancer Day, Bladder Cancer Awareness Month, Prostate Cancer Awareness Month, **"We See You"** campaign, World Kidney Day, Testicular Cancer Month and World Continence Week. Highlights include:

- To mark Prostate Cancer Awareness Month, TUF attended an event at Network Rail's Head Office to showcase the work of the charity and to talk about prostate cancer. In March TUF staff were invited to hold an event at Kings Cross Station where they distributed free resources and held important conversations about prostate cancer with passengers.
- During Men's Health Week, UTI Information Nurse Helen Lake was interviewed by Man V Fat about men's urology health, why it's important and what they should look out for. MAN v FAT is a national movement for men who want to lose weight. They run the award-winning weight loss programme MAN v FAT Football, providing guidance, resources and community support to thousands of men every year. The video was shared with their thousands of members across the country during Men's Health Week. TUF launched a campaign web page and included information on men's health issues and health statistics.
- To mark World Continence Week 2024, we developed a new campaign **'The Face of Continence in the UK'**. We highlighted that one in five people in the UK experience bladder problems and aimed to challenge the assumption that bladder health is an older people's issue. The campaign highlighted the changing face of continence. We also produced a 'Face of Continence' video that highlighted images of people from all ages, ethnicities and demographics in a mosaic of our teardrop logo. Quotes from people and healthcare professionals were placed throughout the video to show the serious impact continence has on a person's life. We produced an infographic titled **'Spotlight on continence in the UK'** with the key stats and facts about continence alongside a series of posters. Our thanks to Convatec for their support of the campaign.

Urology Awareness Month

September is Urology Awareness Month, an annual campaign which brings together our urology community – researchers, urologists, nurses and allied healthcare professionals, influencers and decision makers, patients and their families and those with an interest in urology health – to raise awareness of urological cancers and conditions.

This year's theme was **'Men's Urology Health: Myths and Legends'**. We addressed common myths around men's urology health and encouraged men to 'be a legend' and open up about their own urology health. From prostate cancer and other urology cancers to bladder issues, erectile dysfunction and kidney stones, we spent the month urging males to recognise when something's "not right below the belt" and speak out to get help. We created a range of resources to encourage good urology health including posters, infographics and informative leaflets.

As part of the campaign, we commissioned a survey via OnePoll exploring general awareness and perceptions of over 2000 men in the UK about urology health. Highlights from the survey include:

- Only four in ten men recognised the significance of a family history in the diagnosis of prostate cancer.
- Seven in ten men didn't know the function of their prostate.
- Only 53% of men could correctly identify the location of the prostate.
- Seven in ten men in the UK would delay speaking to a healthcare professional if they saw blood in their pee. One in four said they would turn to the internet for information and advice and 40% said they would drink more water. Half revealed they would only speak to a healthcare professional if it happened regularly.
- Men were more likely to think that their prostate was involved in the flow of urine (48%) than its primary function of producing fluid that becomes semen (30%).

We also ran our own survey inviting UK nurses to give their views on men's urology health and the barriers nurses face in supporting men. Highlights from the survey include:

- Over 66% of nurses believe their average male patients have 'little' or 'no' understanding of their urology health.
- Over 90% of nurses said that more than 50% of their male urology patients waited too long before seeing a healthcare professional about their symptoms.
- The most common myths nurses hear from male patients is that they think getting up several times a night to urinate is a normal part of ageing (92% of nurses agreed) followed by the myth that patients believed their chronic back pain was due to wear and tear (72% of nurses hear this from patients).
- Over 90% of nurses think common myths and misunderstandings about male urology health affect patient outcomes.
- Nurses answered that the biggest worries for men about their urology health is erectile dysfunction (88%), cancer (78%) and incontinence (72%).
- 25% of nurses said the one change that would make the biggest positive impact for their continuing education in order to benefit their patients would be to have access to more educational resources to give out to patients and the protected time to create them.

The outcomes of the surveys provided an excellent platform to secure national coverage and promote a better understanding of the issues. Our thanks to Coloplast for supporting the survey and Infographics.

Other activities during Urology Awareness Month included:

- A highly supportive video from TUF Ambassador, Sir Stephen Fry who harnessed our campaign messaging and called for men to 'Be a legend' and reach out for support.
- We attended an FA Cup Derby match between Tilbury FC and Chelmsford FC and distributed materials to supporters. Posters were displayed at Tilbury FC's stadium for the duration of the month. Tilbury FC also promoted our messages and resources via their X/Twitter account to their 7,600 followers.
- New guides including: **'Busting Myths: Men's Urology Health'** – this guide seeks to bust the myths and encourage people to recognise when to seek medical attention and **'UTIs in Men'** a guide for healthcare professionals.
- Coverage in national and international press including Mail Online and the New York Post highlighting the results of our survey.

We are grateful to everyone who supported UAM.

Movember

We were delighted to support Movember's men's health campaign and their new report, '***The Real Face of Men's Health***'. The report examines how men engage with the health system and the full consequences of poor health on men, those immediately around men and those within their broader communities. It sets out recommendations that decision makers can take to improve men's health outcomes, save costs within the NHS, and tackle the health inequalities that exist between different men. The report generated incredible support and coverage - from the media to policy makers, from patients to the global Movember community.

National Policy Activities

TUF has actively engaged in national policy conversations and inputted into national consultations that impact urology care throughout 2024. Highlights include:

- Working with our wider cancer community, including Cancer52 and One Cancer Voice, to collectively call on the government to commit to developing a long-term cancer strategy. We were delighted that this was successful, and the Government committed to develop a national cancer plan in 2025.
- TUF responded to the consultation on the 10 Year Plan for Health in England and will continue to call for urology to receive the policy priority it deserves.
- Working with Cancer52, TUF fed into a consultation response on the NHS Commercial Framework for New Medicines around patient access to new medicines.
- TUF joined 16 other health charities to co-sign a letter outlining our concerns about a consultation to repeal the Hospital Parking Charges Act 2022 in Northern Ireland.
- We believe that boys deserve to be educated about their own bodies and have responded to a consultation on the national curriculum urging the government to consider including education on testicular, penile and prostate health in schools across the country.

UROLOGY PLEDGES 2024

In June we launched our Urology Pledges '**Excellent Urology Health for All**' to influence health policy and increase awareness of the needs of the urology field to the next generation of parliamentarians and the new government. This provided the Foundation with valuable collateral with which to engage policy makers, proposing solutions and urging prospective parliamentary candidates and then the newly elected MPs to adopt them. The pledges were:

1. Commit to investing in vital urology research
2. Commit to investing in our urology community
3. Commit to putting patients at the heart of decisions on urology care

Pre-election, we successfully launched the pledges at Cancer52's Big Conversation event in Canary Wharf, London where we discussed the pledges and key issues with advisors at the Department of Health and Social Care who were tasked with developing briefings for the incoming government on cancer policy. The document was then shared widely on social media before being discussed with the community at the BAUS Annual Conference and shared via the BAUS Weekly Newsletter. Copies of the pledges were sent to key health spokespeople in each of the main parties including the Secretary of State for Health, Wes Streeting.

IN THE MEDIA

One in two of us will be affected by a urological cancer or condition yet these still do not attract the public profile of many other disease areas. A big part of our work is to raise the profile of urological cancers and conditions in order to encourage an early diagnosis, access to treatment and care and to ensure better outcomes and a quality of life alongside raising awareness of TUF and its vital work. Throughout the year we provided media spokespeople and commented on topical issues. Highlights included an interview on LBC on the subject of UTIs, as well as coverage in national press including The Telegraph, The Sunday Telegraph, Mail Online and The Mirror.

LAUNCH OF THE NEW WEBSITE

Our new website launched in May and has been extremely well received. With its distinct and contemporary look, the new website reflects our breadth of activities, our wider engagement and the impact we are making. It is a platform to connect with our urology community and for those with an interest in urology including the clinical and scientific community, patients and their families, decision makers and influencers, media, charity partners, and our supporters. Alongside celebrating our achievements, offering opportunities to get involved and showcasing patient experience, the site features our UTI Information Hub and information resources for patients and their families. Sincere thanks to The Champniss Foundation and The Champniss Charitable Trust for their generous support of the new website.

COLLABORATIONS AND PARTNERSHIPS

We value the importance of working with other organisations to achieve our aims. Throughout the year we engaged with a range of organisations and charity partners working in the area of urology. These included the BAUS, BAUN, Urology Trade Association, Prostate Cancer UK, Prostate Cancer Research, Fight Bladder Cancer, Action Bladder Cancer, Kidney Cancer UK and UCare.

TUF CEO was appointed as Vice Chair of Cancer52. Cancer52 is an organisation that represents over 100 charities and patient organisations focused on rare and less common cancers.

We were delighted to become a member of One Cancer Voice. One Cancer Voice is a coalition of over 60 cancer charities that advocate for better cancer care and outcomes in England and is coordinated by Cancer Research UK.

We welcomed the opportunity to meet and work with a range of companies including Medac Pharma, Johnson & Johnson, Androlab, Peppy Health, Intuitive Health, Boston Scientific, Pfizer UK, Peak Medical Ltd, Astellas Pharma, Bayer, Lloyds Pharmacy Online Doctor, Coloplast and Convatec to promote awareness of urology health.

CREATING STRONG FOUNDATIONS: INVESTING IN OUR TEAM

Developing our people and infrastructure is vital as it underpins the delivery of our charitable activities. The Trustees committed to infrastructure investment to support sustainability, effectiveness, collaboration and impact, particularly within the charity's programmes and grants portfolio which has expanded significantly over the last three years, across fundraising and the expansion of funding streams and to ensure we have a "voice" within the urology community - in driving change, improving outcomes and patient care. The first stage of the investment saw the appointment of Laura Thorne as the new Director of Communications and Policy in 2023.

The second stage of the investment saw the following appointments in 2024:

- Claire O'Sullivan, Fundraising Manager (Events and Individual Giving), to manage and expand a portfolio of events, to develop an individual giving programme and to grow the supporter base.
- Rosie Cockroft, Grants Executive and PPIE Lead, to support for the growing programmes and grants portfolio and the development of our PPIE Programme.
- The appointment of dedicated support for the Major Appeal to support the delivery of the new Research Strategy.

PLANS FOR THE FUTURE

In 2025 we will continue to build on our work and achievements alongside:

- Delivering our Research Strategy **'Improving urology health: transforming lives through research. Research Strategy 2024-2028'** and campaigning for further investment in research. The launch of our Research Appeal will aim is to raise £5million to support the delivery of the new Strategy.

- Investing in and supporting our urology community, the next generation of urology researchers and allied healthcare professionals through the expansion of our research, training and education programme, study and travel awards and other opportunities.

- Developing our work in UTIs and bladder health through the UTI Research Programme, expanding the Nurse-led UTI Information Service, training and education resources, developing our work as a partner on the James Lind Alliance (JLA) Chronic and Recurrent Urinary Tract Infection Priority Setting Partnership (PSP), campaigning and awareness raising.

- Delivering on our Communications Strategy to

    - Raise awareness of urology health and the work of The Urology Foundation.
    - Drive change in urology care and practice through our policy work, campaigning and health awareness initiatives.
    - Improve patient outcomes by delivering change in specific urology areas based on research outcomes and patient need.
    - Strengthen our partnerships with the wider urology community to drive meaningful change.


- Giving a voice to the people affected by or at risk of urological disease ensuring they have the opportunity to be heard, to influence and drive change. We will look to support and develop closer relationships with seldom heard communities, those at greater risk of specific disease and those with poorer outcomes.

- Raising awareness and developing our campaigning and policy work in urological cancers and conditions with a particular focus on prostate cancer, UTIs and bladder heath including urinary incontinence and bladder cancer.

- Mark the 30th Anniversary of TUF: highlight the charity's history and impact, celebrate our achievements and commitment to changing the future / face of urology.

FINANCIAL REVIEW

FINANCIAL RESULTS OF ACTIVITIES & EVENTS



The total value of net assets held by The Urology Foundation on 31 December 2024 was £3,762,840 (2023 £3,111,987). The Foundation's fundraising activities and other initiatives during the course of 2024 generated a total of £2,018,269 of voluntary income (2023 £1,384,437) and a further £50,874 (2023 £66,800) from specific fundraising event income.

FUNDRAISING

The Foundation is reliant on voluntary income to fulfil its remit. Following a review of the charity's fundraising function in 2022, the decision was made to invest in this area in order diversify the existing income streams and to look to increase the charity's income. Our new fundraising initiatives have contributed to this growth, particularly Trusts and Foundations and the business community providing the charity with diversified, sustainable sources of income. We are pleased to report income for year totalled £2,090,290 against the previous year total of £1,470,272. The following information summarises the various disciplines:

- Donations. Income from donations totalled £186,971.
- Legacy. During the year The Foundation was fortunate to receive a generous legacy of £697,285. This gift will support scholarships - advancing knowledge, skills and careers or our urology community.
- Business Community Engagement. We are proud to collaborate with a wide range of companies, including those in the pharmaceutical and MedTech sectors to help achieve our mission. Under the leadership of our Business Development Manager, we have significantly expanded our corporate engagement while continuing to strengthen long-standing partnerships. Highlights from the year include a Parliamentary Reception in collaboration with the Urology Trade Association (UTA) to bring key stakeholders together to discuss pressing issues in urology and community events at ASDA, helping to engage the public and raise awareness of urology issues. We partnered with Network Rail' Wellbeing Champion to promote awareness across the business. For World Continence Week we collaborated with Convatec to break down the stigma surrounding continence issues, promoting openness about

its impact on quality of life. Coloplast continued their support for UAM initiatives. Medac Pharma and Johnson & Johnson provided generous grants to fund two new bladder cancer projects which we will be delivering in 2025. Boston Scientific kindly supported the annual Bike4TUF. Looking ahead to 2025, we aim to further develop existing relationships while also exploring new partnerships to expand our reach and deliver even more impactful projects. We are deeply grateful to our many corporate partners for their continued support and generosity. Their contribution plays a vital role in enabling our work to improve the lives of those affected by urological cancers and conditions.

- Trusts and Foundations. Income from a range of both small and large trusts and foundations totalled £951,002 and included support towards research, awareness, community-based projects, education and training. This included a grant from The UK Government Post COVID Recovery Medical Research Charity Support Fund totalling £351,264 towards helping to sustain early-career researchers supported by medical research charities impacted by the COVID 29 pandemic.
- Events. We are delighted that so many of our supporters and friends organised and took part in a wide range of events throughout the year. These included the TUF Sri Lanka Trek which saw our President Professor Roger Kirby and former Trustee Roland Morley together with TUF supporters raised an incredible £101,180. His Excellency, Rohitha Bogollagama, Sri Lanka High Commissioner kindly hosted a Reception on the 11 November which was attended by many of the cyclists and TUF staff. The ever-popular London Landmarks Half Marathon (LLHM) saw seven runners take to the streets of London to raise over £5,400. Bike4TUF London to Nantes, 13-16 June 2024 was led by Consultant Urologist, Ben Starmer, Ben Challacombe and TUF supporter David Plummer and saw 28 supporters cycle over 300 miles and raise £40,000. This is one of the highest amounts raised from this popular annual event. BSoT TUF Fun Run returned to the 2024 BAUS Conference, with an impressive 50 runners completing an early morning 5km run – over £1100 was raised. Three supporters took part in the popular Vitality 10,000 London 10K run raising over £110. The Royal Parks Half Marathon was a new addition to the Challenge Events programme and our runners raised an impressive £1,330. During the month of June, we launched a new fundraising awareness campaign – Bake4TUF - in which we encouraged supporters to host a bake sale and encourage people to talk about urology health. We are grateful to all our supporters and friends for their incredible efforts and fundraising challenges including Simon Lord who undertook 24 hours cycling challenge from London to Amsterdam and Bill Hall and friends who completed the West Highland Way Walk.

We are registered with the Fundraising Regulator and adhere to the code of fundraising when carrying out our activities. Our staff are committed to following codes of good practice and standards developed by the fundraising community through the work of the Chartered Institute of Fundraising (IoF) and other professional bodies. The Foundation operates a clear and stringent complaints handling procedure that is reported to the Senior Management team and the Board. As part of our supporter care programme, we have agreed policies and procedures in place and written agreements with external agencies that we engage to help us or who raise funds for the charity. We ensure that anyone engaged to work for us is trained in and respects our aims and objectives and carries out their activities with the same high standards and care we would ourselves. During the year we received less than five complaints in relation to our fundraising activities. We remain committed to improving our practice, learning from supporter feedback.

RESERVES & LIQUIDITY POLICY

The Foundation currently total funds of £3,762,840 of which £1,813,138 are held as restricted funds, £2,921 are held as tangible fixed assets and £1,550,000 are held as designated funds (£500,000 minimum required reserves, £800,000 for research and £250,000 for infrastructure – see details below). Therefore, the Foundation has 'free reserves' of £396,781 (31 December 2023: £2,213,621).

The Foundation's policy is to maintain reserves sufficient to continue to fund its objectives on a long term basis, and to ensure that the charity operates with an adequate level of liquidity to (i) minimise the risk associated with a temporary or unforeseen shortfall in liquidity; (ii) manage its cash and investments to meet its liabilities and remain a going concern for at least 1 year in the event of an unplanned drop in income. Liquidity is defined as cash and the investment portfolio held as unrestricted funds. The Policy establishes a minimum liquidity target of £500,000 ("Minimum Required Reserve") subject to future modification by the Finance Committee and Trustees' approval.

The Trustees consider that reserves held in excess of the amounts required to fund all future commitments together with the initial fund of £500,000, will be available to increase its visibility and expand its operations including funding for further research and a wider range of projects. The Trustees plan levels of expenditure from unrestricted and restricted funds for the year ahead based upon the level of incoming resources for the current year as well as utilising restricted funds.

DESIGNATED FUNDS

In September 2024 the Board of Trustees approved designated funds for the following purpose:

Research Strategy 2024-2028 and Research Appeal	A dedicated fund to support the new Research Strategy 2024-2028 and associated Research Appeal. The strategy is an exciting and ambitious plan to improve urology health and transform lives through research over the next five years. It builds on our history of clinical and academic innovation that has already helped to revolutionise urology care. Trustees have agreed to designate £1.5 million to enable the charity to achieve its long-term vision and mission. £800,000 of this is funded from designated unrestricted funds and £700,000 from a restricted legacy donation for scholarships.
Infrastructure	A dedicated fund of £250k to invest in the development of the charity's infrastructure including patient experience, campaigning, marketing, communications and to advance our fundraising capabilities to further diversify income and secure long-term sustainability.

STATEMENT OF GOING CONCERN

The Foundation's unrestricted net funds generated in 2024 are judged to be sufficient to meet the requirements of the charity for charitable giving in the coming year.

INVESTMENTS POLICY

The Foundation's investments are managed by Rothschild Bank (CI) Limited. The Treasurer and the Chief Executive are responsible for managing the relationship with Rothschild but changes in investment strategy are subject to approval by the Board of Trustees. The investment manager is asked to attend at least one Board of Trustees and one Finance Committee meeting annually.

The Board follows a medium risk 'Balanced' investment strategy which is intended to achieve steady growth over the long term through a diversified approach to investment. Capital preservation in real terms over a long-term horizon is the primary objective and some volatility is acceptable in order to achieve this. The charity's investments are held in the Exbury Fund, an ethical portfolio managed by Rothschild. The fund achieved a 7.2% return over 2024.

All other Foundation funds are held in accounts with the charity's bankers, National Westminster Bank plc.

REMUNERATION POLICY

In setting salary levels, The Urology Foundation follows the National Council for Voluntary Organisation's guidance that a charity's pay policy should be to offer fair pay to attract and keep appropriately-qualified staff to lead, manage, support and/or deliver the charity's aims. It also conducts online research of charity salaries and uses surveys to benchmark levels of pay. The Urology Foundation does not automatically award its staff with annual salary increases, either incremental or cost of living.

PENSIONS POLICY

The charity offers a stakeholder pension, operated by The People's Pension (B&CE Holdings), in line with statutory requirements. All new staff are automatically enrolled but can opt out if desired.

EQUAL OPPORTUNITIES AND DIVERSITY POLICY

The charity is committed to being an Equal Opportunities employer and to respecting diversity, and is determined to ensure that no job applicant, employee, or Trustee receives less favourable treatment on the grounds of their age, disability, gender reassignment, marriage and civil partnership, pregnancy or maternity, race, religion or belief, sex or sexual orientation. The charity also seeks to ensure that its employees are not victimised or subjected to harassment.

The policy applies to recruitment and selection for jobs in the Foundation, career development and training, promotion, performance management, pay, redundancy, disciplinary and grievance procedures, the application of terms and conditions of employment and any other aspects of employment with the Foundation.

The policy also applies to third parties such as Trustees and committee volunteers, clients (i.e. grant applicants) and suppliers.

PRINCIPAL RISKS AND UNCERTAINTIES

The Trustees take the management of risks seriously. The Chair of the Board of Trustees and the Chief Executive are charged with responsibility to ensure that the risks which have been identified are adequately assessed and properly mitigated on a regular basis. The potential risks have been discussed with the Chairman and the charity and a formal risk register is kept, updated and discussed by the Finance Committee and Board of Trustees on a quarterly basis.

Impact of war in Ukraine and economic outlook
The ongoing war in Ukraine and wider economic outlook have broader economic implications, some of which will be reflected in our investment fund holdings. Our Investment Manager keeps us regularly updated and there is no immediate cause for concern or action.

Risks to Data
The charity takes its responsibilities for data very seriously. We follow a Data Protection policy based on the GDPR and have a nominated Trustee (Mr Mark Becker) who has Board oversight for data compliance. We use a professional data base provider that stores all information in the cloud and this is secured using a two-step password verification. We review our records on an ongoing basis and

delete old or historical records that are no longer relevant, and remove people who no longer wish to hear from us (provided that there is no financial information that we need to retain).

Other key risks are assessed as follows:

Governance /Environmental	Impact of the external environment on fundraising, in particular: public confidence in charities; new fundraising regulations; Data Protection Regulations.
Income Sources	TUF is reliant upon voluntary income as an annual source of funding. It is the role of the Trustees to manage risk exposure on fundraising activities and in doing so to accept an appropriate level of risk in order to raise income from a wide range of sources.
Risk of data breach	The charity uses a professional database provider that stores all information in the Cloud and this is secured using a two-step password verification. The charity's own day to day working documents are also stored on a cloud-based system. TUF staff are regularly made aware of possible phishing scams and to be alert to any potential email or system data breaches.
Key Person risk	The small staff base makes TUF heavily reliant on the Chief Executive and a few key Trustees so the unexpected loss or departure of the Chief Executive or certain Trustees is a risk. Succession planning processes are in place.
Investment Risk	TUF's success is directly related to the amount of resource it can devote to its objectives, so the key risk identified by Trustees relates to the proper management of its funds. Imprudent or unprofessional decisions could majorly impact on the performance of those funds. In common with similar charities, TUF employs professional fund managers, whose performance is regularly reviewed by the Treasurer together with other Trustees.
Risk to Employees	Employees are not subject to risks other than those likely to be associated with routine office work. Apart from obtaining statutory Employers Liability Insurance, TUF nonetheless treats the welfare of its staff as a priority. The Chief Executive is the Nominated Safety Officer for the purposes of the Health and Safety at Work Act. The premises are checked and maintained by the landlord / managing agency to ensure appropriate mitigation of the risk of fire. Employees are aware of the location of fire extinguishers. The charity also has a number of policies in place covering Equal Opportunities, Lone Working, Working from Home and Safe Guarding Vulnerable People.
Risk that research fails to deliver results	Grants awarded are subject to rigorous review by the SEC and Reviewing Committee. Grantees are expected to submit progress reports and these are reviewed by the SEC and TUF. The charity maintains ongoing communication with grant holders.
Loss of Records	To protect against the loss of records, and to increase data security, files are stored in the cloud. The risk of any unsaved data being critical to TUF is regarded as insignificant. Other similar risks are dealt with by insurance.

STRUCTURE, GOVERNANCE & MANAGEMENT

The Urology Foundation is a charity and a company limited by guarantee and was established on 12 February 2009 to incorporate the charitable activities of the British Urological Foundation (BUF), an unincorporated charitable trust established in 1994 by the British Association of Urological Surgeons and BJU International, and a registered charity since 17 March 1995. The Urology Foundation itself became a registered charity on 19 March 2009.

CHARITY GOVERNANCE CODE

The Board and Executive of the charity abide by the standards set by the Charity Governance Code when executing their duties. The overall strategic direction of the charity is determined by the Trustees, who meet three times each year including an Annual General Meeting.

TRUSTEE RECRUITMENT, TRAINING AND INDUCTION

The Foundation seeks to achieve a balance of lay and medical Trustees. Appointed Trustees are recruited on the basis of fulfilling the criteria to provide a balance of experience and knowledge. Members of the charity's Scientific and Education Committee (see below) are recruited through calls in industry publications.

All new Trustees are provided with an induction programme and an induction pack. They are provided with relevant Charity Commission publications and regularly briefed on developments and opportunities that will support their general understanding of the voluntary sector, healthcare and medical research issues.

Trustees contribute to every aspect of the charity: governance; fundraising; financial planning; management expertise and leadership. We are truly grateful for their service and to all our Trustees, who selflessly contribute their time, expertise and networks whenever they are called upon.

APPOINTMENT & ELECTION

The Trustees and Chairman are appointed for an initial period of three years that can be extended for a further three-year term. A further extension may be made if it is deemed to be in the best interests of the Charity. The governing document requires that there should be a minimum of seven Trustees.

Two of the Trustees are required to be representative Trustees, one nominated by The British Association of Urological Surgeons (BAUS) and one nominated by British Journal of Urology International (BJUI). All other Trustees, known as appointed Trustees, are appointed by unanimous written resolution of all the Trustees present and/or voting at a special meeting of Trustees called to take place immediately before or after an ordinary meeting of Trustees.

The representative Trustee nominated by BAUS is the President of BAUS and the appointment to the board is concurrent with their post at BAUS, which is for a period of two years.

The Executive Team

The Chief Executive is responsible for the day-to-day management of the charity.

The Chief Executive deals with the implementation of policy and strategic decisions taken by the Board of Trustees. She and the appropriate staff members attend the meetings of the Board of Trustees and sub-committees, and report on the day-to-day operations of the charity. The Foundation currently operates the following sub-committees:

Scientific and Education Committee (SEC)
The SEC is responsible for the development and assessment of The Foundation's research, education and training programmes and the review and administration of The Foundation's grant making policy. The Chairman of the SEC is also a member of the Board of Trustees, and reports back to the Board on the work of the Committee. The SEC is made up of clinical and academic urologists and scientists with an interest in urology, and lay representatives.

Research Review Panel
The Research Review Panel is responsible for assessing applications for our major research grants and marking these according to the requisite criteria being met. In this task it assists the SEC in its final decision on who should receive grants. The Research Review Panel is made up of clinical Trustees and academic urologists and scientists with an interest in urology.

Membership of the SEC and Review Panel can be viewed on the charity's website. They provide their services as volunteers and we are enormously grateful to them.

Finance Committee
The charity Finance Committee is chaired by the Treasurer, Ms Angela Daniel. Membership includes The Chair of the Board and the Chairman of the SEC, and two other Trustees and the Chief Executive. Any recommendations made by the Finance Committee are brought to the Board of Trustees for discussion and ratification. The Treasurer has oversight of the charity's bank and investment accounts.

IT Oversight Committee
The IT Oversight Committee was formed in 2023 on the recommendation of the Board of Trustees. The purpose of the IT Oversight Committee is to advise the Board of Trustees on IT governance, IT implementation and other strategic IT-related issues including legal and regulatory compliance, investment in IT projects including telecommunications, risk and opportunities and to ensure these are managed through appropriate internal controls. The IT Oversight Committee consists of a minimum of three Trustees including the Chair, the Chief Executive, Director of Research and Senior Administrative Officer.

RELATIONSHIPS WITH RELATED PARTIES

The Urology Foundation continues to maintain close links with its two founding charities, BAUS and the BJUI, whose representatives are Trustees.

REPRESENTATION ON OTHER BODIES

The Urology Foundation is a member of the Association of Medical Research Charities (AMRC), which confers a quality mark for our peer review processes, as well as advocating for charity-funded research with government. The charity is a National Institute for Health Research (NIHR) non-commercial Partner. This means the studies that the Foundation funds may be eligible to access the NIHR Study Support Service which is provided by the NIHR Clinical Research Network.

The charity is also a member of Cancer52, Charities Research Involvement Group, the National Council for Voluntary Organisations (NCVO), Charity Finance Group, One Cancer Voice and UNSEEN, a UK leading anti-slavery charity working with survivors, businesses, governments, police and NHS to end slavery.

REFERENCE AND ADMINISTRATIVE DETAILS

The registered charity name is "The Urology Foundation" (sometimes referred to as "TUF"), a charity and a company limited by guarantee.

Trustees
Ms Mary Garthwaite (Chair)
Ms Angela Daniel (Treasurer)
Mr Mark Becker (Secretary)
Prof Rakesh Heer
Ms Hilary Baker (appt 21 March 2024)
Mr Mo Belal (appt 21 March 2024)
Mr Ben Challacombe
Ms Jo Creswell (resigned 17 June 2024)
Mr Mike Griggs
Prof Alan McNeill
Mr Roland Morley (resigned 21 March 2024)
Mr Kieran O'Flynn
Mr Ian Pearce (appt 17 July 2024)
Ms Julia Taylor (appt 21 March 2024)
Ms Hannah Warren

President
Prof Roger Kirby

Patrons
Mr Handel Evans
Sir Ranulph Fiennes OBE
Mrs Rosemary Macaire
Ms Jane Macquitty MBE
Mr Steven Norris

Ambassadors
Mr Alex Corbisiero
Sir Stephen Fry
Mrs Kate Holmes

Chief Executive
Ms Rebecca Porta

Registered Office
1-2 St Andrew's Hill
London
EC4V 5BY

Charity number
1128683 (England & Wales)

Company number
06817868

Auditors
Sumer Auditco Limited
Hermes House,
Fire Fly Avenue,
Swindon, Wiltshire, SN2 2GA

Bankers
National Westminster Bank plc
PO Box 2021
10 Marylebone High Street
London W1A 1FH

Investment Manager
Rothschild Bank (CI) Limited
St. Julian's Court, St. Julian's Avenue
St. Peter Port
Guernsey GY1 3UA

TRUSTEES' & DIRECTORS' RESPONSIBILITIES IN THE PREPARATION OF FINANCIAL STATEMENTS

The Trustees (who are also the directors of The Urology Foundation for the purposes of company law) are responsible for preparing the Trustees' Annual Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company as at the balance sheet date, and of the incoming resources and application of resources, including income and expenditure, for that period. In preparing those financial statements, the Trustees and directors are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The Trustees are responsible for keeping proper accounting records, which disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with Companies Acts 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from the legislation in other jurisdictions.

AUDITOR

Following a review of auditors, the charity's Trustees appointed Sumer Auditco Limited to undertake the 2024 audit. Mr James Gare (FCA), of Sumer Auditco Limited has agreed to act as Auditor.

STATEMENT AS TO DISCLOSURE OF INFORMATION TO THE AUDITOR

The Trustees and directors at the date of approval of this Trustees' annual report confirm that so far as each of them is aware, there is no relevant information of which the charity's auditor is unaware, and the Trustees and directors have taken all steps that they ought to have taken to make themselves aware of any relevant information and to establish that the auditor is aware of that information.

M. Garthwaite

Mary Garthwaite, Chair
Date: 21/09/2025

Report of the Independent Auditors to the Members of
The Urology Foundation (Registered Number:06817868)

Opinion

We have audited the financial statements of The Urology Foundation (the 'charitable company') for the year ended 31 December 2024 which comprise the Statement of Financial Activities, the Balance Sheet, the Cash Flow Statement and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 December 2024 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The trustees are responsible for the other information. The other information comprises the information included in the Annual Report, other than the financial statements and our Report of the Independent Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Report of the Independent Auditors to the Members of
The Urology Foundation (Registered Number:06817868)

Opinions on other matters prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of the audit:

- the information given in the Report of the Trustees for the financial year for which the financial statements
  are prepared is consistent with the financial statements; and
- the Report of the Trustees has been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception
In the light of the knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the Report of the Trustees. We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept or returns adequate for our audit have not been received
  from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the trustees were not entitled to take advantage of the small companies exemption from the requirement
  to prepare a Strategic Report or in preparing the Report of the Trustees.

Responsibilities of trustees
As explained more fully in the Statement of Trustees' Responsibilities, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Our responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Independent Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Based on our understanding of the charity and its grant making activity, we identified that the principal risks of non-compliance with laws and regulations related to health and safety, employment law, Companies Act 2006 and Charity Law, and we considered the extent to which non-compliance might have a material effect on the financial statements of the charity. We also considered those laws and regulations that have a direct impact on the preparation of the financial statements such as the Companies Act 2006 and the Charities Statement of Recommended Practice.

We evaluated management's incentives and opportunities for fraudulent manipulation of the financial statements (including the risk of override of controls) and determined that the principal risks were

related to revenue recognition, management override, occurrence of grants and completeness of grants payable, and the potential lack of segregation of duties. Audit procedures performed by the audit engagement team included:
- discussions with management, including consideration of known or suspected instances of non-compliance with laws and regulations and fraud;
- understanding and review of management's internal controls designed to prevent and detect irregularities, and fraud;
- review of the minutes of the Trustees meetings;
- review of tax compliance;
- designing audit procedures to incorporate unpredictability;
- performing analytical procedures to identify any unusual or unexpected relationships that might indicate risks of material misstatement due to fraud;
- review of the financial statements disclosures and testing to supporting documentation to assess compliance with relevant laws and regulations discussed above;
- enquiring of management about actual and potential litigation and claims;
- testing transactions entered into outside of the normal course of the charity's business; and
- identifying and testing journal entries, in particular any journal entries with fraud characteristics such as journals with round numbers.

There are inherent limitations in the audit procedures described above and the further removed non-compliance with laws and regulations is from the events and the transactions reflected in the financial statements, the less likely we would become aware of it. Also, the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Independent Auditors.

Use of our report
This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed.



James Gare FCA DChA (Senior Statutory Auditor)
for and on behalf of Sumer Auditco Limited
Statutory Auditors
Hermes House
Fire Fly Avenue
Swindon
Wiltshire
SN2 2GA

Date: 22/09/2025 .....

THE UROLOGY FOUNDATION

STATEMENT OF FINANCIAL ACTIVITIES
for the year ended 31 December 2024

	Note	Unrestricted Funds £	Restricted Funds £	Total 2024 £	Total 2023 £
INCOME					
Donations and legacies	1	316,232	1,702,037	2,018,269	1,384,437
Other trading activities	2	50,874	-	50,874	66,800
Investments	3	21,147	-	21,147	19,035
TOTAL INCOME		388,253	1,702,037	2,090,290	1,470,272
EXPENDITURE					
Raising Funds					
Donations and legacies	4	41,843	2,039	43,882	35,852
Trading activities	5	46,201	2,009	48,210	37,315
Investment management costs		-	-	-	78
Expenditure on Charitable activities					
Raising Awareness	6	167,654	8,038	175,692	137,135
Grant making	7	548,218	789,958	1,338,176	1,078,079
TOTAL EXPENDITURE		803,916	802,044	1,605,960	1,288,459
Net Gains on investment assets	11	166,315	208	166,523	(289,833)
NET (EXPENDITURE)/INCOME		(249,348)	900,201	650,853	471,646
Transfer between funds		(14,571)	14,571	-	-
NET MOVEMENT BETWEEN FUNDS		(263,919)	914,772	650,853	471,646
RECONCILIATION OF FUNDS					
Fund balances brought forward at 1 January 2024		2,213,621	898,366	3,111,987	2,640,341
FUND BALANCES CARRIED FORWARD AT 31 DECEMBER 2024		1,949,702	1,813,138	3,762,840	3,111,987

The net movement in funds for the year arises from the charity's continuing operations.

No separate statement of total changes in equity has been presented as all such gains and losses have been dealt with in the statement of financial activities.

The notes on pages 39 to 50 form part of these accounts

THE UROLOGY FOUNDATION

THE UROLOGY FOUNDATION
STATEMENT OF FINANCIAL ACTIVITIES
for the year ended 31 December 2023 (Full fund comparative)

	Note	Unrestricted Funds £	Restricted Funds £	Total 2023 £
INCOME				
Donations and legacies	1	140,195	1,244,242	1,384,437
Other trading activities	2	66,800	-	66,800
Investments	3	19,035	-	19,035
TOTAL INCOME		226,030	1,244,242	1,470,272
EXPENDITURE				
Raising Funds				
Donations and legacies	4	24,761	11,091	35,852
Trading activities	5	21,357	15,959	37,315
Investment management costs		78	-	78
Expenditure on Charitable activities				
Raising Awareness	6	82,382	54,753	137,135
Grant making	7	198,193	879,886	1,078,079
TOTAL EXPENDITURE		326,771	961,689	1,288,459
Net Gains on investment assets	11	289,471	362	289,833
NET INCOME		188,730	282,915	471,646
Transfer between funds		(59,706)	59,706	-
NET MOVEMENT BETWEEN FUNDS		129,024	342,621	471,646
RECONCILIATION OF FUNDS				
Fund balances brought forward at 1 January 2023		2,084,597	555,744	2,640,341
FUND BALANCES CARRIED FORWARD AT 31 DECEMBER 2023		2,213,621	898,366	3,111,987

The net movement in funds for the year arises from the charity's continuing operations.

No separate statement of total changes in equity has been presented as all such gains and losses have been dealt with in the statement of financial activities.

The notes on pages 39 to 50 form part of these accounts

THE UROLOGY FOUNDATION

THE UROLOGY FOUNDATION

BALANCE SHEET
as at 31 December 2024

Company Number 06817868

	Note	2024 £	2023 £
FIXED ASSETS			
Tangible assets	10	2,921	3,895
Investments	11	3,637,562	3,453,644
		3,640,483	3,457,540
CURRENT ASSETS			
Debtors	12	1,226,409	440,181
Cash at bank and in hand		214,796	415,083
		1,441,205	855,264
LIABILITIES: amounts falling due within one year	13	792,092	966,337
NET CURRENT ASSETS/(LIABILITIES)		649,113	(111,073)
LIABILITIES: amounts falling due in more than one year	13	526,756	234,479
NET ASSETS		3,762,840	3,111,987
THE FUNDS OF THE CHARITY			
Restricted income funds	15		
Robotic Surgery Training Fund		83,964	106,448
Prostate Cancer Research Fund		197,616	208,149
Champniss Fund		416,595	344,862
Team Corbs - Testicular		7,314	7,313
Charles Reynolds		9,461	13,002
Thompson Family Charitable Trust		212,086	126,556
Innovation & Research Awards		137,475	85,197
Small Research Projects		44,502	-
Events		6,840	6,839
Vivienne Irene Meader - Scholarships		697,285	-
Total Restricted income funds		1,813,138	898,366
Unrestricted income funds	15		
General Fund		399,702	1,713,621
Designated Fund (British Urology Foundation)		500,000	500,000
Research Strategy 2024-2028 and Research Appeal		800,000	-
Infrastructure		250,000	-
TOTAL CHARITY FUNDS	16	3,762,840	3,111,987

These financial statements have been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small charitable companies and with the Financial Reporting Standard 102.

The financial statements on pages 35 to 38 were approved by the trustees and authorised for issue on 19 September 2025, and are signed on their behalf by

M. Garthwaite

..... Chair
Mary Garthwaite

21/09/2025

Angela Daniel (Sep 22, 2025 11:54:22 GMT+1)

..... Treasurer
Angela Daniel

22/09/2025

The notes on pages 39 to 50 form part of these accounts

THE UROLOGY FOUNDATION

STATEMENT OF CASHFLOWS
for the year ended 31 December 2024

	Note	2024 £	2023 £
CASH FLOWS FROM OPERATING ACTIVITIES:	14		
Net cash used in operating activities		(200,286)	(162,921)
Cash flows from investing activities:			
Dividends and interest from investments		17,394	14,039
Management fees paid from investments		-	(78)
Purchase of equipment		-	(1,856)
Transfer from cash		-	-
Proceeds from sale of investments		319,643	551,126
Purchase of investments		(337,038)	(307,833)
Net cash used in investing activities:		(1)	255,399
Change in cash and cash equivalents in the reporting period		(200,287)	92,477
Cash equivalents at the beginning of the reporting period		415,083	322,605
Cash and cash equivalents at the end of the reporting period		214,796	415,083

The notes on pages 39 to 50 form part of these accounts

THE UROLOGY FOUNDATION

THE UROLOGY FOUNDATION

Financial statements for the year ended 31 December 2024

ACCOUNTING POLICIES

STATUTORY INFORMATION

The Urology foundation is a company limited by guarantee, without share capital, registered in England and Wales. In the event of the charity being wound up, the liability in respect of the guarantee is limited to £1 per member of the charity. The charity's registration number is 1128683, registered company number is 06817868 and registered office address is 1-2 St Andrew's Hill, London EC4V 5BY.

BASIS OF ACCOUNTING

The financial statements have been prepared under the historical cost convention with items recognised at cost or transaction value unless otherwise stated in the relevant notes to these accounts. The financial statements have been prepared in accordance with the Statement of Recommended Practice: Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) issued on 1 January 2019 and Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102) and Charities Act 2011. The trust constitutes a public benefit entity as defined by FRS 102. The financial statements are prepared in sterling which is the functional currency of the charity and rounded to the nearest pound. There are no significant areas of judgements or key sources of estimation uncertainty.

GOING CONCERN

The Trustees as Directors of the Charity believe that there are no material uncertainties that may cast significant doubt about the ability of the Charity to continue as a going concern, due to the significant unrestricted reserves as at 31st December and the forecast income expected in 2024. As we prepare this statement in 2025, it is clear that the long tail of the COVID-19 pandemic, and its impact on the NHS workload, continues to have a bearing on the charity's operations, with applications for programmes such as fellowships and travel grants still low. It remains to be seen whether our events fundraising and income will be impacted by global issues such as the war in Ukraine and the current cost of living crisis, which may affect future budgets for research and training.
The trustees believe, however, that given the level of available cash and reserves, the charity can continue as a going concern.

INCOME

Grants, donations and other similar types of voluntary income are brought into account when it is probable that they will be received, except that donated income is included gross of any attributable tax recoverable, where relevant. Donations given for specific purposes are treated as restricted income. Tax recoverable is recognised when claims are submitted to HM Revenue and Customs. Legacy gifts are recognised in the period in which the Charity becomes entitled to receive the income.

Income receivable from activities for generating funds and from investment income is accounted for on an accrual basis. Deferred income represents revenues collected but not earned as of 31 December 2024. This is primarily composed of income collected in advance of a fundraising event taking place and deferred until the charity is entitled to that income as and when the event takes place.

EXPENDITURE

Resources expended are allocated to the costs of generating funds or to the charity's principal activity where the costs can be identified as being directly related. All other costs are categorised as either support costs or governance costs and are allocated in proportions based upon a suitable ratio applicable to the nature of the cost involved.

Grants payable are recognised in full in the period in which the approved offer is conveyed to the recipient. Grants are recognised and deferred where there is a long-term commitment for the Charity. Where grants are recognised and conditions for staged grant payments are not met in subsequent years, an adjustment to grants payable will be made in the relevant accounting period. Expenditure includes irrecoverable VAT which is reported as part of the expenditure to which it relates.

THE UROLOGY FOUNDATION

THE UROLOGY FOUNDATION

Financial statements for the year ended 31 December 2024

ACCOUNTING POLICIES

TANGIBLE FIXED ASSETS

All tangible assets purchased that have an expected useful economic life that exceeds one year are capitalised and classified as fixed assets. Tangible fixed assets are stated at historical cost less depreciation. Depreciation is provided on all tangible fixed assets at rates calculated to write each asset down to its estimated residual value evenly over its expected useful life, as follows:

Office equipment	25% reducing balance

OPERATING LEASES

Rentals under operating leases are charged to the Statement of financial activities on a straight-line basis over the lease term.

INVESTMENTS

The charity's investments are included in the balance sheet at their market value. The gains or losses arising upon their annual revaluation are included in the statement of financial activities.

FUND ACCOUNTING

The general fund comprises the accumulated surpluses of unrestricted incoming resources over resources expended, which are available for use in the furtherance of the general objective of the charity.

Designated funds are a particular form of unrestricted funds consisting of amounts, which have been allocated or designated for specific purposes by the trustees. The use of designated funds remains at the discretion of the trustees.
Restricted funds are funds subject to specific conditions imposed by donors. The purpose and use of the restricted funds are set out in the notes to the accounts. Amounts unspent at the year-end are carried forward in the balance sheet.

DEFINED BENEFIT PENSION SCHEME

The charity operates a defined contribution pension scheme. Contributions payable to the charity's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.

DEBTORS

Trade debtors, other debtors and accrued income are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

CREDITORS

Creditors are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors are normally recognised at their settlement amount after allowing for any trade discounts due.

CASH AT BANK AND IN HAND

Cash at bank and cash in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

TAXATION

The charity is exempt from corporation tax on its charitable activities.

THE UROLOGY FOUNDATION

Financial statements for the year ended 31 December 2024

ACCOUNTING POLICIES

FOREIGN EXCHANGE

Receipts and payments which occur in foreign currencies are included in the accounts at the amount into which they are converted in sterling, using the exchange rate on the day in which the transaction occurs.

FINANCIAL INSTRUMENTS

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

		Unrestricted funds £	Restricted funds £	2024 £	2023 £
1.	**INCOME FROM DONATIONS AND LEGACIES**				
	Grants received from charitable trusts and corporate sponsors	99,494	1,004,752	1,104,246	1,238,227
	Donations	186,971	-	186,971	136,210
	Legacies	29,767	697,285	727,052	10,000
		316,232	1,702,037	2,018,269	1,384,437
2.	**INCOME FROM OTHER TRADING ACTIVITIES**				
	Income from fundraising events	50,874	-	50,874	66,800
3.	**INVESTMENT INCOME**				
	Bank interest receivable on short term cash deposits	3,753	-	3,753	4,996
	Income from investments listed on a recognised stock exchange:				
	UK investments	17,394	-	17,394	14,039
	Overseas investments	-	-	-	-
		21,147	-	21,147	19,035
4.	**COSTS OF RAISING FUNDS VOLUNTARY INCOME**				
	Direct costs	5,931	30	5,961	5,812
	Support costs (see note 8)	35,912	2,009	37,921	30,040
		41,843	2,039	43,882	35,852

		Unrestricted funds £	Restricted funds £	2024 £	2023 £
5.	**COSTS OF RAISING FUNDS TRADING ACTIVITIES**				
	Costs of fundraising events	10,289	-	10,289	7,276
	Support costs (see note 8)	35,912	2,009	37,921	30,040
		46,201	2,009	48,210	37,315
6.	**COSTS OF RAISING AWARENESS**				
	Costs of fundraising events	24,007	-	24,007	16,976
	Support costs (see note 8)	143,647	8,038	151,685	120,159
		167,654	8,038	175,692	137,135

7. **GRANT MAKING**

	Unrestricted funds £	Restricted funds £	2024 £	2023 £
Innovation & Research Awards	10,570	516,939	527,509	435,592
TUF Trials Unit (TTU)	152,192	-	152,192	-
Champniss Fund	-	-	-	143,304
David Thompson Fellowship	-	110,000	110,000	120,000
Small Research Projects awarded to 5 (2023: 6) teams	-	43,500	43,500	55,759
Education Bursaries and Grants	27,000	-	27,000	-
Prizes and awards	16,141	-	16,141	-
BAUN/TUF Nurse	14,391	-	14,391	6,100
Robotic Centres of Training	11,271	-	11,271	18,938
Other direct costs	7,357	272	7,629	26,001
Travel Grants	5,474	-	5,474	3,591
Strategic Funding	3,000	-	3,000	-
Urolink Fellowship	298	-	298	1,493
Burst	(9,996)	-	(9,996)	9,996
Keith Yeates medals awarded to 0 (2023: 1) individuals	(4,000)	-	(4,000)	1,415
BAUS	-	-	-	1,199
Research Scholarships awarded to 0 (2023: 0) individuals	-	-	-	(24,918)
Movement in present value of grant accruals	51,166	-	51,166	5,824
	284,865	670,712	955,576	804,292
Salary costs	-	104,511	104,511	53,495
Support costs (see note 8)	263,353	14,736	278,089	220,291
	548,218	789,958	1,338,176	1,078,079

NOTES TO THE FINANCIAL STATEMENTS
for the year ended 31 December 2024

	Costs of generating voluntary income 7.5% £	Fundraising trading: Cost of goods sold 7.5% £	Awareness raising 30% £	Giving grants 55% £	2024 £	2023 £
8. SUPPORT AND GOVERNANCE COSTS (UNRESTRICTED)						
Staff costs (see note 9)	16,652	16,652	66,608	122,114	222,025	122,035
Other staff costs including recruitment	1,373	1,373	5,491	10,067	18,304	11,932
Committee and other staff welfare expenses	839	839	3,357	6,155	11,190	4,605
Other office costs	6,321	6,321	25,285	46,355	84,282	57,117
Audit fee	683	683	2,733	5,011	9,112	3,196
Accountancy and advisory services	1,759	1,759	7,037	12,902	23,458	13,738
Other costs	8,215	8,215	32,859	60,241	109,528	47,267
Depreciation-owned assets	69	69	277	508	924	513
	35,912	35,912	143,647	263,353	478,823	260,403

8. SUPPORT AND GOVERNANCE COSTS (RESTRICTED)						
Staff costs (see note 9)	887	887	3,549	6,507	11,831	39,851
Other staff costs including recruitment	74	74	294	540	981	3,896
Committee and other staff welfare expenses	45	45	180	330	600	1,504
Other office costs	428	428	1,714	3,142	5,713	73,742
Audit fee	37	37	147	269	488	1,044
Accountancy and advisory services	94	94	377	692	1,258	4,486
Other costs	440	440	1,762	3,230	5,872	15,435
Depreciation-owned assets	4	4	15	27	50	167
	2,009	2,009	8,038	14,736	26,793	140,126

9. STAFF COSTS

	2024	2023
	No.	No.
The average monthly number of persons employed by the charity (excluding trustees) during the period was, as follows:		
Office and administration	6.6	3.7
	£	£
Staff costs for the above persons:		
Wages and salaries	304,724	195,161
Social security costs	28,158	17,330
Employer's Contribution to Defined contribution Pension Scheme	5,484	2,891
	338,366	215,382

One employee received total emoluments in excess of £60,000 per annum during the period ended 31 December 2024 (2023: 1). The total emoluments of these employees during the year were in the following ranges:

Key management personnel
The remuneration of the key management personnel (including gross pay, employers' national insurance and employers pension contributions) was £104,051 (2023: £101,654).

		2024	2023
£90,000 - £100,000	No.	1	1

The Charity considers its key management personnel comprise the Chief Executive, with remuneration as noted above. In setting salary levels, The Urology Foundation follows the National Council for Voluntary Organisation's advice that a charity's pay policy should be to offer fair pay to attract and keep appropriately-qualified staff to lead, manage, support and/or deliver the charity's aims. It also conducts online research of charity salaries and uses surveys to benchmark levels of pay. The Urology Foundation does not automatically award its staff with annual salary increases, either incremental or cost of living.

No Director received any remuneration from the Company during the year (2023: £nil).
No trustee received any remuneration for services provided to the charity during the current or previous period.
Trustees expenses are included in note 20.

10. TANGIBLE ASSETS

	Office Equipment £
Cost:	
1 January 2024	24,350
Additions	-
31 December 2024	24,350
Depreciation:	
1 January 2024	20,455
Charge for year	974
31 December 2024	21,429
Net book value:	
31 December 2024	2,921
31 December 2023	3,895

		2024 £	2023 £
11.	**INVESTMENTS**		
	Investments listed on a recognised stock exchange at market value:		
	1 January 2024	3,453,644	3,407,104
	Transfers from cash		
	Additions at cost	337,038	307,833
	Disposal proceeds	(319,643)	(551,126)
	Realised gains	-	3
	Unrealised (losses)/gains	166,523	289,830
	31 December 2024	3,637,562	3,453,644
	At the balance sheet date, the market value of the portfolio comprised:		
	UK investments	3,637,562	3,453,644
		3,637,562	3,453,644
	Fixed income securities	323,544	306,382
	Multi-Asset & Hybrid Instruments	3,314,018	3,147,262
		3,637,562	3,453,644

At the balance sheet date, the historical cost of the investments was £2,718,286 (2023: £2,700,892).
The following holdings had a value of >5% of the market value of the investments:

Name	Holding	Value £ 2024	Value £ 2023
Rothschild & Co WM SICAV-SIF Exbury Fund GBP		3,314,018	3,147,262
Pentairs QIAIF PLC - Vanda Fund Shs -F- USD Shs			-
InstitutionalCash SeriesPLC - BlackRock ICS Sterling Liquidity Fund		323,544	306,382

		2024 £	2023 £
12.	**DEBTORS**		
	Amounts falling due within one year:		
	Prepayments	17,348	18,978
	Accrued Income	1,209,061	421,203
		1,226,409	440,181

THE UROLOGY FOUNDATION

NOTES TO THE FINANCIAL STATEMENTS
for the year ended 31 December 2024

13. CREDITORS	2024 £	2023 £
Amounts falling due within one year:		
Deferred income	959	13,382
Trade creditors	150,239	150,500
General accruals	11,939	7,183
Grant accruals	611,010	795,272
Other creditors	17,945	-
	792,092	966,337
Deferred income b/fwd at 1 January 2024	13,382	
Amounts released in the year	(13,382)	
New amounts deferred in the year	959	
Deferred income c/fwd at 31 December 2024	959	

CREDITORS	2024 £	2023 £
Amounts falling due in more than one year:		
Grant accruals	526,756	234,479
	526,756	234,479

14. RECONCILIATION OF NET INCOME/(EXPENDITURE) TO NET CASHFLOW FROM OPERATING ACTIVITIES		
Net income/(expenditure) for the reporting period per the statement of financial activities	650,853	471,646
Adjustments for:		
Depreciation charges	974	680
Gains on investments	(166,523)	(289,833)
Dividends and interest from investments	(17,394)	(14,039)
Management fees paid from investments	-	78
(Increase)/Decrease in debtors	(786,229)	(26,732)
Increase/(Decrease) in creditors	118,033	(304,721)
Net cash used in operating activities	(200,286)	(162,921)

15. THE FUNDS OF THE CHARITY

	1 January 2024 £	Transfer £	Income £	Expenditure £	Gains/(losses) on Investments £	31 December 2024 £
Restricted income funds:						
Robotic Surgery Training Fund	106,448	-	-	(22,500)	16	83,964
Prostate Cancer Research Fund	208,149	-	170,988	(181,558)	37	197,616
Champniss Fund	344,862	-	97,000	(25,345)	78	416,595
Team Corbs - Testicular	7,313	-	-	-	1	7,314
Charles Reynolds	13,002	-	-	(3,543)	2	9,461
Thompson Family Charitable Trust	126,556	-	300,000	(214,510)	40	212,086
Innovation & Research Awards	85,197	-	396,093	(343,841)	26	137,475
Small Research Projects	-	14,571	40,671	(10,748)	8	44,502
Events	6,839	-	-	-	1	6,840
Vivienne Irene Meader Scholarships	-		697,285			697,285
	898,366	14,571	1,702,037	(802,045)	209	1,813,138
Unrestricted income funds:						
General Fund	1,713,621	(1,064,571)	388,252	(803,915)	166,315	399,702
Designated Fund (BUF)	500,000	-	-	-	-	500,000
Research Strategy 2024-28 & Research Appeal	-	800,000	-	-	-	800,000
Infrastructure	-	250,000	-	-	-	250,000
	3,111,987	-	2,090,289	(1,605,959)	166,523	3,762,840

RESTRICTED FUNDS

Small Research Projects	The transfer from General Funds to Small Research Projects is to cover expenditure not externally funded in 2024.

DESIGNATED FUNDS

In September 2024 the Board of Trustees approved designated funds for the following purpose:

Research Strategy 2024-2028 and Research Appeal	A dedicated fund to support the new Research Strategy 2024-2028 and associated Research Appeal. The strategy is an exciting and ambitious plan to improve urology health and transform lives through research over the next five years. It builds on our history of clinical and academic innovation that has already helped to revolutionise urology care. Trustees have agreed to designate £1.5 million to enable the charity to achieve its long-term vision and mission. £800,000 of this is funded from designated unrestricted funds and £700,000 from a restricted legacy donation for scholarships.
Infrastructure	A dedicated fund of £250k to invest in the development of the charity's infrastructure including patient experience, campaigning, marketing, communications and to advance our fundraising capabilities to further diversify income and secure long-term sustainability.

15. THE FUNDS OF THE CHARITY (Continued)

THE FUNDS OF THE CHARITY (Full Fund Comparative)

	1 January 2023 £	Transfer £	Income £	Expenditure £	Gains/(losses) on Investments £	31 December 2023 £
Restricted income funds:						
Robotic Surgery Training Fund	160,170	-	-	(53,765)	43	106,448
Prostate Cancer Research Fund	137,269	-	45,879	24,918	84	208,149
Bladder Cancer Fund	184,851	-	359,000	(199,128)	139	344,862
Travel Fellowship Fund	648	-	-	(648)	0	0
Team Corbs - Testicular	7,311	-	-	-	3	7,313
Charles Reynolds	65,497	(52,500)	-	-	5	13,002
Thompson Family Charitable Trust	-		300,000	(173,495)	51	126,556
Innovation & Research Awards	-	72,500	491,614	(478,951)	34	85,197
Small Research Projects	-	51,456	11,000	(62,456)	0	0
Campaigns	-	(11,750)	11,750		0	0
Events	-		25,000	(18,164)	3	6,839
	555,744	59,706	1,244,242	(961,689)	362	898,366
Unrestricted income funds:						
General Fund	1,584,597	(59,706)	226,030	(326,771)	289,471	1,713,621
Designated Fund (BUF)	500,000	-	-	-	-	500,000
	2,640,341	-	1,470,272	(1,288,460)	289,833	3,111,987

- The Trustees have designated the original 1995 start-up funding for the BUF of £500,000 as the Trustees feel strongly that The Foundation should seek to maintain reserves sufficient to continue to fund its objectives on a long-term basis.
- The Robotic Surgery Training Fund was set up in 2009 following the receipt of restricted donation income from the British Urological Foundation and a generous private donation. The funds are mainly used to award grants towards robotically assisted surgery training, education, and research into robotic training techniques.
- Bladder Cancer Fund: Thanks to the generosity of the Champniss Foundation and the Champniss Charitable Trust, The Urology Foundation has been able to support a number of projects, including research projects tracking patients' fitness post cancer surgery and to predict complications arising during and post chemotherapy.
- Prostate Cancer Research – Thanks to the support of the John Black Charitable Foundation, The Urology Foundation has been able to support a number of projects furthering our understanding of prostate cancer and its treatments. Two further research grants were awarded in 2023.
- Team Corbs: The Foundation started working with former England and Lions rugby champion, Alex Corbisiero, to raise funds for research into testicular cancer, following Alex's diagnosis. A Just Giving page has been set up and the charity will continue to fundraise with Alex.
- Charles Reynolds funds are put towards supporting a number of our research projects and to support education and training for urology nurses, in particular through nurse bursaries and travel grants.
- The Thompson Family Charitable Trust generously support our charitable aims and objectives, in particular support of research and training, and through funding the David Thompson Fellowships. 2023 was in the inaugural year of the Fellowships and four awards were made.

15. THE FUNDS OF THE CHARITY (Continued)

- Innovation & Research Awards. These are our key research awards, worth up to £60,000 per project to fund research and further our understanding into urological cancers and conditions.
- Small Research projects. These awards are primarily about studies that might improve patient pathways or treatment and care. Projects are worth £10,000 each.
- Campaigns – As part of the NHSE Cancer Programme's abdominal/urological "Help Us, Help You" symptoms awareness campaign and specifically the symptom "Blood in Pee", a series of community-based events were delivered across London. Visitors worried about a "blood in pee" symptom were encouraged to visit their GP or seek an early intervention.
- Events – The Foundation was pleased to receive support towards the TUF Trek to Namibia.

16. ANALYSIS OF NET ASSETS BETWEEN FUNDS

As at 31 December 2024:	Unrestricted funds £	Restricted funds £	2024 £
Fixed assets	2,921	-	2,921
Investments	1,895,719	1,741,843	3,637,562
Current assets	232,145	1,209,061	1,441,206
Current liabilities	(181,083)	(611,010)	(792,093)
Long Term Liabilities	-	(526,756)	(526,756)
	1,949,702	1,813,138	3,762,840

ANALYSIS OF NET ASSETS BETWEEN FUNDS (Full Fund Comparative)

As at 31 December 2023:	Unrestricted funds £	Restricted funds £	2023 £
Fixed assets	3,895	-	3,895
Investments	1,946,730	1,506,914	3,453,644
Current assets	434,061	421,203	855,264
Current liabilities	(171,065)	(795,272)	(966,337)
Long term liabilities		(234,479)	(234,479)
	2,213,621	898,366	3,111,987

17. CONTINGENT ASSETS

There were no contingent assets as at 31 December 2024.

18. RELATED PARTY TRANSACTIONS

During the year, travel expenses amounting to £5,593 (2023: £2,257) were reimbursed to the Trustees. Donations of £240 (2023: £240) were received from the Trustees. No further transactions were undertaken such as are required to be disclosed under FRS 102 or the Charities Act.

19. PENSION COMMITTMENTS

The charity operates a defined contribution pension scheme. The costs for the period was £5,484 (2023: £2,891). Contributions amounting to £Nil were payable to the scheme at 31 December 2024 (2023: £Nil) and are included within creditors

THE UROLOGY FOUNDATION


England & Wales - Charity number 1128683

Accounts

THE UROLOGY FOUNDATION

TRUSTEES' REPORT & FINANCIAL STATEMENTS
FOR THE YEAR ENDED DECEMBER 2023

"THE WAY AHEAD 2023-2025"



Contents

Statement from the Chair 3
Overview of the year 3
Statement from the Chief Executive, Rebecca Porta 4
Statement from the Chief Executive, Rebecca Porta *(continued)* 5
Objectives and Activities 6
Our Vision and Mission 6
Our Aims 6
Our Values 6
What we do 6
Public Benefit 7
Grants policy 7
Achievements and Performance in 2023 8
1. Our Strategy: The Way Ahead 2023-2025 8
2. Our Research Programme 8
3. Improving knowledge and skills through education and training 12
Financial Review 19
Financial Results of Activities & Events 19
Fundraising 19
Reserves & Liquidity Policy 20
Statement of going concern 21
Investments Policy 21
Remuneration policy 21
Pensions policy 21
Equal opportunities and diversity policy 21
Principal risks and uncertainties 21
Structure, Governance & Management 23
Charity Governance Code 23
Trustee Recruitment, Training and Induction 23
Appointment & Election 23
Relationships with Related Parties 24
Representation on Other Bodies 24
Reference and administrative details 25
Trustees 25
Registered Office 25
Auditors 25
Trustees' & Directors' Responsibilities in the Preparation of Financial Statements 26
Auditor 26
Statement as to disclosure of information to the auditor 26

Statement from the Chair

Overview of the year

Welcome to our Annual Report for 2023.

1 in 2 people will suffer from a urological disease or condition in their lifetime. This includes urological cancers - prostate, kidney, bladder and male reproductive cancers - and non-malignant conditions including incontinence, urinary tract infections and kidney stones.

People diagnosed and living with these urological cancers and conditions seek information, support and interventions to help navigate the health and social care system and the challenges of everyday life. We are the only charity in the UK representing the entire spectrum of urology health and disease and through our investment in world class research, training and education programmes, raising awareness and driving policy change, we are in the unique position of being the "voice" of the urology community.

This year we launched our new strategy "The Way Ahead 2023-2025". The strategy is a bold, exciting and ambitious vision. Building on our achievements and informed by the knowledge and expertise of a range of stakeholders - the scientific and clinical community, nurses and allied health professionals, patients and their families, volunteers, decision makers and influencers, charity and industry partners and supporters - our aim is to significantly accelerate the progress of urological research, to advance knowledge, to invest in our scientific and medical communities and, guided by research outcomes, to drive change. At the heart of our strategy are patients and their families: involving and working with people affected by urological disease, embedding patient integration and engagement in research and ensuring they have a "voice" in shaping future research agendas and priority areas.

"The Way Ahead 2023-2025" strategy sets out eight priorities:

Priority 1: Significantly accelerate the progress and breakthroughs in urological research.
Priority 2: Invest in our scientific and medical communities, support early career researchers and fund new, innovative ideas.
Priority 3: Facilitate collaborations and partnerships with individual research leaders and research institutes, charities, industry and partners who share our common goals.
Priority 4: Drive change in behaviours, beliefs, policy and practice as a result of research outcomes.
Priority 5: Campaign for further investment in research through working with patients, their families, health and social care professionals, researchers, policy makers, charities, government, industry, funding bodies and those with an interest in research.
Priority 6: Place people affected by urological disease at the heart of research, ensuing they are involved at all stages of research design, delivery, analysis and dissemination.
Priority 7: Give a voice to the people affected by or at risk of urological disease ensuing they have the opportunity to be heard, to influence and drive change.
Priority 8: Transforming The Urology Foundation- ensuring we can build on our success and deliver our objectives, for the benefit of our stakeholders.

We are ambitious for the future and what can be achieved. Ensuring patients and their families have better outcomes, live longer, and with a better quality of life, remains at the heart of our work.

M. Garthwaite

Mary Garthwaite, Chair

Statement from the Chief Executive, Rebecca Porta

This has been another successful year for the Foundation thanks to the support and commitment of our stakeholders - the scientific and clinical community, nurses and allied health professionals, patients and their families, volunteers, decision makers and influencers, charity and industry partners and supporters.

We awarded eight new Research and Innovation Projects and five Small Project Grants covering kidney and prostate cancers, urinary tract infections, urothelial cancer and the management of Haematuria. We introduced new training and career development opportunities, study and travel grants to support our scientific and medical communities and encourage the "rising stars" in urology. The TUF Trials Unit (TTU), a partnership with The Centre for Healthcare Randomised Trials (CHaRT) at the University of Aberdeen delivered impressive results, supporting urologists from across the UK to put forward their ideas and applications for research. TTU has already helped secure an impressive £6.1 million in funding for the research community from our initial investment of £180,000 (£60,000 per annum).

1 in 2 of us will be affected by a urological cancer or condition yet these still don't attract the public profile of many other disease areas. A big part of our work is to raise the profile of urological cancers and conditions in order to encourage an early diagnosis, access to treatment and care and ensure better outcomes and a quality of life. Throughout the year we provided media spokespeople, ran campaigns and awareness events, presented at conferences, met with decision makers and influencers and worked with a wide range of stakeholders to drive policy change. A key focus this year has been prostate cancer and bladder health - with opportunities to attend Roundtables and contribute to discussions and recommendations on the care pathway and improving outcomes.

Awareness highlights include the annual Urology Awareness Month, World Continence Week, a "Catheter Care Challenge" at the House of Commons, a Parliamentary Reception and a series of community-based events encouraging anyone concerned by "blood in pee" to contact their GP practice. This was part of the NHS England "Help Us, Help You" symptom awareness campaign. In November we were delighted to welcome our first Director of Communications and Policy, Laura Thorne to help drive forward our awareness, campaigning and policy programme.

As part of our commitment to put our patient community at the centre of everything we do, we launched our Patient and Public Involvement Programme to bring together researchers, patients, carers and those with an interest in urology. The Programme offers an opportunity to influence and shape research including planning, design, management, evaluation and communication and identifying priorities.

Our success and achievements would not have been possible were it not for the efforts and commitment of so many people and the generosity of our wonderful supporters. Income rose by over 9.6% from £1,355,713 in 2022 to £1,470,272 in 2023. Our new fundraising initiatives have contributed to this growth, particularly Trusts and Foundations and the business community providing the charity with diversified, sustainable sources of income. Sincere thanks to all those who have supported us.

Statement from the Chief Executive, Rebecca Porta *(continued)*

It is two years since I joined The Urology Foundation as Chief Executive and as each month passes my ambition for what I want the Foundation to achieve continues to grow. "The Way Ahead 2023-2025" sets out our ambitions and goals for the future and already we are making great progress towards the eight priorities outlined in the strategy. The aim is to improve the outlook for people affected by urological cancers and conditions ensuring they have better outcomes and a better quality of life. I hope that you will join me in this important and exciting journey.



Rebecca Porta, Chief Executive

Objectives and Activities

The Urology Foundation's objects are to:

"Advance, promote, encourage, develop and improve the study and knowledge of urology, urological surgery and the general knowledge of science and medicine and all matters relating to the progress and development of that branch of science and medicine and for that purpose to fund, aid, maintain and endow scholarships, fellowships, chairs and bursaries and generally to assist in the funding, instruction and support of persons and institutions engaged or involved in urological research work."

Our Vision and Mission

We see a world where people will not die early from urological cancers and diseases, and where people with bladder, kidney and prostate problems can still lead full, active and productive lives.

Our mission is to improve survival and quality of life for urology patients through research and training, so patients receive the best possible treatment and care and fewer lives are devastated.

Our Aims

The Urology Foundation is committed to reducing the suffering caused by urological diseases. We work with researchers, urology and health care professionals to improve the diagnosis, treatment and management of urological disease and the nation's urology care.

We rely on donations from individuals, trusts and foundations, and from companies to help fund our work. The money we raise is invested directly into research to find better treatments and cures, and in training for urology professionals to care for and help people affected by urology conditions.

The Foundation is governed by the rules and regulations set down in its company memorandum and articles of association originally dated 12 February 2009 and last updated by a special resolution on 29 June 2009.

Our Values

In undertaking our remit we are:

- ***Ambitious*** to see UK urology care, treatment and practice is the best in the world.
- ***Dedicated*** to beating all urology diseases through research and training.
- ***Proud*** of working in urology and committed to transforming the lives of people with a urology condition.
- ***Collaborative***; working with researchers, urologists, nurses and health care professionals, influencers and decision makers, charity partners, patients and their families we are improving the nation's urology care.

What we do

We seek to improve patient treatment and care through investing in world class research, education and training programmes, raising awareness and driving change in policy. We fund research that increases our understanding of urological cancers and conditions and that can bring about change in urology practice and guidelines for the benefit of patients and their families. We are also looking for ways that can make treatments more effective and kinder. We are driving improvement in standards in urology practice through training and we are developing the next generation of urological experts who can meet the challenge of the increased burden of disease and who put excellence of care at their core.

Awareness campaigns such as Urology Awareness Month in September bring urological cancers and conditions to the public eye, breaking the stigma and taboos associated with these diseases and conditions and encouraging people to seek an early diagnosis where they may be concerned about potential early warning signs and symptoms.

Public Benefit

The Trustees have taken The Charity Commission's general guidance on public benefit into consideration in preparing their statements on public benefit contained within this trustees' annual report. In accordance with its charitable objectives, The Foundation gives grants to individuals and not-for-profit organisations to:

- Promote the study of urological cancers and conditions by supporting and carrying out research into the causes, prevention, diagnosis and method of treatment of this disease and by publishing the useful results of such research;
- Provide opportunities for training and education of health professionals working in urology, in order to advance practice and improve patient treatment and care;
- Such other purposes for the benefit of the community as shall be exclusively charitable as the trustees from time to time shall decide.

In addition, the charity provides information on urological cancers and conditions, raises awareness, campaigns and drives policy change.

Grants policy

The Foundation advertises its programmes and awards on its website, through its professional e-newsletter and networks. Applications for research are assessed by an independent Scientific and Education Committee (SEC) and Review Panel.

The charity is a member of the Association of Medical Research Charities (AMRC) and abides by its standards and guidelines for peer review and funding. It is also a National Institute for Health Research (NIHR) non-commercial Partner. Research studies funded through our NIHR approved funding streams are automatically eligible for consideration for NIHR Clinical Research Network (CRN) support subject to meeting the standard study eligibility criteria.

Achievements and Performance in 2023

1. Our Strategy: The Way Ahead 2023-2025

In April our new strategy "The Way Ahead 2023-2025" was launched. The strategy is a bold, exciting and ambitious vision. Building on our achievements and informed by the knowledge and expertise of a range of stakeholders - the scientific and clinical community, nurses and allied health professionals, patients and their families, volunteers, decision makers and influencers, charity and industry partners and supporters - our aim is to significantly accelerate the progress of urological research, to advance knowledge, to invest in our scientific and medical communities and, guided by research outcomes, to drive change. At the heart of our strategy are patients and their families: involving and working with people affected by urological disease, embedding patient integration and engagement in research and ensuring they have a "voice" in shaping future research agendas and priority areas.

"The Way Ahead 2023-2025" strategy sets out eight priorities:

Priority 1. Significantly accelerate the progress of urological research
Priority 2. Invest in our scientific and medical communities
Priority 3. Facilitate collaborations and partnerships
Priority 4. Drive change as a result of research outcomes
Priority 5. Campaign for further investment in research
Priority 6. Place people affected by urological disease at the heart of research
Priority 7. Give a voice to the people affected by or at risk of urological disease
Priority 8. Transforming The Urology Foundation.

2. Our Research Programme

Innovation & Research Awards

Our Innovation & Research Award funds projects up to a value of £60,000 that seek to use new, exciting, innovative approaches to address urological diseases and disorders. The projects must either (a) aim to create innovative treatments or devices, (b) aim to deliver innovative care pathways or (c) aim to use innovative research techniques or methods.

We are pleased to report that eight awards totalling £431,592 were made in 2023 (in 2022 there were 8 awards totalling £375,096). The eight projects were:

Impact of body composition on patients with advanced prostate cancer: The main treatment for advanced prostate cancer is androgen deprivation therapy (ADT), which lowers the male hormone called testosterone. ADT stops prostate cancer growth, but can cause men to lose muscle and to gain fat. This can make men weaker reducing mobility and quality of life. The STAMPEDE trial has studied more than 12,000 men with advanced prostate cancer, testing different combinations of treatments. This project will use images from these men to look at how muscle and fat change with different combinations of ADT. It will determine if muscle and fat distributions are linked to how well the treatment works and if patients experience greater side-effects. This work will be the world's largest study of body changes in men with advanced prostate cancer. The results will allow us to understand how different treatments act to drive these changes, enabling tailoring treatment to the individual.

Using a living model of the human bladder to study Urinary Tract Infections (UTIs): This project will use a living model of the human bladder to study how antimicrobial resistance (AMR) develops during the treatment of urinary tract infection (UTIs) and to study the effects AMR mutations have on Escherichia coli, the most common bug in UTIs. It will use antibiotics recommended for the treatment of UTIs, with E. coli isolated from the urine of patients with UTIs. The data produced in this study will be used as an evidence base to guide the sustainable use of antibiotics for the treatment of UTIs. Additionally, the researchers will generate a database of possible mutations which can arise during antibiotic therapy for UTIs and the corresponding effect on the activity of an antibiotic(s). This will

improve understanding of how the use of antibiotics in humans directly affects the development of AMR, leading to improved patient outcomes and reduced healthcare and economic burdens.

Investigating Immune Priming Interventions in Kidney Cancer: Worldwide, over 40,0000 people are diagnosed with a kidney tumour every year. An operation to remove the tumour is currently the only way to completely cure the cancer. This operation is associated with the risks of having major surgery. There are several new treatments which don't involve surgery called ablation treatments (including freezing and radiotherapy) which can destroy kidney tumours. The first aim of this project is to find out if any of these ablation treatments can increase the activity of our immune system. A more active immune system has been shown to lead to better results for patients. The second aim will see if changes in the immune system, detectable in a blood test can be used to monitor patients, to tell if the tumour will grow quickly or slowly. Both these aims could reduce the number of patients undergoing major surgery and the risks associated with it.

DESNT biomarker for the prediction of prostate cancer outcomes: This study is developing a test to identify more aggressive cancer that can be used by hospitals, based on patterns of genes being turned on or off in cancer cells at an early stage of the disease. In this project, prostate cancer tissue, from patients who have had their whole prostate surgically removed to treat their cancer, is compared to the results obtained from their urine and biopsy samples. The researchers will measure whether genes are switched off or on for all genes in urine, biopsy material and whole prostate samples. They have also collected tissue and genetic information from a separate group of patients with multiple, separate tumours within their prostate and are aiming to look at genetic similarities and differences between these tumours. Through analysis of the cell markers, they hope to determine classifications that pick up on aggressive cancers. This study will provide a greater understanding of how a test of cancer aggressiveness actually works, bringing it closer to being used as a test in clinical use to help patients make decisions about their treatment.

How Oestrogen, or lack of, affects the susceptibility of post-menopausal women to recurrent urinary tract infections: Urinary tract infections (UTIs) are common in post-menopausal women. Treatment is usually antibiotics, but re-infections are problematic often resulting in multi-drug resistant bacteria. It is known that women prescribed vaginal oestrogen creams by their doctor have reduced susceptibility to re-infections, but it is not really understood why. The research proposition is that oestrogen treatment alters the physical structure of genetic material or DNA, which helps protect the urinary tract from infection. The project will use samples from postmenopausal women who have either been prescribed vaginal oestrogen or not, and compare the DNA structures of key genes functioning to protect the urinary tissues from bacterial infections. Results will provide better knowledge of how oestrogen helps reduce UTIs and support the development of non-antibiotic UTI therapies, including oestrogen mimics, to reduce antibiotic use.

A Postal Pilot Study for a National Lynch Syndrome Urothelial Cancer Screening Programme: Newcastle University has designed a urine-based cancer test (the Newcastle MSI-Plus assay). This test identifies characteristic changes in urine samples when there is a cancer in the urinary tract that has been caused by Lynch syndrome, an inherited condition associated with an increased risk of urinary tract cancer. The project aims to establish if this test could become a screening test for urinary tract cancers for individuals with Lynch Syndrome. Researchers will collect urine samples from a minimum of 100 healthy individuals with Lynch Syndrome. They expect that most of these tests will be 'negative' or 'normal' and this sample collection will provide proof that healthy individuals with Lynch Syndrome get an accurate result. They will also collect urine samples from patients known to have a urinary tract cancer to gather data about the ability of the urine test to pick up these cancers within urine.

Ex vivo real-time analysis of radical prostatectomy margins using fluorescence confocal microscopy (FCM): One of the most common curative treatment options for localised prostate cancer is radical prostatectomy (RP); a keyhole operation to remove the whole prostate. In some cases, cancer extends very close to the surface of the prostate (the 'margin') and there is a risk of some cancer

being left behind after RP. Leaving cancer behind may mean it could spread, potentially leading to earlier death. There is currently no accepted technique to test the margins for cancer during RP. This study will test a new technology called fluorescence confocal microscopy (FCM) on the prostate immediately after it is removed during RP. We hope to show that FCM is as accurate as a pathologist in detecting cancer at the surgical margins and, in the future, be used to guide surgeons to remove areas of cancer that have been missed. We are grateful to the John Black Charitable Foundation for their funding for this award.

Augmenting the efficacy of sonodynamic therapy against metastatic castration-resistant prostate cancer This project will form the basis towards the design and development of new combination treatments with significantly improved therapeutic outcomes for prostate cancer. The team has developed a treatment called sonodynamic therapy utilizing sound waves and small particles that can eradicate tumours within the prostate in a targeted and minimally invasive manner, with minimum side effects. A large proportion of patients develop prostate cancer types that are very aggressive and difficult to treat with existing therapies. These types of cancer also exhibit relatively increased resistance to sonodynamic therapy, and a potential resistance mechanism that lowers the efficacy of this therapeutic approach has been identified. This research will investigate what prostate cancer types are equipped with the newly discovered mechanism of resistance. Then, it will investigate the efficiency of a non-toxic agent to reduce any relative resistance phenomena to sonodynamic therapy, as well as to radiotherapy and certain chemotherapies. We are grateful to the John Black Charitable Foundation for their funding for this award.

Smaller Research Projects Fund

The Smaller Research Projects fund is focused on improving treatment and care and supports projects up to the value of £10,000. The Fund is aimed at projects that can be delivered quickly (within 2 years) and are focused on supporting vital research that seeks to improve the quality of clinical services and patient treatments and care.

We are pleased to report that five awards totalling £50,000 were made in 2023 (in 2022 there were four awards totalling £40,000). The projects were:

- A UK multi-centre validation of the novel TARGET scoring system for detecting in-field recurrences after focal therapy for prostate cancer.
- Improving ways of detecting susceptibility to myocardial (heart) injury after kidney cancer surgery.
- Reducing the Morbidity of Radical Prostatectomy - helping men to regain their erections after surgery for prostate cancer.
- What a “good improvement” looks like post BPH Surgery: The patients’ Perspective.
- Investigating the barriers to inclusivity in prostate cancer and exercise research within the NHS.

A £10,000 award was also made to BURST (British Urology Researchers in Surgical Training), who are a UK-based research collaborative that designs and delivers large-scale research studies in urology, for their study: Ward Admission of Symptomatic Haematuria: An Observational mUlticentre sTudy (WASHOUT).

Strategic research funding

In 2023 the Foundation awarded a grant of £167,000 to Professor Kelly of UCL, for his research “Developing algorithms from biometric data to predict complications occurring in patients during and after chemotherapy (HALO Trak).” The HALO Trak study follows on from research emanating from the iROC Trial, which established that robot-assisted bladder cancer surgery reduced time spent in hospital, reduced readmissions, and led to better levels of fitness and a quality of life. It also showed that there was a striking reduction in blood clots in patients receiving robotic surgery; indicating a safe surgery with patients benefiting from far less complications, early mobilisation and a quicker return to normal life.

The HALO-Trak study is examining ongoing recovery after surgery using smart, wearable tracking devices to monitor patients remotely, to assess whether a decline in fitness signifying a potential relapse or recurrence of cancer can be detected through biometric readings. We are grateful to the Champniss Foundation and the Champniss Charitable Foundation for their joint funding of this research.

The TUF Trials Unit

In 2020 the TUF Trials Unit (TTU) launched in partnership with The Centre for Healthcare Randomised Trials (CHaRT) at the University of Aberdeen. The unit is led by Professor Graeme MacLennan, a medical statistician and Professor James N'Dow, a consultant urologist. The role of the TTU is to identify promising and important research ideas from urology units and provide a team of medical investigators to bring those ideas to fruition. This approach enables more high-quality urology trials to take place, leading to better care, quicker recovery times and fewer long-term issues. Successful trials are catalysts for change, provide potential for transformational discoveries and drive improvements in treatment and care.

With an initial investment of £180,000 (£60,000 per annum) we are pleased to report the TTU has leveraged this funding to secure an impressive £6.1 million in funding from the National Institute of Health and Social Care (NIHR) to conduct three large-scale, multi-centre trials across the United Kingdom (PARTIAL, ELIPSE, The FOLLOW UP Study). Each of these studies addresses major gaps in the evidence base for prostate and kidney cancer and findings will feed directly into national and international guidelines when completed.

Moreover, this infrastructure funding has supported more urologists to put forward their ideas for clinical research. The TTU has worked closely with 17 chief investigators (CIs) from all across the UK to support the workup of 15 submitted grant applications, currently four being reviewed by funders, and four more in preparation for early 2024 submission. The scale of applications varies, the combined amount is over £15 million, but every application is multicentre, requiring clinical trials unit expertise for design and delivery if successful.

The clinical areas cover the four streams of urology health that The Urology Foundation supports research in (prostate, kidney, bladder, male reproductive organs). The research questions range from early phase research on medical device development through to natural experiments evaluating follow-up care after prostate cancer treatment. The TTU research managers have prepared applications and financial details for nine distinct funding platforms, greatly easing the administrative burden on CIs, letting them concentrate on the scientific aspect of applications.
The TTU has made a significant impact in advancing urology research over the past three years and the charity of proud to have played an important part in its success.

TUF Grant Management System

The charity currently has over 70 active grants and awards. In 2023 it was agreed that a Grants Management System be implemented to enable a more comprehensive / streamlined tracking of the status of the existing grants. The system will also enable reporting on awards across the four nations, regions, disease areas etc. The database could provide historical data for comparison, and also make it easier to collect information on research results and impact. A bespoke system has been developed - the TUF Grant Tracker facilitates the recording of applications, donors, recipients, reviewers, timelines, deliverable outputs, payments, and liabilities for each grant.

Patient and Public Involvement (PPI) Programme

Individuals with experience of living with a disease or condition, or having significant others with a disease or condition, can bring substantial benefit and insight to charities. More and more charities are actively incorporating their experiences into conversations about the design of services, awareness programmes and medical research.

During the year the charity launched its Patient and Public Involvement (PPI) programme. The Programme will play a key role in acting as a bridge between the research community and people affected by urological cancers and conditions. The Programme is overseen by a PPI Development Board - members include Imran Ahmed (Professor of Urological Oncology / Urological & Robotic Surgeon at the University of Glasgow), Hannah Warren (Trustee of The Urology Foundation), Helen Lake (Urology Nurse) and Susannah La-Touche (Urology Consultant at St George's University Hospital). A recruitment drive and series of events and webinars are scheduled for 2024.

Our Research Strategy

Building on our achievements, we are developing our research strategy which will improve urological health and transform lives through research over the next five years. We are consulting with researchers, clinicians, nurses, allied healthcare professionals, decision makers and influencers, charity and industry partners, patients and their families as well as those with an interest in urology to help inform our strategy and identify key areas - from specific disease areas to health inequalities, prevention measures and treatments to training and improving care pathways. The strategy will launch in 2024.

3. Improving knowledge and skills through education and training

Fellowships

Fellowships enhance urological training, education, knowledge transfer and collaboration. They are an important stage in professional and career development, and in building and supporting outstanding surgical leaders in their field. Fellows go to study a particular specialism or technique, so they can provide that service in their own hospitals on return. Through the acquisition of new skills and knowledge, Fellows make an important contribution to the advancement of science and practice thereby ensuring better outcomes for patients. The Foundation offers a variety of different Fellowship opportunities.

David Thompson Fellowship

The David Thompson Fellowships are worth up to £35,000 per fellow. The grant supports attending a centre or centres of excellence for up to one year to enable candidates to gain invaluable experience and skills in urology care and best practice, and to make contributions to research in their area of specialty. Successful candidates will act as Ambassadors promoting best practice and sharing knowledge amongst their own team, hospital and wider urology community.

2023 was the inaugural year of the awards. The standard of applications was exceptionally high and a decision was made to award four Fellowships:

- Andrew Deytrikh, currently working in Sheffield, who will visit the University of British Columbia hospital in Vancouver, to learn more about robotic surgery for kidney & testicular cancer patients.
- Clare O'Connell, currently training in Dublin, who will visit University of Toronto to learn more about robotic surgery for kidney, bladder & testicular cancer patients.
- Eoin Dineen, currently at UCL, who will visit the Peter MacCallum Cancer Centre in Melbourne to undertake Prostate cancer surgery & research.
- Stefanie Croghan, currently in Dublin, who will undertake Newcastle Endourology Fellowship at the Freeman Hospital to learn more about Endourology and stone disease.

We are grateful to the Thompson Family Charitable Trust for enabling these Fellowships.

Malcolm Coptcoat Travelling Fellowship

The Malcolm Coptcoat Fellowship, worth £5,000, enables trainees to travel to international centres of excellence for a period of four to six weeks to gain invaluable experience and skills in urology care and best practice. In 2023, its inaugural year, the Fellowship was awarded to Miss Eleanor Zimmerman, an ST6 Urology Specialist Registrar training at the Freeman Hospital, Newcastle. She will visit The Kulkarni Institute in Pune, India, a world-renowned centre for genito-urethral reconstruction, in particular urethroplasty. This high-volume unit performs in excess of 500 urethroplasties per year, with referrals received from not just across India, but also internationally. The unit regularly performs complex cases that are rarely seen or attempted in the UK, and the international training Professor Kulkarni and Dr Joshi offer is highly regarded and respected globally.

TUF/Urolink Fellowships

The TUF/Urolink Fellowships, worth up to £1,500, are open to those senior level trainees who have completed their FRCS (Urol), enabling them to experience working in Low or Middle Income (LMIC) countries. The Fellowships help develop urological services in those countries as well as enabling the cross-fertilisation of knowledge and skills, benefiting the professional development of both the Fellow and those working in healthcare systems where the annual per capita income is less than $1,135 a year.

In 2023 four awards were made:

- Katie Brodie, a Urology ST6 at the Western General Hospital, Edinburgh
- Rory Ferguson, a Urology ST3 at Royal Cornwall Hospitals NHS Trust
- Wilson To, a Urology ST7 at Great Ormond Street Hospital for Children
- Danielle Whiting, a Urology ST6 at Royal Surrey County Hospital

All four will be visiting the Kilimanjaro Christian Medical Centre (KCMC) in Tanzania, to provide a mixture of teaching, training and hands-on surgery.

Support for urology trainees and urology nurses

Keith Yeates Medal/Ralph Shackman prize
The Medal and prize is conferred when candidates achieve over 90% in their Intercollegiate Specialty Examination in Urology. In 2023 Dr Ben Odusaya, a trainee at Bolton NHS Foundation Trust, won the medal and the Shackman travelling fellowship worth £2,000. He will use the opportunity to attend a cadaveric masterclass in the use of HOLEP (Holmium laser enucleation of the prostate), a treatment for people with benign prostatic hyperplasia (BPH).

Nurse education and training
We are committed to ensuring urology nurses and allied healthcare professionals have opportunities to enhance their skills and practice and increase their specialist knowledge. We also believe career advancement goals should be supported, and that further education may open up specialist urology nursing positions in oncology or stones, or roles such as advanced nurse practitioner and urology nurse clinician.

TUF's first Nurse Bursary, worth £2,000, was awarded to Catherine Borrington, a senior staff nurse at The Royal Oldham Hospital who is attending the PG Certificate in Urology at Edge Hill University. Catherine's aspiration is to become a Urology Clinical Nurse Specialist, supporting patients with benign and cancer diagnoses on treatment options and patient education, and helping to alleviate the consultant workload. We are grateful to the Charles Reynolds Foundation for funding these awards.

Regional Trainee Awards and Best of the Regions
In 2023, the Foundation provided £500 prizes to the Best Trainee Presentation or Paper given at a regional meeting of the British Association of Urological Surgeons (BAUS). There are 16 regions throughout the British Isles and Republic of Ireland. The winners of each region were then invited to present their papers at the annual BAUS Conference, at which the overall 'Best of the Regions' would be selected and win a further £500 prize. The overall winner in 2023 was George Sturgess, a trainee in the Yorskhire & Humber region, for his paper on Ketamine Uropathy: Clinical Experience in a High Prevalence Centre. George was invited to present his paper at the International Continence Society meeting taking place in Toronto.

Support for robotic surgery training
Once again, TUF provided support to two of our TUF Centres of Robotic Training, to run cadaveric courses for trainees. The courses are designed for surgeons, urologists, and multi-disciplinary teams to gain system knowledge and develop a working understanding of the robot and learn technical skills useful in the operating theatre. The Freeman Hospital in Newcastle, and Guy's Hospital in London were each given £10,000 to provide the training courses over 2 days. The courses mixed lectures and videos with hands-on robotic surgery practice.

Supporting Advanced Consultant Training
TUF funded the **Advanced Urology Simulation Boot Camp** course with a £12,000 grant. The course is aimed at senior urology trainees and new consultants, supporting the transition to a consultant role and provides training in often overlooked areas such as dealing with stress, effective leadership and the day-to-day challenges of consultant practice. The course was extremely well attended and received.

Support for travel and attending conferences and educational programmes
During the year a number of small grants were made to urologists and nurses to travel to, or attend, training courses or conferences. Further small grants were also made for researchers to hold meetings with patients and stakeholders to understand further the impact of particular disease conditions.

Training and education

As part of our commitment to training and supporting our urology community and those with an interest in urological cancers and conditions, the charity delivered training sessions throughout the year on a range of topics. Highlights included:

- Working with Knowlex, who provide healthcare leaders and commissioning organisations with a range of resources, we took part in their 2023 Infection Prevention and Control Conference in Birmingham. This is Europe's largest Infection Prevention and Control Conference. TUF Trustee and Consultant Urologist Roland Morley presented on the subject of UTIs. We were also invited to run a webinar in March on the topic of "Female Urinary Incontinence Pathways: Where do they lead?" which brought together Mary Garthwaite (TUF's Chair), Mehwash Nadeem (Consultant Urological Surgeon at South Tees University Hospitals Trust) and Sarah Hillery (President of British Association of Urological Nurses).
- We were delighted to attend the British Association of Urological Surgeons (BAUS) Annual Conference in Birmingham and the British Association of Urological Nurses (BAUN) Annual Conference in Edinburgh. Both events provided the opportunity to meet with urology colleagues and industry.
- TUF's Chair was invited to speak at the Convatec Continence Care Customer Symposium in November which was attended by urology nurses, continence professionals, GPs and Convatec staff. TUF's Chair presented two sessions - 'The work of The Urology Foundation' and 'Patient choice in self-catheterisation care'.

4. Improving public awareness of urological cancers and conditions

The Urology Foundation is committed to improving public awareness of urological cancers and conditions, to promoting research progress and highlighting research developments, to commenting on topical issues and sharing patient experience.

In April we hosted a Parliamentary Reception together with the Urology Trade Association (UTA) titled "Keeping patient choice at the heart of NHS and MedTec reform" at the House of Commons. Over 90 patients, scientists and clinicians, charity partners, policy makers and industry attended the event.

In July we partnered with the MS Trust and the Spinal Injuries Association (SIA) to host a unique parliamentary event aimed at raising awareness of the challenges faced by people who use urinary catheters and encourage policy makers to talk about catheters and bladder issues. The event at the Churchill Room, House of Commons saw Parliamentarians participate in the Catheter Care Challenge, an escape-room style 'challenge', competing against colleagues to access a toilet, answering quick-fire questions about catheters and ultimately racing against the clock to complete the quiz and 'catheterise' safely. Paul Bristow MP hosted the event and we were joined by Parliamentarians including Sarah Owen MP (Lab), Margaret Ferrier MP (Independent), Christina Rees MP (Independent), Anna Firth MP (Con), Diana Mary Warwick and Baroness Warwick of Undercliffe (Lab). Sincere thanks to Coloplast for their support with the project.

"Help Us, Help You"

A highlight of the year was the opportunity to take part in the NHSE Cancer Programme's abdominal/urological "Help Us, Help You" symptoms awareness campaign and specifically the symptom "Blood in Pee". These community-based events - held at indoor venues such as libraries, football stadiums and shopping centres - encouraged visitors worried by a "blood in pee" symptom to visit their GP or seek an early intervention. There was a particular focus on targeting black and minority ethnic groups, people from socio-economically deprived communities and people with other co- morbidities. In conjunction with the charity UCARE events were held across Oxfordshire and the London Boroughs of Newham and Tower Hamlets. London based events included Stratford Library, Better Gym, the Ideas Store and the East London Mosque.

Roundtable Events

This year our CEO was invited to participate in a number of Roundtable discussions. Highlights included:

- In September she attended a cross-party Parliamentary Roundtable at the House of Commons "Harnessing innovation to address challenges in prostate cancer care" which brought together key stakeholders to discuss how the UK can better use innovations in diagnosis and treatment of prostate cancer to improve patient care. Guests included prostate cancer clinicians and patient group representatives.
- In October she attended the "Overcoming Inequalities in Cancer Care", a Parliamentary drop-in event organised by Pfizer. The event provided an opportunity for Parliamentarians, clinicians and cancer charities to discuss the regional inequalities that exist in access to cancer care. Further discussions and activities are planned to look at ensuring patients and their families have better outcomes and experiences.

Campaigns

Throughout the year we took part and supported a number of campaigns including World Cancer Day, Bladder Cancer Awareness Month, World Kidney Day, Testicular Cancer Month and World Continence Week. Highlights include:

- A campaign during Men's Health Week in partnership with Male Health platform TRTed to raise awareness of the underlying symptoms of Erectile Dysfunction and encourage men to talk about this issue. The campaign included a survey and the launch of a new Factsheet written by Mr Hussain M Alnajjar, Consultant Urological Surgeon and Andrologist, Honorary Associate Professor at University College London (UCL).
- As part of World Continence Week 2023 we worked with Convatec to develop a series of posters to highlight continence issues, to challenge the stigma and taboo that surrounds incontinence and to encourage people to seek help and support.

Urology Awareness Month

September is Urology Awareness Month, an annual campaign which brings together our urology community - researchers, urologists, nurses and allied health professionals, influencers and decision makers, patients and their families and those with an interest in urology health - to raise awareness of urological cancers and conditions. This year's theme was bladder health with a particular focus on urinary tract infections (UTIs), urinary incontinence and bladder cancer. Throughout the Month we highlighted stats and facts on bladder health alongside launching new videos, delivering webinars, Roadshows and health and well-being sessions. Highlights included:

- Knowlex invited TUF to run a webinar to mark the Month. TUF's Chair, Mary Garthwaite, together with Trustee and Consultant Urologist Roland Morley, President of BAUN Sarah Hillery and Locum Consultant Urological Surgeon Yasmin Abu Ghanem, presented a webinar 'Bladder Health: The Hidden Issue'. The webinar examined managing an overactive or under active bladder, the burden of urinary incontinence, bladder cancer and urinary tract infections (UTIs). Over 600 people registered for the event.
- Asda supermarket chain supported our London based Roadshows inviting customers and staff to learn about urology health.
- Together with Network Rail we were able to reach thousands of people through our health messages on their public notice boards at Manchester Piccadilly Station, Kings Cross Station and Liverpool Lime Street Station during September. We also had messaging on payroll slips that reached over 40,000 employees. TUF Chair, attended wellbeing sessions for Network Rail employees to highlight the signs and symptoms of urology conditions, including prostate cancer.
- TUF's Chair took part in a podcast on 'Why urology awareness matters'. This was part of Coloplast Professional's 'Stoma and Continence Conversations' podcast.

People were invited to support the campaign by holding events, posting messages of support on social media, displaying posters and given talks about urology health.

In the media

1 in 2 of us will be affected by a urological cancer or condition yet these still don't attract the public profile of many other disease areas. A big part of our work is to raise the profile of urological cancers and conditions in order to encourage an early diagnosis, access to treatment and care and ensure better outcomes and a quality of life alongside raising awareness of The Urology Foundation and its vital work. Throughout the year we provided media spokespeople and commented on topical issues. Highglights included an interview on Radio 4 Woman's Hour on the subject of UTIs and the proposed changes to prescribing - via the pharmacy setting - for uncomplicated UTIs. In June our Chair was interviewed on popular television show, Steph's Packed Lunch on the subject of male incontinence. As part of Men's Health Week, an erectile dysfunction campaign with the Men's Health platform, TRTed saw coverage in the Daily Mail, Huffington Post and Daily Star online.

Appointment of the Director of Communications and Policy

In November the charity appointed its first Director of Communications and Policy, Laura Thorne. Laura has over ten years' experience in public affairs and communications, implementing national and local change, providing strategic advice and delivering targeted, awareness-raising campaigns. Prior to joining The Urology Foundation, she was Head of Health Public Affairs at a communications and marketing agency. Her expertise includes public affairs and policy; strategic campaigns; communications; issues management; and relationship building across Westminster and the devolved nations. She has worked collaboratively with pharmaceutical and MedTech companies, charities, patient groups, All-Party Parliamentary Groups and trade bodies to deliver positive change. She is a member of the Cancer52 Policy and Public Affairs Steering Group where she works to improve outcomes for people experiencing less common urology cancers. With over three years' experience working for a Member of Parliament, she also has a strong understanding of the workings of Parliament and Government.

5. Collaborations and partnerships

We value the importance of working with other organisations to achieve our aims. Throughout the year we engaged with a range of organisations and charity partners working in the area of urology. These included the BAUS, BAUN, Urology Trade Association, Prostate Cancer UK, Prostate Research UK, Fight Bladder Cancer, Action Bladder Cancer, Kidney Cancer UK and UCare.

We welcomed the opportunity to meet and work with a range of companies including Peppy Health, Intuitive Health, Boston Scientific, Pfizer UK, Peak Medical Ltd, Astellas Pharma, Janssen, Bayer, Lloyds Pharmacy Online Doctor, Coloplast and Convatec to promote awareness of urology health.

6. Investment in our Team

Developing our people and infrastructure is vital as it underpins the delivery of our charitable and fundraising activities. The Trustees have committed to infrastructure investment which will support sustainability, effectiveness, collaboration and impact particularly within the charity's programmes and grants portfolio which has expanded significantly over the last two years, across fundraising and the expansion of funding streams and to ensure we have a "voice" within the urology community - in driving change, improving outcomes and patient care.

The first stage of the investment saw the appointment of Laura Thorne as the new Director of Communications and Policy in November. Two new roles have been approved and recruitment will commence in January 2024:

- Fundraising Manager (Events and Individual Giving) to manage and expand a portfolio of events, to develop an individual giving programme and to grow the supporter base.

- Grants & Programmes Executive to support for the growing programmes and grants portfolio

7. Plans for the future

Our strategy "The Way Ahead 2023-2025" has set out a clear direction and our ambitions for the next three years. Building on our achievements and informed by the knowledge and expertise of a range of stakeholders, in 2024 we will look to:

- Launch a new Research Strategy outlining how we will accelerate the progress and breakthroughs in urological research, the key disease area we will focus on and campaigning for further investment in research.


- Support our urology community and allied healthcare professionals through training and education, study and travel awards and other opportunities.

- Launch a UTI Programme to include a dedicated research grant call to better understand UTIs, a nurse-led UTI Information Service and training for health professionals.
- Develop a Communications Strategy to
    - Raise awareness of urology health and the work of The Urology Foundation
    - Drive change in urology care and practice through our policy work, campaigning and health awareness initiatives
    - Strengthen our partnerships

  This will include the launch of a new website, information and promotional resources, media relations and our annual Urology Awareness Month campaign which will focus on Men's Urology Health.
- Give a voice to the people affected by or at risk of urological disease ensuing they have the opportunity to be heard, to influence and drive change. We will look to support and develop closer relationships with seldom heard communities, those at greater risk of specific disease and those with poorer outcomes.
- Build on our current work and achievements in prostate cancer, UTIs and bladder heath.
- Invest in our fundraising programme with the launch a Fundraising Appeal to support the delivery of our new Research Strategy

Financial Review

Financial Results of Activities & Events



The total value of net assets held by The Urology Foundation on 31 December 2023 was £3,111,987 (2022 £2,640,341). The Foundation's fundraising activities and other initiatives during the course of 2023 generated a total of £1,384,437 of voluntary income (2022 £1,318,353) and a further £66,800 (2022 £30,980) from specific fundraising event income.

Fundraising

The Foundation is reliant on voluntary income to fulfil its remit. Following a review of the charity's fundraising function in 2022, the decision was made to invest in this area in order to diversify the existing income streams and to look to increase the charity's income. Our new fundraising initiatives have contributed to this growth, particularly Trusts and Foundations and the business community providing the charity with diversified, sustainable sources of income.

We are pleased to report income for year totalled £1,470,272 against the previous year total of £1,355,713. The following information summarises the various disciplines:

- Donations. Income from donations totalled £136,210. Our sincere thanks to everyone who has supported us during the year.
- Business Community. We are committed to working with a wide range of companies including those in the pharmaceutical and Med tech industry in order to meet our objectives. Under the direction of Lucy Noakes, our Business Development Manager we have significantly grown this area during the year alongside building and strengthening our existing relationships. With our partners we are raising awareness of urological cancers and conditions and driving change to ensure better outcomes for patients and their families. Highlights during the year include, partnering with Coloplast on the Catheter Care Challenge at the House of Commons which saw Parliamentarians participate in the Catheter Care Challenge. For World Continence Week we collaborated with Convatec and together challenged the taboos around continence - calling for people to foster more openness around the impact it can cause to quality of life. We hosted a Parliamentary Reception together with the Urology Trade Association (UTA) Parliamentary Reception "Keeping patient choice at the heart of NHS and MedTec reform" at the House of Commons. Over 90 patients, scientists and clinicians, charity partners, policy

makers and industry attended the event. Reaching different audiences is a key objective for us and last year we were delighted to partner with Network Rail Wellbeing champion to deliver urology focussed webinars for employees, with a special focus on men's health in urology. Looking ahead to 2024, we will further develop our relationship and look to explore new ones to help us grow and deliver more exciting projects. We are grateful for the generosity of our many corporate partners who continue to support our vital work.

- Trusts and Foundations. Income from a range of both small and large trusts and foundations totalled £1,248,227 and included support towards research, awareness, community-based projects, education and training. This included a grant from The UK Government Covid Medical Research Support Fund totalling £282,018 towards helping to sustain early-career researchers supported by medical research charities impacted by the COVID 29 pandemic.
- Events. We are pleased to report that supporters organised and took part in a wide range of events throughout the year. These included the TUF Trek to Namibia which saw our President Professor Roger Kirby and Trustee Roland Morley together with eight TUF supporters raise an incredible £65,000. The Great North Run saw five dedicated runners, led by Jo Creswell President of BAUS, take to the streets of Newcastle to raise £3,762. The ever popular London Landmarks Half Marathon (LLHM) saw five runners take to the streets of London to raise an incredible £4,664. Ride London cyclists raised over £2,000 and a Rock Choir Concert organised by supporter Anne Stotesbury raised £2,000. A highlight of 2023 was the Bike4TUF, London to Paris Cycle Ride, in June. This year marked the 10th anniversary of this popular and successful Bike4TUF Ride organised by consultants Ben Eddy, Ben Challacombe and TUF supporter David Plummer. An incredible £56,650 was raised for TUF. We are grateful to everyone who undertook various fundraising challenges for the charity

We are registered with the Fundraising Regulator and adhere to the code of fundraising when carrying out our activities. Our staff are committed to following codes of good practice and standards developed by the fundraising community through the work of the Chartered Institute of Fundraising (IoF) and other professional bodies. The Foundation operates a clear and stringent complaints handling procedure that is reported to the Senior Management team and the Board. As part of our supporter care programme, we have agreed policies and procedures in place and written agreements with external agencies that we engage to help us or who raise funds for the charity. We ensure that anyone engaged to work for us is trained in and respects our aims and objectives and carries out their activities with the same high standards and care we would ourselves. During the year we received less than five complaints in relation to our fundraising activities. We remain committed to improving our practice, learning from supporter feedback.

Reserves & Liquidity Policy

The Foundation currently has 'free reserves' of £2,213,621 (31 December 2022: £2,084,596). Our free reserves relate to un-designated unrestricted reserves. During the next financial year, the Trustees intend to transfer funds from unrestricted funds to designated funds.

The Foundation's policy is to maintain reserves sufficient to continue to fund its objectives on a long term basis, and to ensure that the charity operates with an adequate level of liquidity to (i) minimise the risk associated with a temporary or unforeseen shortfall in liquidity; (ii) manage its cash and investments to meet its liabilities and remain a going concern for at 12 months in the event of an unplanned drop in income. Liquidity is defined as cash and the investment portfolio held as unrestricted funds. The Policy establishes a minimum liquidity target of €500,000 ("Minimum Required Reserve") subject to future modification by the Finance Committee and Trustees' approval.

The Trustees consider that reserves held in excess of the amounts required to fund all future commitments together with the initial fund of €500,000, will be available to increase its visibility and expand its operations including funding for further research and a wider range of projects.

The Trustees plan levels of expenditure from unrestricted and restricted funds for the year ahead based upon the level of incoming resources for the current year as well as utilising restricted funds.

Statement of going concern

The Foundation's unrestricted net funds generated in 2023 are judged to be sufficient to meet the requirements of the charity for charitable giving in the coming year.

Investments Policy

The Foundation's investments are managed by Rothschild Bank (CI) Limited. The Treasurer and the Chief Executive are responsible for managing the relationship with Rothschild but changes in investment strategy are subject to approval by the Board of Trustees. The investment manager is asked to attend at least one Board of Trustees and one Finance Committee meeting annually.

The Board follows a medium risk 'Balanced' investment strategy which is intended to achieve steady growth over the long term through a diversified approach to investment. Capital preservation in real terms over a long-term horizon is the primary objective and some volatility is acceptable in order to achieve this. The charity's investments are held in the Exbury Fund, an ethical portfolio managed by Rothschild. The fund achieved a 1.4% return over 2023.

All other Foundation funds are held in accounts with the charity's bankers, National Westminster Bank plc.

Remuneration policy

In setting salary levels, The Urology Foundation follows the National Council for Voluntary Organisation's guidance that a charity's pay policy should be to offer fair pay to attract and keep appropriately-qualified staff to lead, manage, support and/or deliver the charity's aims. It also conducts online research of charity salaries and uses surveys to benchmark levels of pay. The Urology Foundation does not automatically award its staff with annual salary increases, either incremental or cost of living.

Pensions policy

The charity offers a stakeholder pension, operated by The People's Pension (B&CE Holdings), in line with statutory requirements. All new staff are automatically enrolled but can opt out if desired.

Equal opportunities and diversity policy

The charity is committed to being an Equal Opportunities employer and to respecting diversity, and is determined to ensure that no job applicant, employee, or trustee receives less favourable treatment on the grounds of their age, disability, gender reassignment, marriage and civil partnership, pregnancy or maternity, race, religion or belief, sex or sexual orientation. The charity also seeks to ensure that its employees are not victimised or subjected to harassment.

The policy applies to recruitment and selection for jobs in the Foundation, career development and training, promotion, performance management, pay, redundancy, disciplinary and grievance procedures, the application of terms and conditions of employment and any other aspects of employment with the Foundation.

The policy also applies to third parties such as Trustees and committee volunteers, clients (i.e. grant applicants) and suppliers.

Principal risks and uncertainties

The Trustees take the management of risks seriously. The Chair of the Board of Trustees and the Chief Executive are charged with responsibility to ensure that the risks which have been identified are adequately assessed and properly mitigated on a regular basis. The potential risks have been discussed with the Chairman and the charity and a formal risk register is kept, updated and discussed by the Board of Trustees on a quarterly basis.

Impact of war in Ukraine and economic outlook
The ongoing war in Ukraine and wider economic outlook has broader economic implications, some of which will be reflected in our investment fund holdings. Our Investment Manager keeps us regularly updated and there is no immediate cause for concern or action.

Risks to Data
The charity takes its responsibilities for data very seriously. We follow a Data Protection policy based on the GDPR and have a nominated Trustee (Mr Adrian Joyce) who has Board oversight for data compliance. We use a professional data base provider that stores all information in the cloud and this is secured using a two-step password verification. We review our records on an ongoing basis and delete old or historical records that are no longer relevant, and remove people who no longer wish to hear from us (provided that there is no financial information that we need to retain).

Other key risks are assessed as follows:

Governance /Environmental	Impact of the external environment on fundraising, in particular: public confidence in charities; new fundraising regulations; Data Protection Regulations.
Income Sources	TUF is reliant upon voluntary income as an annual source of funding. It is the role of the trustees to manage risk exposure on fundraising activities and in doing so to accept an appropriate level of risk in order to raise income from a wide range of sources.
Risk of data breach	The charity uses a professional database provider that stores all information in the cloud and this is secured using a two-step password verification. The charity's own day to day working documents are also stored on a cloud-based system. TUF staff are regularly made aware of possible phishing scams and to be alert to any potential email or system data breaches.
Key Person risk	The small staff base makes TUF heavily reliant on the Chief Executive and a few key Trustees so the unexpected loss or departure of the Chief Executive or certain Trustees is a risk. Succession planning processes are in place.
Investment Risk	TUF's success is directly related to the amount of resource it can devote to its objectives, so the key risk identified by Trustees relates to the proper management of its funds. Imprudent or unprofessional decisions could majorly impact on the performance of those funds. In common with similar charities, TUF employs professional fund managers, whose performance is regularly reviewed by the Treasurer together with other Trustees.
Risk to Employees	Employees are not subject to risks other than those likely to be associated with routine office work. Apart from obtaining statutory Employers Liability Insurance, TUF nonetheless treats the welfare of its staff as a priority. The Chief Executive is the Nominated Safety Officer for the purposes of the Health and Safety at Work Act. The premises are checked and maintained by the landlord and by the fire service to ensure appropriate mitigation of the risk of fire. Employees are aware of the location of fire extinguishers. The charity also has a number of policies in place covering Equal Opportunities, Lone Working, Working from Home and Safe Guarding Vulnerable People.
Risk that research fails to deliver results	Grants awarded are subject to rigorous review by the SEC and Reviewing Committee. Grantees are expected to submit progress reports and these are reviewed by the SEC and TUF. The charity maintains ongoing communication with grant holders.
Loss of Records	To protect against the loss of records, and to increase data security, files are stored in the cloud. The risk of any unsaved data being critical to TUF is regarded as insignificant. Other similar risks are dealt with by insurance.

Structure, Governance & Management

The Urology Foundation is a charity and a company limited by guarantee and was established on 12 February 2009 to incorporate the charitable activities of the British Urological Foundation (BUF), an unincorporated charitable trust established in 1994 by the British Association of Urological Surgeons and BJU International, and a registered charity since 17 March 1995. The Urology Foundation itself became a registered charity on 19 March 2009.

Charity Governance Code

The Board and Executive of the charity abide by the standards set by the Charity Governance Code when executing their duties. The overall strategic direction of the charity is determined by the trustees, who meet three times each year including an Annual General Meeting.

Trustee Recruitment, Training and Induction

The Foundation seeks to achieve a balance of lay and medical Trustees. Appointed Trustees are recruited on the basis of fulfilling the criteria to provide a balance of experience and knowledge. Members of the charity's Scientific and Education Committee (see below) are recruited through calls in industry publications.

All new Trustees are provided with an induction programme and an induction pack. They are provided with relevant Charity Commission publications and regularly briefed on developments and opportunities that will support their general understanding of the voluntary sector, healthcare and medical research issues.

Trustees contribute to every aspect of the charity: governance; fundraising; financial planning; management expertise and leadership. We are truly grateful for their service and to all our Trustees, who selflessly contribute their time, expertise and networks whenever they are called upon.

Appointment & Election

The Trustees and Chairman are appointed for an initial period of three years that can be extended for a further three-year term. A further extension may be made if it is deemed to be in the best interests of the Charity. The governing document requires that there should be a minimum of seven trustees.

Two of the Trustees are required to be representative Trustees, one nominated by The British Association of Urological Surgeons (BAUS) and one nominated by British Journal of Urology International (BJUI). All other trustees, known as appointed Trustees, are appointed by unanimous written resolution of all the trustees present and/or voting at a special meeting of Trustees called to take place immediately before or after an ordinary meeting of Trustees.

The representative trustee nominated by BAUS is the President of BAUS and the appointment to the board is concurrent with their post at BAUS, which is for a period of two years.

The Executive Team

The Chief Executive, is responsible for the day-to-day management of the charity.

The Chief Executive deals with the implementation of policy and strategic decisions taken by the Board of Trustees. She and the appropriate staff members attend the meetings of the board of trustees and sub-committees, and report on the day-to-day operations of the charity. The Foundation currently operates the following sub-committees:

Scientific and Education Committee (SEC)

The SEC is responsible for the development and assessment of The Foundation's research, education and training programmes and the review and administration of The Foundation's grant making policy.

The Chairman of the SEC is also a member of the Board of Trustees, and reports back to the Board on the work of the Committee. The SEC is made up of clinical and academic urologists and scientists with an interest in urology, and lay representatives.

Research Review Panel
The Research Review Panel is responsible for assessing applications for our major research grants and marking these according to the requisite criteria being met. In this task it assists the SEC in its final decision on who should receive grants. The Research Scholarship Review Panel is made up of clinical trustees and academic urologists and scientists with an interest in urology.

Membership of the SEC and Review Panel can be viewed on the charity's website. They provide their services as volunteers and we are enormously grateful to them.

Finance Committee
The charity Finance Committee is chaired by the Treasurer, Ms Angela Daniel. Membership includes The Chair of the Board and the Chairman of the SEC, and two other Trustees and the Chief Executive. Any recommendations made by the Finance Committee are brought to the Board of Trustees for discussion and ratification. The Treasurer has oversight of the charity's bank and investment accounts.

IT Oversight Committee
The IT Oversight Committee was formed in 2023 on the recommendation of the Board of Trustees. The purpose of the IT Oversight Committee is to advise the Board of Trustees on IT governance, IT implementation and other strategic IT-related issues including legal and regulatory compliance, investment in IT projects including telecommunications, risk and opportunities and to ensure these are managed through appropriate internal controls. The IT Oversight Committee consists of a minimum of three Trustees including the Chair, the Chief Executive, Director of Research and Senior Administrative Officer.

Relationships with Related Parties

The Urology Foundation continues to maintain close links with its two founding charities, BAUS and the BJUI, whose representatives are Trustees.

Representation on Other Bodies

The charity is a member of the Association of Medical Research Charities (AMRC), which confers a quality mark for our peer review processes, as well as advocating for charity-funded research with government. The Urology Foundation is a National Institute for Health Research (NIHR) non-commercial Partner. This means the studies that the Foundation funds may be eligible to access the NIHR Study Support Service which is provided by the NIHR Clinical Research Network.

The charity is also a member of Cancer 52, Charities Research Involvement Group, the National Council for Voluntary Organisations (NCVO) and UNSEEN, a UK leading anti-slavery charity working with survivors, businesses, governments, police and NHS to end slavery.

Reference and administrative details

The registered charity name is "The Urology Foundation" (sometimes referred to as "TUF"), a charity and a company limited by guarantee.

Trustees

Ms Mary Garthwaite *(Chair)*
Ms Angela Daniel (*Treasurer)*
Mr Mark Becker *(Secretary)*
Prof Grant Stewart (*Chair, SEC resigned 14 March 2023)*
Prof Rakesh Heer *(Chair SEC, appt 14 March 2023)*
Ms Hilary Baker (appt 21 March 2024)
Mr Mo Belal (appt 21 March 2024)
Mr Ben Challacombe
Ms Jo Cresswell *(resigned 17 June 2024)*
Mr Mike Griggs (*appt 1 January 2023*)
Mr Adrian Joyce *(resigned 8 December 2023)*
Prof Alan McNeill *(appt 10 Feb 2023)*
Mr Roland Morley *(resigned 21 March 2024)*
Mr Kieran O'Flynn *(appt 8 December 2023)*
Mr Ian Pearce *(appt 17 July 2024)*
Ms Julia Taylor *(appt 21 March 2024)*
Ms Hannah Warren

President

Prof Roger Kirby

Patrons

Mr Handel Evans
Sir Ranulph Fiennes OBE
Mrs Rosemary Macaire
Ms Jane Macquitty MBE
Mr Steven Norris

Ambassadors

Mr Alex Corbisiero
Mr Stephen Fry
Mrs Kate Holmes

Chief Executive

Ms Rebecca Porta

Registered Office

1-2 St Andrew's Hill
London
EC4V 5BY

Charity number

1128683 (England & Wales)

Company number

06817868

Auditors

Dunkley & Co Ltd
Woodlands Grange, Woodlands Lane
Bradley Stoke
Bristol BS32 4JY

Bankers

National Westminster Bank plc
PO Box 2022
10 Marylebone High Street
London W1A 1FH

Investment Manager

Rothschild Bank (CI) Limited
St. Julian's Court, St. Julian's Avenue
St. Peter Port
Guernsey GY1 3UA

Trustees' & Directors' Responsibilities in the Preparation of Financial Statements

The trustees (who are also the directors of The Urology Foundation for the purposes of company law) are responsible for preparing the trustees' Annual Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company as at the balance sheet date, and of the incoming resources and application of resources, including income and expenditure, for that period. In preparing those financial statements, the trustees and directors are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The trustees are responsible for keeping proper accounting records, which disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with Companies Acts 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from the legislation in other jurisdictions.

Auditor

Mr Matthew Dobbins (FCA), of Dunkley & Co Ltd. has agreed to act as Auditor.

Statement as to disclosure of information to the auditor

The trustees and directors at the date of approval of this trustees' annual report confirm that so far as each of them is aware, there is no relevant information of which the charity's auditor is unaware, and the trustees and directors have taken all steps that they ought to have taken to make themselves aware of any relevant information and to establish that the auditor is aware of that information.

Mary Garthwaite

Mary Garthwaite (Sep 26, 2024 17:27 GMT+1)

Mary Garthwaite, Chair

Date: 26/09/2024

Report of the Independent Auditors to the Trustees of The Urology Foundation (Registered number: 06817868)

Opinion
We have audited the financial statements of The Urology Foundation (the 'charitable company') for the year ended 31 December 2023 which comprise the Statement of Financial Activities, the Balance Sheet, the Cash Flow Statement and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 December 2023 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern
In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate. Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information
The trustees are responsible for the other information. The other information comprises the information included in the Annual Report, other than the financial statements and our Report of the Independent Auditors thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Matters on which we are required to report by exception
We have nothing to report in respect of the following matters where the Charities (Accounts and Reports) Regulations 2008 requires us to report to you if, in our opinion:

- the information given in the Report of the Trustees is inconsistent in any material respect with the financial statements; or
- the charitable company has not kept adequate accounting records; or
- the financial statements are not in agreement with the accounting records and returns; or
- we have not received all the information and explanations we require for our audit.

Report of the Independent Auditors to the Trustees of The Urology Foundation (Registered number: 06817868)

Responsibilities of trustees

As explained more fully in the Statement of Trustees' Responsibilities, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Report of the Independent Auditors to the Trustees of
The Urology Foundation (Registered number: 06817868)

Our responsibilities for the audit of the financial statements
We have been appointed as auditors under Section 144 of the Charities Act 2011 and report in accordance with the Act and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Independent Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Extent to which the audit was considered capable of detecting irregularities, including fraud

We identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and then design and perform audit procedures responsive to those risks, including obtaining audit evidence that is sufficient and appropriate to provide a basis for our opinion.

Identifying and assessing potential risks related to irregularities

In identifying and assessing risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, we considered the following:

- The nature of the charitable sector, control environment and performance including the design of the organisation's remuneration policies;

- Any matters we identified, having obtained and reviewed the organisation's documentation of their policies and procedures relating to:

o Identifying, evaluating and complying with laws and regulations and whether they were aware of any instances of non-compliance;

o Detecting and responding to the risks of fraud and whether they have knowledge of any actual, suspected or alleged fraud;

o The internal controls established to mitigate risks of fraud or non-compliance with laws and regulations;

o The matters discussed among the audit engagement team regarding how and where fraud might occur in the financial statements and any potential indicators of fraud.

As a result of these procedures, we considered the opportunities and incentives that may exist within the organisation for fraud and identified the greatest potential for fraud in the areas of management override of controls, going concern, income recognition, and the appropriateness of expenditure.

We also obtained an understanding of the legal and regulatory framework that the organisation operates in, focusing on provisions of those laws and regulations that had a direct effect on the determination of material amounts and disclosures in the financial statements.

Audit response to risks identified

Our procedures to respond to risks identified included the following:

- Enquiring of management, concerning actual and potential litigation and claims;

- Substantive testing to vouch source records to the financial statements;

- Performing analytical procedures to identify any unusual or unexpected relationships that may indicate risks of material misstatement due to fraud;

- Enquiring of management the internal controls in, evaluating each control for weakness and vouching to evidence of the control taking place;

- In addressing the risk of fraud through management override of controls, testing the appropriateness of journal entries and other adjustments; assessing whether the judgements made in making accounting estimates are indicative of a potential bias; and evaluating the business rationale of any significant transactions that are unusual or outside the normal course of business.

We also communicated relevant identified laws and regulations and potential fraud risks to all engagement team members, and remained alert to any indications of fraud or non-compliance with laws and regulations throughout the audit.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Independent Auditors.

Use of our report
This report is made solely to the charitable company's trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. Our audit work has been undertaken so that we might state to the charitable company's trustees those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's trustees as a body, for our audit work, for this report, or for the opinions we have formed.

Matthew Dobbins (Sep 26, 2024 21:27 GMT+1)

Matthew Dobbins FCA
Dunkley's
Chartered Accountants
Registered Auditors
Eligible to act as an auditor in terms of Section 1212 of the Companies Act 2006
Woodlands Grange
Woodlands Lane
Bradley Stoke
Bristol
BS32 4JY

Date: 26/09/2024

THE UROLOGY FOUNDATION

STATEMENT OF FINANCIAL ACTIVITIES
for the year ended 31 December 2023

	Note	Unrestricted Funds £	Restricted Funds £	Total 2023 £	Total 2022 £
INCOME					
Donations and legacies	1	140,195	1,244,242	1,384,437	1,318,353
Other trading activities	2	66,800	-	66,800	30,980
Investments	3	19,035	-	19,035	6,380
TOTAL INCOME		226,030	1,244,242	1,470,272	1,355,713
EXPENDITURE					
Raising Funds					
Donations and legacies	4	24,761	11,091	35,852	43,308
Trading activities	5	21,357	15,959	37,315	42,830
Investment management costs		78	-	78	74
Expenditure on Charitable activities					
Raising Awareness	6	82,382	54,753	137,135	141,011
Grant making	7	198,193	879,886	1,078,079	680,136
Net losses/(Gains) on investment assets	11	(289,471)	(362)	(289,833)	255,897
TOTAL EXPENDITURE		37,300	961,326	998,626	1,163,256
NET INCOME/(EXPENDITURE)		188,730	282,917	471,646	192,457
RECONCILIATION OF FUNDS					
Fund balances brought forward at 1 January 2023		2,084,597	555,744	2,640,341	2,447,884
Transfer between funds		(59,706)	59,706	-	-
FUND BALANCES CARRIED FORWARD AT 31 DECEMBER 2023		2,213,621	898,366	3,111,987	2,640,341

The net movement in funds for the year arises from the charity's continuing operations.

No separate statement of total changes in equity has been presented as all such gains and losses have been dealt with in the statement of financial activities.

The notes on pages 35 to 44 form part of these accounts

THE UROLOGY FOUNDATION

STATEMENT OF FINANCIAL ACTIVITIES
for the year ended 31 December 2022 (Full fund comparative)

	Note	Unrestricted Funds £	Restricted Funds £	Total 2022 £
INCOME				
Donations and legacies	1	1,016,881	301,472	1,318,353
Other trading activities	2	30,980	-	30,980
Investments	3	6,380	-	6,380
TOTAL INCOME		1,054,241	301,472	1,355,713
EXPENDITURE				
Raising Funds				
Donations and legacies	4	38,978	4,330	43,308
Trading activities	5	38,547	4,283	42,830
Investment management costs		74	-	74
Expenditure on Charitable activities				
Raising Awareness	6	126,910	14,101	141,011
Grant making	7	606,675	73,461	680,136
Net (Gains) on investment assets	11	255,577	320	255,897
NET INCOME/(EXPENDITURE)		1,066,761	96,495	1,163,256
NET (EXPENDITURE)		(12,520)	204,977	192,457
RECONCILIATION OF FUNDS				
Fund balances brought forward at 1 January 2022		2,097,116	350,768	2,447,884
Transfer between funds		-	-	-
FUND BALANCES CARRIED FORWARD AT 31 DECEMBER 2022		2,084,596	555,745	2,640,341

The net movement in funds for the year arises from the charity's continuing operations.

No separate statement of total changes in equity has been presented as all such gains and losses have been dealt with in the statement of financial activities.

The notes on pages 35 to 44 form part of these accounts

THE UROLOGY FOUNDATION

BALANCE SHEET
as at 31 December 2023 Company Number 06817868

	Note	2023 £	2022 £
FIXED ASSETS			
Tangible assets	10	3,895	2,719
Investments	11	3,453,644	3,407,104
		3,457,540	3,409,823
CURRENT ASSETS			
Debtors	12	440,181	413,449
Cash at bank and in hand		415,083	322,606
		855,263	736,055
LIABILITIES: amounts falling due within one year	13	966,337	1,102,738
NET CURRENT LIABILITIES		(111,073)	(366,683)
LIABILITIES: amounts falling due in more than one year	13	234,479	402,799
NET ASSETS		3,111,987	2,640,341
THE FUNDS OF THE CHARITY			
Restricted income funds	15		
Robotic Surgery Training Fund		106,448	160,170
Prostate Cancer Research Fund		208,149	137,269
Bladder Cancer Fund		344,862	184,851
Travel Fellowship Fund		0	648
Team Corbs - Testicular		7,313	7,311
Charles Reynolds		13,002	65,497
Thompson Family Charitable Trust		126,556	-
Innovation & Research Awards		85,197	-
Small Research Projects		0	-
Campaigns		0	-
Events		6,839	-
Total Restricted income funds		898,366	555,744
Unrestricted income funds	15		
General Fund		1,713,621	1,584,597
Designated Fund (British Urology Foundation)		500,000	500,000
TOTAL CHARITY FUNDS	16	3,111,987	2,640,341

These financial statements have been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small charitable companies and with the Financial Reporting Standard 102.

The financial statements on pages 25 to 28 were approved by the trustees and authorised for issue on 20 September 2024, and are signed on their behalf by

Mary Garthwaite
Mary Garthwaite (Sep 26, 2024 17:27 GMT+1)
..... **Chair**
Mary Garthwaite

Angela Daniel (Sep 26, 2024 21:58 GMT+2)
..... **Treasurer**
Angela Daniel

The notes on pages 35 to 44 form part of these accounts

THE UROLOGY FOUNDATION

STATEMENT OF CASHFLOWS
as at 31 December 2023

	Note	2023 £	2022 £
CASH FLOWS FROM OPERATING ACTIVITIES:	14		
Net cash used in operating activities		(162,921)	84,134
Cash flows from investing activities:			
Dividends and interest from investments		14,039	5,855
Management fees paid from investments		(78)	(72)
Purchase of equipment		(1,856)	0
Transfer from cash		-	-
Proceeds from sale of investments		551,126	150
Purchase of investments		(307,833)	(5,882)
Net cash used in investing activities:		255,399	51
Change in cash and cash equivalents in the reporting period		92,477	84,185
Cash equivalents at the beginning of the reporting period		322,605	238,420
Cash and cash equivalents at the end of the reporting period		415,083	322,605

The notes on pages 35 to 44 form part of these accounts

ACCOUNTING POLICIES

BASIS OF ACCOUNTING

The financial statements have been prepared under the historical cost convention with items recognised at cost or transaction value unless otherwise stated in the relevant notes to these accounts. The financial statements have been prepared in accordance with the Statement of Recommended Practice: Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) issued on 1 January 2019 and Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102) and Charities Act 2011. The trust constitutes a public benefit entity as defined by FRS 102.

INCOME

Grants, donations and other similar types of voluntary income are brought into account when it is probable that they will be received, except that donated income is included gross of any attributable tax recoverable, where relevant. Donations given for specific purposes are treated as restricted income. Tax recoverable is recognised when claims are submitted to HM Revenue and Customs. Legacy gifts are recognised in the period in which the Charity becomes entitled to receive the income.

Income receivable from activities for generating funds and from investment income is accounted for on an accruals basis. Deferred income represents revenues collected but not earned as of 31 December 2023. This is primarily composed of income collected in advance of a fundraising event taking place and deferred until the charity is entitled to that income as and when the event takes place.

EXPENDITURE

Resources expended are allocated to the costs of generating funds or to the charity's principal activity where the costs can be identified as being directly related. All other costs are categorised as either support costs or governance costs, and are allocated in proportions based upon a suitable ratio applicable to the nature of the cost involved.

Grants payable are recognised in full in the period in which the approved offer is conveyed to the recipient. Grants are recognised and deferred where there is a long term commitment for the Charity. Where grants are recognised and conditions for staged grant payments are not met in subsequent years, an adjustment to grants payable will be made in the relevant accounting period. Expenditure includes irrecoverable VAT which is reported as part of the expenditure to which it relates.

TANGIBLE FIXED ASSETS

All tangible assets purchased that have an expected useful economic life that exceeds one year are capitalised and classified as fixed assets. Tangible fixed assets are stated at historical cost less depreciation. Depreciation is provided on all tangible fixed assets at rates calculated to write each asset down to its estimated residual value evenly over its expected useful life, as follows:

Office equipment	25% reducing balance

OPERATING LEASES

Rentals under operating leases are charged to the Statement of financial activities on a straight line basis over the lease term.

ACCOUNTING POLICIES

INVESTMENTS

The charity's investments are included in the balance sheet at their market value. The gains or losses arising upon their annual revaluation are included in the statement of financial activities.

FUND ACCOUNTING

The general fund comprises the accumulated surpluses of unrestricted incoming resources over resources expended, which are available for use in the furtherance of the general objective of the charity.

Designated funds are a particular form of unrestricted funds consisting of amounts, which have been allocated or designated for specific purposes by the trustees. The use of designated funds remains at the discretion of the trustees.
Restricted funds are funds subject to specific conditions imposed by donors. The purpose and use of the restricted funds are set out in the notes to the accounts. Amounts unspent at the year-end are carried forward in the balance sheet.

FOREIGN EXCHANGE

Receipts and payments which occur in foreign currencies are included in the accounts at the amount into which they are converted in sterling, using the exchange rate on the day in which the transaction occurs.

GOING CONCERN

The Trustees as Directors of the Charity believe that there are no material uncertainties that may cast significant doubt about the ability of the Charity to continue as a going concern, due to the significant unrestricted reserves as at 31st December and the forecast income expected in 2024.

FINANCIAL INSTRUMENTS

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

		Unrestricted funds £	Restricted funds £	2023 £	2022 £
1.	**INCOME FROM DONATIONS AND LEGACIES**				
	Grants received from charitable trusts and corporate sponsors	28,985	1,219,242	1,248,227	929,835
	Donations	111,210	25,000	136,210	388,518
	Legacies	-	-	-	-
		140,195	1,244,242	1,384,437	1,318,353
2.	**INCOME FROM OTHER TRADING ACTIVITIES**				
	Income from fundraising events	66,800	-	66,800	30,980
3.	**INVESTMENT INCOME**				
	Bank interest receivable on short term cash deposits	4,996	-	4,996	525
	Income from investments listed on a recognised stock exchange:				
	UK investments	14,039	-	14,039	5,855
	Overseas investments	-	-	-	-
		19,035	-	19,035	6,380
4.	**COSTS OF RAISING FUNDS VOLUNTARY INCOME**				
	Direct costs	5,231	581	5,812	18,664
	Support costs (see note 8)	19,530	10,509	30,040	24,644
		24,761	11,091	35,852	43,308

		Unrestricted funds £	Restricted funds £	2023 £	2022 £
5.	**COSTS OF RAISING FUNDS TRADING ACTIVITIES**				
	Costs of fundraising events	1,826	5,449	7,276	18,186
	Support costs (see note 8)	19,530	10,509	30,040	24,644
		21,357	15,959	37,315	42,830
6.	**COSTS OF RAISING AWARENESS**				
	Costs of fundraising events	4,261	12,715	16,976	42,433
	Support costs (see note 8)	78,121	42,038	120,159	98,578
		82,382	54,753	137,135	141,011
7.	**GRANT MAKING**				
	Innovation & Research Awards	-	435,592	435,592	-
	iROC Bladder Cancer Trial	-	143,304	143,304	(2,342)
	David Thompson Fellowship	-	120,000	120,000	-
	Small Research Projects awarded to 6 (2022: 5) teams	-	55,759	55,759	38,914
	Robotic Centres of Training	-	18,938	18,938	(1,050)
	Research Scholarships awarded to 0 (2022: 5) individuals	-	(24,918)	(24,918)	369,082
	Urolink Fellowship	1,493	-	1,493	4,500
	BAUS	1,199	-	1,199	3,032
	Burst	9,996	-	9,996	-
	Keith Yeates medals awarded to 1 (2022: 5) individuals	1,415	-	1,415	10,000
	Travel Grants	2,943	647	3,591	500
	Other direct costs	26,001	-	26,001	-
	BAUN/TUF Nurse	6,100	-	6,100	(2,083)
	PPI in Research/patient engagement	-	-	-	39,203
	Patient Advocacy Research	-	-	-	(4,449)
	Awareness campaigns (WCW & UAM)	-	-	-	1,350
	Movement in present value of grant accruals	5,824	-	5,824	42,752
		54,971	749,321	804,292	499,409
	Salary costs		53,495	53,495	
	Support costs (see note 8)	143,222	77,069	220,291	180,727
		198,193	879,886	1,078,079	680,136

	Costs of generating voluntary income 7.5% £	Fundraising trading: Cost of goods sold 7.5% £	Awareness raising 30% £	Giving grants 55% £	2023 £	2022 £
8. SUPPORT AND GOVERNANCE COSTS (UNRESTRICTED)						
Staff costs (see note 9)	9,153	9,153	36,611	67,119	122,035	194,741
Other staff costs including recruitment	895	895	3,580	6,563	11,932	3,118
Committee and other staff welfare expenses	345	345	1,382	2,533	4,605	4,010
Other office costs	4,284	4,284	17,135	31,414	57,117	58,912
Audit fee	240	240	959	1,758	3,196	298
Accountancy and advisory services	1,030	1,030	4,121	7,556	13,738	10,518
Other costs	3,545	3,545	14,180	25,997	47,267	23,320
Depreciation-owned assets	38	38	154	282	513	816
	19,530	19,530	78,121	143,222	260,403	295,733

8. SUPPORT AND GOVERNANCE COSTS (RESTRICTED)						
Staff costs (see note 9)	2,989	2,989	11,955	21,918	39,851	21,638
Other staff costs including recruitment	292	292	1,169	2,143	3,896	347
Committee and other staff welfare expenses	113	113	451	827	1,504	445
Other office costs	5,531	5,531	22,123	40,558	73,742	6,546
Audit fee	78	78	313	574	1,044	32
Accountancy and advisory services	336	336	1,346	2,467	4,486	1,170
Other costs	1,158	1,158	4,631	8,489	15,435	2,590
Depreciation-owned assets	13	13	50	92	167	91
	10,509	10,509	42,038	77,069	140,126	32,859

9. STAFF COSTS

		2023	2022
		No.	No.
The average monthly number of persons employed by the charity (excluding trustees) during the period was, as follows:			
Office and administration		3.7	3.3
		£	£
Staff costs for the above persons:			
Staff	Wages and salaries	105,352	137,779
Staff	Social security costs	8,376	13,374
Key management personnel	Wages and salaries	92,700	59,655
Key management personnel	Social security costs	8,954	5,571
		215,382	216,379

One employee received total emoluments in excess of £60,000 per annum during the period ended 31 December 2023 (2022: 2). The total emoluments of these employees during the year were in the following ranges:

		2023	2022
£100,000 - £110,000	No.	1	0
£90,000 - £100,000	No.	0	1
£60,000 - £70,000	No.	0	1

The Charity considers its key management personnel comprise the Chief Executive, with remuneration as noted abov
In setting salary levels, The Urology Foundation follows the National Council for Voluntary Organisation's advice tha
charity's pay policy should be to offer fair pay to attract and keep appropriately-qualified staff to lead, manage, support and/or deliver the charity's aims. It also conducts online research of charity salaries and uses surveys to benchmark levels of pay. The Urology Foundation does not automatically award its staff with annual salary increase either incremental or cost of living.

No Director received any remuneration from the Company during the year (2022: £nil).
No trustee received any remuneration for services provided to the charity during the current or previous period.
Trustees expenses reimbursed in respect of Trustee's meetings and travel for the year ended 31st December 2023 amounted to £0 paid to no Trustees (2022 £0 paid to no Trustees).

10. TANGIBLE ASSETS

	Office Equipment £
Cost:	
1 January 2023	22,494
Additions	1,856
31 December 2023	24,350
Depreciation:	
1 January 2023	19,775
Charge for year	680
31 December 2023	20,455
Net book value:	
31 December 2023	3,895
31 December 2022	2,719

		2023 £	2022 £
11.	**INVESTMENTS**		
	Investments listed on a recognised stock exchange at market value:		
	1 January 2023	3,407,104	3,657,270
	Transfers from cash		
	Additions at cost	307,833	5,882
	Disposal proceeds	(551,126)	(150)
	Realised gains	3	29
	Unrealised (losses)/gains	289,830	(255,926)
	31 December 2023	3,453,644	3,407,104
	At the balance sheet date, the market value of the portfolio comprised:		
	UK investments	3,453,644	3,407,104
		3,453,644	3,407,104
	Fixed income securities	306,382	549,597
	Multi-Asset & Hybrid Instruments	3,147,262	2,857,508
		3,453,644	3,407,104

At the balance sheet date, the historical cost of the investments was £2,700,892 (2022: £2,944,132).
The following holdings had a value of >5% of the market value of the investments:

Name	Holding	Value £ 2023	Value £ 2022
Rothschild & Co WM SICAV-SIF Exbury Fund GBP		3,147,262	2,857,508
Pentairs QIAIF PLC - Vanda Fund Shs -F- USD Shs			-
InstitutionalCash SeriesPLC - BlackRock ICS Sterling Liquidity Fund		306,382	549,597

		2023 £	2022 £
12.	**DEBTORS**		
	Amounts falling due within one year:		
	Prepayments	18,978	14,086
	Accrued Income	421,203	399,363
		440,181	413,449

13. CREDITORS

	2023	2022
	£	£
Amounts falling due within one year:		
Deferred income	13,382	504
Trade creditors	150,500	-
General accruals	7,183	45,971
Grant accruals	795,272	1,049,953
Other creditors	-	6,310
	966,337	1,102,738
Deferred income b/fwd at 1 January 2023	504	
Amounts released in the year	(504)	
New amounts deferred in the year	13,382	
Deferred income c/fwd at 31 December 2023	13,382	

CREDITORS

	2023	2022
	£	£
Amounts falling due in more than one year:		
Grant accruals	234,479	402,799
	234,479	402,799

14. RECONCILIATION OF NET INCOME/(EXPENDITURE) TO NET CASHFLOW FROM OPERATING ACTIVITIES

Net Income/(expenditure) for the reporting period per the statement of financial activities	471,646	192,458
Adjustments for:		
Depreciation charges	680	907
Losses/(gains) on investments	(289,833)	255,897
Dividends and interest from investments	(14,039)	(5,855)
Management fees paid from investments	78	72
(Increase) in debtors	(26,732)	(314,726)
(Decrease) in creditors	(304,721)	(44,619)
Net cash used in operating activities	(162,921)	84,134

15. THE FUNDS OF THE CHARITY

	1 January 2023	Transfer	Income	Expenditure	Gains/(losses) on Investments	31 December 2023
	£	£	£	£	£	£
Restricted income funds:						
Robotic Surgery Training Fund	160,170	-	-	(53,765)	43	106,448
Prostate Cancer Research Fund	137,269	-	45,879	24,918	84	208,149
Bladder Cancer Fund	184,851	-	359,000	(199,128)	139	344,862
Travel Fellowship Fund	648	-	-	(648)	0	0
Team Corbs - Testicular	7,311	-	-	-	3	7,313
Charles Reynolds	65,497	(52,500)	-	-	5	13,002
Thompson Family Charitable Trust	-		300,000	(173,495)	51	126,556
Innovation & Research Awards	-	72,500	491,614	(478,951)	34	85,197
Small Research Projects	-	51,456	11,000	(62,456)	0	0
Campaigns	-	(11,750)	11,750		0	0
Events	-		25,000	(18,164)	3	6,839
	555,744	59,706	1,244,242	(961,689)	362	898,366
Unrestricted income funds:						
General Fund	1,584,597	(59,706)	226,030	(326,771)	289,471	1,713,621
Designated Fund (BUF)	500,000	-	-	-	-	500,000
	2,640,341	-	1,470,272	(1,288,460)	289,833	3,111,987

15. THE FUNDS OF THE CHARITY (Continued)

- The Trustees have designated the original 1995 start-up funding for the BUF of £500,000 as the Trustees feel strongly that The Foundation should seek to maintain reserves sufficient to continue to fund its objectives on a long term basis.
- The Robotic Surgery Training Fund was set up in 2009 following the receipt of restricted donation income from the British Urological Foundation and a generous private donation. The funds are mainly used to award grants towards robotically assisted surgery training, education, and research into robotic training techniques.
- Bladder Cancer Fund: Thanks to the generosity of the Champniss Foundation and the Champniss Charitable Trust, The Urology Foundation has been able to support a number of projects, including research projects tracking patients' fitness post cancer surgery and to predict complications arising during and post
- Prostate Cancer Research – Thanks to the support of the John Black Charitable Foundation, The Urology Foundation has been able to support a number of projects furthering our understanding of prostate cancer and its treatments. Two further research grants were awarded in 2023.
- Team Corbs: The Foundation started working with former England and Lions rugby champion, Alex Corbisiero, to raise funds for research into testicular cancer, following Alex's diagnosis. A Just Giving page has been set up and the charity will continue to fundraise with Alex.
- Charles Reynolds funds are put towards supporting a number of our research projects and to support education and training for urology nurses, in particular through nurse bursaries and travel grants.
- The Thompson Family Charitable Trust generously support our charitable aims and objectives, in particular support of research and training, and through funding the David Thompson Fellowships. 2023 was in the inaugural year of the Fellowships and four awards were made.
- Innovation & Research Awards. These are our key research awards, worth up to £60,000 per project to fund research and further our understanding into urological cancers and conditions.
- Small Research projects. These awards are primarily about studies that might improve patient pathways or treatment and care. Projects are worth £10,000 each.
- Campaigns – As part of the NHSE Cancer Programme's abdominal/urological "Help Us, Help You" symptoms awareness campaign and specifically the symptom "Blood in Pee", a series of community based events were delivered across London. Visitors worried about a "blood in pee" symptom were encouraged to visit their GP or seek an early intervention.
- Events – The Foundation was pleased to receive support towards the TUF Trek to Namibia.

16. ANALYSIS OF NET ASSETS BETWEEN FUNDS

	Fixed Assets £	Net Assets/(Liabilities) £	Total £
Restricted income funds:			
Robotic Surgery Training Fund	118,135	(11,687)	106,448
Prostate Cancer Research Fund	231,002	(22,853)	208,149
Bladder Cancer Fund	382,723	(37,862)	344,862
Travel Fellowship Fund	0	0	0
Team Corbs - Testicular	8,117	(804)	7,313
Charles Reynolds	14,429	(1,428)	13,002
Thompson Family Charitable Trust	140,450	(13,894)	126,556
Innovation & Research Awards	94,550	(9,354)	85,197
Small Research Projects	0	0	0
Campaigns	0	0	0
Events	7,590	(751)	6,839
Unrestricted income funds:			
General Fund	1,901,754	(188,133)	1,713,621
Designated Fund (British Urology Foundation)	554,893	(54,893)	500,000
NET ASSETS	3,453,644	(341,658)	3,111,987

17. ULTIMATE CONTROLLING PARTY

The Charity is controlled by the board of Trustees.

18. COMMITMENTS UNDER OPERATING LEASES

As at 31st December 2023, the Charity had annualised operating commitments under non-cancellable operating leases expiring as follows:

	2023 £	2022 £
Expiring within one year		
- Land and Buildings	12,500	10,937
- Others	-	-
	12,500	10,937
Expiring within two to five years		
- Land and Buildings	-	12,500
- Others	-	-
	-	12,500

19. CONTINGENT ASSETS

There were no contingent assets as at 31 December 2023.

20. RELATED PARTY TRANSACTIONS

During the year, travel expenses amounting to £2,257 were reimbursed to the Trustees. Donations of £240 were received from the Trustees. No further transactions were undertaken such as are required to be disclosed under FRS 102 or the Charities Act.

THE UROLOGY FOUNDATION

England & Wales - Charity number 1128683

Accounts

THE UROLOGY FOUNDATION

TRUSTEES' ANNUAL REPORT & FINANCIAL STATEMENTS
DECEMBER 2022



Contents

Statement from the Chair 3
Overview of the year 3
Statement from the Chief Executive, Rebecca Porta 4
Objectives and Activities 5
Our Vision and Mission 5
Our Aims 5
Our Values 5
What we do 5
Public Benefit 6
Grants policy 6
Achievements and Performance in 2022 7
1. Our Research Programme 7
2. Improving knowledge and skills through education and training 9
3. Improving public awareness of urological conditions and symptoms 11
4. Collaborations and partnerships 12
5. Plans for the future 12
Financial Review 13
Financial Results of Activities & Events 13
Fundraising 13
Reserves & Liquidity Policy 14
Statement of going concern 14
Investments Policy 14
Remuneration policy 15
Pensions policy 15
Equal opportunities and diversity policy 15
Principal risks and uncertainties 15
Structure, Governance & Management 17
Charity Governance Code 17
Trustee Recruitment, Training and Induction 17
Appointment & Election 17
Relationships with Related Parties 18
Representation on Other Bodies 18
Reference and administrative details 19
Trustees 19
Registered Office 19
Auditors 19
Trustees' & Directors' Responsibilities in the Preparation of Financial Statements 20
Auditor 20
Statement as to disclosure of information to the auditor 20

Statement from the Chair

Overview of the year

Welcome to our Annual Report for 2022.

As the UK's only charity representing the entire spectrum of urology health and disease, from the urological cancers - prostate, kidney, bladder and male reproductive cancers - to non-malignant conditions including incontinence, urinary tract infections and kidney stones, we are incredibly proud of our commitment to ensuring patients and their families experience improved outcomes and live longer, with a better quality of life.

1 in 2 people will suffer from a urological disease or condition in their lifetime. This health burden is already having a significant impact on the mental, emotional, social and physical well-being of millions of men, women and children in the UK and this figure continues to rise. We are committed to improving outcomes, ending suffering and saving lives through investment in world class research, technical skills training, development and adoption of innovative technologies and practices, education programmes, raising public awareness and campaigning for policy improvement.

This has been an exceptionally busy year for the Foundation. We awarded seven new Research and Innovation Projects and four Small Project Grants covering kidney, bladder, penile and prostate cancers, urinary tract infections, female reconstructive surgery and recovery after paediatric urology surgery. These projects take us one step closer to making a significant step change in the delivery of urological care and to changing the lives of current and future generations of patients.

Alongside research we invested in our scientific and medical communities through training and career development opportunities; supporting urology colleagues and encouraging the "rising stars" in the field. In particular, our Travel Fellowships enabled trainee urologists to further their own development, experience new horizons in urological care and to undertake teaching opportunities across the globe. Our "Power of Successful Communication" course brought together nursing professionals to explore ways in which to enhance their public speaking skills and facilitate successful communication with colleagues, patients and their families.

Awareness of urology falls far behind other health and disease areas and we remain committed to ensuring these cancers and conditions receive the recognition they deserve. We work to challenge taboos and stigmas and raise awareness of potential warning signs and symptoms, as early diagnosis can have a significant impact on outcomes. Throughout the year we were involved in campaigns and awareness events, presented at conferences and teaching days, met with decision makers and influencers and worked with a wide range of stakeholders to raise awareness of urological cancers and conditions and drive improvements in patient care. Highlights included the annual Urology Awareness Month, a Parliamentary Reception highlighting the importance of patient choice and an Early Day Motion for MPs.

Working with the UK's leading scientists, clinicians, nurses and allied health professionals, influencers and decision makers, charity partners, supporters, patients and their families, we are proud of the progress we have made and the success we have achieved this year.

Building on these achievements, we are excited to be setting out our goals for the future and will launch our new three-year strategy 'The Way Ahead 2023-2025' next year. Ensuring patients and their families have better outcomes, live longer and with a better quality of life remains at the heart of our work.

M. Garthwaite

Mary Garthwaite, Chair

Statement from the Chief Executive, Rebecca Porta

I was delighted to join the Urology Foundation as its Chief Executive at the beginning of 2022.

My involvement with The Urology Foundation first began in 2009 and over the years I've had the privilege of working closely with the Trustees, staff and supporters. I have seen the impact of the Foundation's work and the difference it has made to the lives of patients and their families.

This is the start of an important and exciting journey. Building on our knowledge, expertise and achievements we have an opportunity to make a significant step change in urology. With the support of our stakeholders – the scientific and clinical community, nurses and allied health professionals, patients and their families, volunteers, decision makers and influencers, charity partners and of course our incredible supporters - we can and will improve the outlook for people affected by urological cancers and conditions ensuring they have better outcomes and a better quality of life.

During the year we took the opportunity to consult with our stakeholders to identify priorities for the future. Investment in world class research, supporting our clinical and scientific community and the next generation of researchers, training and education programmes, driving and improving standards of care and raising awareness were key issues and we look forward to taking these forward as part of our new strategy, The Way Ahead 2023-2025.

People diagnosed and living with urological cancers and conditions need information, support and interventions that will help them. It is essential that we listen to their needs, work collaboratively and adaptably, across and between professional boundaries, share competencies and knowledge, campaign for research investment and remain committed to making a change. Together we can ensure that patients and their families have better outcomes, live longer, and with a better quality of life.

I hope that you will join me in this important and exciting journey.



Chief Executive

Objectives and Activities

The Urology Foundation's objects are to:

"Advance, promote, encourage, develop and improve the study and knowledge of urology, urological surgery and the general knowledge of science and medicine and all matters relating to the progress and development of that branch of science and medicine and for that purpose to fund, aid, maintain and endow scholarships, fellowships, chairs and bursaries and generally to assist in the funding, instruction and support of persons and institutions engaged or involved in urological research work."

Our Vision and Mission

We see a world where people will not die early from urological cancers and conditions and where people with bladder, kidney and prostate problems can still lead full, active and productive lives.

Our mission is to improve survival and quality of life for urology patients through research and training, so patients receive the best possible treatment and care and fewer lives are devastated.

Our Aims

The Urology Foundation is committed to reducing the suffering caused by urological diseases. We work with researchers, urology and health care professionals to improve the diagnosis, treatment and management of urological disease and the nation's urology care.

We rely on donations from individuals, trusts and foundations, and from companies to help fund our work. The money we raise is invested directly into research to find better treatments and cures, and in training for urology professionals to improve care for and help people affected by urology conditions.

The Foundation is governed by the rules and regulations set down in its company memorandum and articles of association originally dated 12 February 2009 and last updated by a special resolution on 29 June 2009.

Our Values

In undertaking our remit we are:

- *Ambitious* to see UK urology care, treatment and practice is the best in the world.
- *Dedicated* to beating all urology diseases through research and training.
- *Proud* of working in urology and committed to transforming the lives of people with a urology condition.
- *Collaborative*; working with researchers, urologists, nurses and health care professionals, influencers and decision makers, charity partners, patients and their families we are improving the nation's urology care.

What we do

We seek to improve patient treatment and care through investing in world class research, education and training programmes, raising awareness and driving change in policy. We fund research that increases our understanding of urological cancers and conditions and that can bring about change in urology practice and guidelines for the benefit of patients and their families. We are also looking for ways that can make treatments more effective and kinder. We are driving improvement in standards in urology practice through training and we are developing the next generation of urological experts who can meet the challenge of the increased burden of disease and who put excellence of care at their core.

Awareness campaigns such as Urology Awareness Month in September bring urological cancers and conditions to the public eye, breaking the stigma and taboos associated with these diseases and

conditions and encouraging people to seek an early diagnosis where they may be concerned about potential early warning signs and symptoms.

Public Benefit

The Trustees have taken The Charity Commission's general guidance on public benefit into consideration in preparing their statements on public benefit contained within this trustees' annual report. In accordance with its charitable objectives, The Foundation gives grants to individuals and not-for-profit organisations to:

- Promote the study of urological cancers and conditions by supporting and carrying out research into the causes, prevention, diagnosis and method of treatment of this disease and by publishing the useful results of such research;
- Provide opportunities for training and education of health professionals working in urology, in order to advance practice and improve patient treatment and care;
- Such other purposes for the benefit of the community as shall be exclusively charitable as the trustees from time to time shall decide.

In addition, the charity provides information on its website on urological cancers and conditions, and raises awareness through social media channels and media such as press and radio.

Grants policy

The Foundation advertises its programmes and awards on its website and via social media, through its professional e-newsletter and networks. Applications for research are assessed by an independent Scientific and Education Committee (SEC) and Review Panel.

The charity is a member of the Association of Medical Research Charities (AMRC) and abides by its standards and guidelines for peer review and funding. It is also a National Institute for Health Research (NIHR) Non-commercial Partner. Research studies funded through our NIHR approved funding streams are automatically eligible for consideration for NIHR Clinical Research Network (CRN) support subject to meeting the standard study eligibility criteria.

Achievements and Performance in 2022

1. Our Research Programme

Research plays a key role in helping us all live longer, healthier lives and no more so than for people with urological cancers and conditions.

Innovation & Research Awards

Following on from the launch of our Innovation & Research Award in 2021, which attracted a high number of applications from across the UK and a wide range of urological cancers and conditions, it was good to see applications to this fund increase by 20% in 2022. The Innovation & Research Award funds projects up to a value of £60,000 that seek to use new, exciting, innovative approaches to address urological diseases and disorders. The projects must either (a) aim to create innovative treatments or devices, (b) aim to deliver innovative care pathways or (c) aim to use innovative research techniques or methods.

We are pleased to report that seven awards totalling £375,096 were made in 2022. This was a significant increase on the previous year when five awards totalling £296,594 were made.

Seven projects were selected for funding:

Bladder and Kidney cancers: Bladder cancer (BC) and kidney cancer (KC) are the second and third most common urology cancers. Worldwide, 375,000 patients die each year from these cancers and survival for patients with these advanced cancers has not significantly improved since the 1980s, largely because many of the drugs don't work because of the specific genetic make-up of the tumours. This project aims to improve the choice and personalisation of treatments for patients with BC and KC by analysing the individual patient's tumour responses to the drugs that work, while highlighting ineffective treatments so that they can be avoided. This will reduce the number of patients undergoing lengthy, toxic and expensive treatments that do not control the spread of their cancer. It will also speed up testing of new, effective treatments for these cancers - initial data suggests that a new treatment can be identified in over 50% of patient tumours tested.

Urinary Tract Infections (UTIs): UTIs are the most common outpatient infection, with post menopausal women being disproportionately affected, often with recurring infections. As the current standard treatment for UTIs is antibiotics, and antimicrobial resistance is becoming ever more common, it is imperative to find alternative means of treating UTIs. This project is a feasibility study into the use of intravaginal laser therapy for treating recurrent UTIs and to examine its effectiveness. We are grateful to the Champniss Foundation for generously supporting this project.

Penile cancer: Penile cancer is a rare disease. Cancer that is confined to the penis can be managed with surgical removal, and the survival outcome is good. However, survival is reduced significantly if the cancer has spread around the body. Unfortunately, the response to chemotherapy is not good. Currently, there are no markers that help predict disease progression or chemotherapy response. This project aims to identify and evaluate blood markers to help predict disease progression and chemotherapy response. It hopes to develop biomarkers allowing a more stratified and personalised approach to treatment.

Kidney cancer: A number of inherited conditions cause increased risk of developing kidney cancer and affected individuals are offered medical surveillance to identify cancers at an earlier, more treatable stage. Despite this, cancers can still present at a more advanced stage and surveillance (e.g. scans) are intensive and costly, so other techniques may also be useful. This project aims to identify cell 'markers' in urine that indicate whether renal cancer is present, for the purpose of early detection, in individuals with a genetic predisposition to that cancer type who have to be monitored

on a frequent basis. This could lead to a safer and less invasive surveillance regime that would also save the NHS money.

Posterior urethral valves (PUV): PUV disease is a rare, congenital condition affecting a boy's development in the womb that can lead to kidney failure and either a lifetime of transplants or early mortality. Because of its rarity it is extremely under researched and, as far as The Urology Foundation is aware, we are the only organisation funding research into understanding the causes of this disease with a view to providing prevention or cure, most other research has focused on treatment. Finding a new therapy to reduce kidney damage in PUV is desperately needed. This project will use new technology to read thousands of genes in every cell to make a cellular atlas of normal and PUV bladders. This will help to identify molecular changes and cellular interactions which drive scarring in PUV. This information will help understanding of the biology of PUV and refine new treatments for this condition. We are grateful to the Miskins for part funding this project.

Prostate cancer surgery: The most common complications of prostate cancer surgery include some cancer left behind, urinary incontinence and erectile dysfunction. A recent pilot study done on a cohort of 10 patients showed a reduction of cancer left behind from 35% to 10% after allowing surgeons to manipulate a physical representation of the patient's prostate during surgery. This is a feasibility study of the effect 3D printed and virtual prostate models have on surgical outcomes after robotic-assisted radical prostatectomy. However, in preparation for a larger randomised control trial, it is necessary to investigate how accurate an automated tool for delineating prostate anatomy could be and what the effect a 3D printed/virtual models available to the surgeon is on the reduction of outcomes. We are grateful to the John Black Charitable Foundation for generously supporting this project.

Prostate cancer: MRI is the primary test for suspected prostate cancer. This often requires multiple visits for MRI, results and biopsies. Novel portable MRI technology has the potential to reduce these to one visit with live MRI-guided needle deployment. This project is a feasibility study to assess this new technology in the prostate cancer diagnostic pathway. If successful, the technology could lead to the following improvements in the diagnostic pathway: 1) Reduced time from referral to diagnostic MRI; 2) More accurate targeting of lesions based on MRI rather than ultrasound image-fusion; 3) Development of future prostate cancer screening programmes to utilise portable MRI.

Smaller Research Projects Fund

The Smaller Research Projects fund is focussed on improving treatment and care and supports projects up to the value of £10,000. The Fund is aimed at projects that can be delivered quickly (within 2 years) and are focused on supporting vital research that seeks to improve the quality of clinical services and patient treatment and care. In 2022 there was a variety of high quality applications. Four awards were made for the following projects:

- A study into the use of stents to treat long-term ureteric obstruction, with a view to improving quality of life, preservation of renal function and cost-effectiveness.
- A study into the role of biopsy in kidney tumour management and improvement of patient information aids.
- A study on whether reconstructive surgery should be integrated into specialist care for survivors of Female Genital Mutilation.
- A project to develop Enhanced Recovery After Surgery (ERAS) protocols for children undergoing urological operations. (ERAS) aims to shorten post-operative recovery through early mobilisation, rationalisation of medications and addressing patient motivation.

The TUF Trials Unit

In 2020 the TUF Trials Unit (TTU) launched in partnership with The Centre for Healthcare Randomised Trials (CHaRT) at the University of Aberdeen. The unit is led by Professor Graeme MacLennan, a

medical statistician and Professor James N'Dow, a consultant urologist. The role of the TTU is to identify promising and important research ideas from urology units and provide a team of medical investigators to bring those ideas to fruition. This approach enables more high-quality urology trials to take place, leading to better care, quicker recovery times and fewer long-term issues. Successful trials are catalysts for change, provide potential for transformational discoveries and drive improvements in treatment and care.

During the year the TTU continued to encourage more research ideas from the urology community. There are three urological trials supported by the TTU, comparing the efficacy of treatment and surgery techniques in kidney cancer, bladder cancer and evaluating robotic surgery in the NHS. There are a further 11 research trial ideas being nursed through the development process.

iROC Study

A highlight of the year was the outcome of a unique, three year research study, conducted by University College London and the University of Sheffield, which discovered that patients having robot-assisted bladder cancer surgery recovered faster and returned home sooner than patients who had open surgery. Robotic surgery reduced the chance of readmission by half (52%), and led to a 77% reduction in the prevalence of blood clots, when compared with patients who had open surgery. The study was supported by a grant from The Urology Foundation and The Champniss Foundation and generated extensive media interest.

Patient and Public Involvement (PPI) Programme

Individuals with experience of living with a disease or condition, or having significant others with a disease or condition, can bring substantial benefit and insight to charities. More and more charities are actively incorporating their experiences into conversations about the design of services, awareness programmes and medical research. During the year the charity took the decision to develop a Patient and Public Involvement (PPI) programme. The Programme will play a key role in acting as a bridge between the research community and people affected by urological cancers and conditions. The aim is to launch the Programme in 2023 supported by a PPI Development Board.

2. Improving knowledge and skills through education and training

Support for urology trainees

The TUF/Urolink Fellowships are open to those senior level trainees who have completed their FRCS (Urol) and it is expected that the successful applicants will accompany established workshop teams in the first instance, and stay to work in that centre (or those centres) for an unspecified time after the workshop team's departure. In 2022 two awards were made:

- Simon Huf of Royal Berkshire Hospital. Simon visited Kisiizi Hospital in Uganda to help provide bladder surgery.
- Matthew Trail of Western General Hospital, Edinburgh. Matthew intends to travel to the Kilimanjaro Christian Medical Centre, Tanzania, in 2023.

The Keith Yeates Medal/Ralph Shackman prize is only conferred when candidates achieve over 90% in their Intercollegiate Specialty Examination in Urology. In 2023 a record five candidates were successful and each receive a travelling fellowship worth £2,000:

- Craig Jones of Salford Royal and Christie NHS Hospitals
- Flora Rodger of Monklands Hospital, Airdrie
- Joshua Hemmant, Liverpool University Hospitals
- Neha Sirha, Guy's and St Thomas' NHS Trust
- Ross Warner, Leicester University Hospitals

Malcolm Coptcoat Travelling Fellowship

The Malcolm Coptcoat Trust (MCT) and The Urology Foundation share a commitment to fostering the professional development of urologists and urology nurses, to promoting the highest standards in care and best practice and to investing in new, innovative technologies and techniques to improve patient outcomes. Following the incorporation of the MCT into The Urology Foundation, we are pleased to announce the launch of the Malcolm Coptcoat Travelling Fellowship. The Fellowship, worth £5,000, will enable trainees to travel to international centres of excellence for a period of four to six weeks to gain invaluable experience and skills in urology care and best practice. Successful candidates will become outstanding surgical leaders in their field, through the acquisition of new skills and knowledge, and will make an important contribution to the advancement of science and practice, thereby ensuring better outcomes for patients. They will also act as ambassadors promoting best practice and sharing knowledge from their own community and country.

"Unlocking Potential - the Power of Successful Communication" course

In May we ran our first course specifically for urology nurses focused on developing communication and influencing skills. "Unlocking Potential - the Power of Successful Communication" originated from successful courses previously held for urology specialist registrars and consultants. Delegates worked with professional trainer Alex Turk and past Presidents of the British Association of Urological Nurses (BAUN), Julia Taylor and Clare Waymont, on an interactive agenda covering areas such as the importance and impact of communication, judging tone, pace and language, clear messaging, presenting skills and how to communicate a message successfully. We are grateful to Peak Medical who made this course possible with an unconditional education grant.

Continence Care

In November the Charity's Chief Executive chaired a Roundtable event of continence care experts. The event was an opportunity to discuss challenges in continence care, share examples of best practice and identify key changes required to ensure high quality overactive bladder (OAB) and continence care across the four nations. We were also awarded a grant to undertake a survey to understand the current landscape of bladder health and specifically continence care in primary and secondary care settings. The survey launched at the end of November targeting continence care teams, urology nurses and a network of healthcare professionals with an interest in continence care. We are grateful to Astellas Pharma for their support with this project.

Training

As part of our commitment to training and supporting our urology community, and those with an interest in urological cancers and conditions, the charity delivered training sessions throughout the year on a range of topics. Highlights included sessions on catheter related UTIs at the Knowlex Infection, Prevention and Control (IPC) Conference in Birmingham, the Northamptonshire Healthcare Foundation Trust IPC Week Conference and the South East Region's IPC Week.

We were delighted to attend the British Association of Urological Surgeons (BAUS) Annual Conference in Birmingham and the BAUN Annual Conference in Edinburgh. Both events provided the opportunity

to meet with colleagues and industry. The Foundation's Chair, Mary Garthwaite, presented a session on UTIs at the BAUN Conference.

3. Improving public awareness of urological conditions and symptoms

The Urology Foundation is committed to improving public awareness of urological cancers and conditions, to promoting research progress and highlighting research developments, to commenting on topical issues and sharing patient experience.

In May we were pleased to host a Parliamentary Reception "Working together to support innovation in the MedTech sector" with the Urology Trade Association (UTA) at the House of Commons. Over 70 patients, scientists and clinicians, policy makers, charity partners and industry attended the event. A pledge on protecting and promoting patient choice was launched at the Reception and will form the basis for further discussions going forward.

We once again partnered with TalkHealth, an online health website, to provide information blogs and expert-led information forums about urological health matters to members of the public, and to provide articles for supplements in national newspapers. The "Ask the Experts" sessions included "Phimosis", with Consultant Urological Surgeon Vaibhav Modgil, and "Erectile Dysfunction", with Consultant Urological Surgeon and Andrologist Mr Hussein Alnajjar.

Throughout the year we took part and supported a number of campaigns including World Cancer Day, Bladder Cancer Awareness Month, World Kidney Day, Testicular Cancer Month and World Continence Week. The annual Urology Awareness Month (UAM) in September was one of our busiest campaigns ever. Activities included:

- An independent survey was commissioned to gain insight into awareness of urological diseases with a particular focus on erectile dysfunction, Urinary Tract Infections (UTIs) and kidney stones. Over 2000 people took part in the online survey. A PR agency, *Emotive* was engaged to support the campaign. A series of assets for social media were developed to accompany the results.
- A new video for healthcare professionals was launched which examined communication and patient engagement ie what works and why, making a lasting impact, how patients listen and remember and how to strike the right balance of information and understanding. The video - released in three parts - featured TV presenter and communications coach, Alex Turk.
- The Smaller Research Projects grant round opened. Grants are available for projects which can be delivered within 2 years and seek to improve the quality of clinical services and patient treatments and care.
- Supporters were invited to produce a short video message of support or to share a photo on their social media platforms and networks.
- New posters were produced to complement existing educational materials and information events took place at sites across the UK.
- A "Lunch and Learn" session on Men's Health with our corporate partner, Peppy Health took place on the 29 September. This was a virtual event attended by clients of Peppy Health.
- A Urology Awareness Month Early Day Motion (EDM) was tabled. It attracted 24 signatures (the average EDM attracts 2-3).

Many of our supporters took part in fundraising events during UAM. Twenty "Tuffers" took part in the Cycle Italy to Slovenia which raised over £62,000, a team of family and friends took part in the Reigate Run raising over £460 and runner Simon Bailey ran in the Berlin Marathon and London Marathon raising an incredible £10,000 in memory of his friend. A highlight of the Month was the Charity Golf Day at the Royal St George's Golf Club on the 30 September. Organised by Club Captain Christopher Kemp and his team of helpers, the event raised over £80,000.

Our social media profile continues to grow with Facebook and Instagram popular among the general public and Twitter and Linked-In with a higher numbers of urology professionals engaging.

Sincere thanks to everyone who promoted and supported this important campaign.

4. Collaborations and partnerships

We value the importance of working with other organisations to achieve our aims.

During the year we became a member of Cancer52. Cancer52 provides a collaborative voice for rare and less common cancers. Rare and less common cancers account for more than half of all cancer deaths in the UK and are severely under represented and underfunded across all areas, including research and policy. Cancer52 campaigns to raise awareness and improve outcomes of these cancers. Cancer52 represents over 100 charities.

We also became a member of the Charities Research Involvement Group. The group of over 40 charities join together to share experience and best practice for patient, carer and public involvement (PPI) in research. The group works together to develop resources, policies and tools to support researchers and people affected by a range of health conditions. Members include Cancer Research UK, Alzheimer's Society, Stroke Association, Macmillan Cancer Support, British Heart Foundation, Alzheimer's Research UK, Asthma & Lung UK, Muscular Dystrophy UK, Brain Tumour Research and Versus Arthritis.

Our staff engaged with a range of organisations and charity partners working in the area of urology. These included BAUS, BAUN, Urology Trade Association, Prostate Cancer UK, Prostate Research UK, Fight Bladder Cancer, Action Bladder Cancer, Kidney Cancer UK and UCare. We value our close relationships and look forward to working together going forward.

The Association of Medical Research Charities (AMRC) is a membership organisation dedicated to supporting medical research charities in saving and improving lives through research and innovation. They bring together and support health and medical charities to produce high-quality research through influencing policy and research and highlighting the sector's contribution to patient and public health. Membership of the AMRC also invokes a high quality control of our peer review processes. We value our membership of the AMRC and the ongoing support of their team.

During the year we welcomed the opportunity to meet and work with a range of companies including Peppy Health, Intuitive Health, Boston Scientific, Pfizer UK, Peak Medical Ltd, Astellas Pharma, Bayer, Lloyds Pharmacy Online Doctor, Coloplast and Convatec to promote awareness of urology health. We look forward to developing our partnerships in the year ahead.

5. Plans for the future

Building on our achievements, informed by the knowledge and expertise of a range of stakeholders, and taking into consideration opportunities and the external environment, we will launch our new strategy "The Way Ahead 2023-2025" early next year. It is a bold and ambitious vision encompassing eight priorities:


Priority 1. Significantly accelerate the progress of urological research
Priority 2. Invest in our scientific and medical communities
Priority 3. Facilitate collaborations and partnerships
Priority 4. Drive change as a result of research outcomes
Priority 5. Campaign for further investment in research
Priority 6. Place people affected by urological disease at the heart of research

Priority 7: Give a voice to the people affected by or at risk of urological disease
Priority 8: Transforming The Urology Foundation.

Next year will also see the launch or our three year research strategy. We will engage with a wider range of stakeholders to identify the key priorities in research.

Financial Review

Financial Results of Activities & Events



The total value of net assets held by The Urology Foundation on 31 December 2022 was £2,640,341 (2021 £2,447,884). The Foundation's fundraising activities and other initiatives during the course of 2022 generated a total of £1,318,353 of voluntary income (2021 £686,522) and a further £30,980 (2021 £83,389) from specific fundraising event income.

Fundraising

The Foundation is reliant on voluntary income to fulfil its remit. During the year a review of the charity's fundraising function was undertaken and a recommendation made to diversify the existing income streams and to invest in additional fundraising support. This saw the appointment of a Business Development Manager and Trust and Foundations Manager, an extended events programme for 2023 and a new campaign with Goodwill Partnership as part of our legacy programme.

We are pleased to report income for year totalled £1,355,713 against the previous year total of £810,931, with strong performance across all areas, reflecting new activities and donations from a wide range of supporters. The following information summarises the various disciplines:

- Donations. Income from donations totalled £703,518.
- Business Community. We were pleased to welcome new partnerships including Peppy Healthcare, Lloyds Pharmacy online, Astellas Pharma and Coloplast.
- Grants: Trusts and Foundations income from a range of both small and large trusts and foundations totalled £614,836 and included grants towards research, awareness, community based projects, education and training.
- Events. As charities slowly began to emerge from the impact of the pandemic, we are pleased to report that supporters organised and took part in a wide range of events. These included Ottilie Quince's London Square OQ Vuelta A Casa challenge, the annual Bike4TUF cycle, a Charity Golf Day at the Royal St George's Golf Club, the Italy to Slovenia Cycle, the

Reigate Run, Berlin and London Marathon. We are grateful to everyone who undertook various fundraising challenges for the charity.

We recognise the importance of listening to and putting supporters at the centre of everything that we do. In taking this approach, we are registered with the Fundraising Regulator and adhere to the code of fundraising when carrying out our activities. Our staff are committed to following codes of good practice and standards developed by the fundraising community through the work of the Chartered Institute of Fundraising (IoF) and other professional bodies. The Foundation operates a clear and stringent complaints handling procedure that is reported to the Senior Management team and the Board. As part of our supporter care programme, we have agreed policies and procedures in place and written agreements with external agencies that we engage to help us or who raise funds for the charity. We ensure that anyone engaged to work for us is trained in and respects our aims and objectives and carries out their activities with the same high standards and care we would ourselves. During the year we received less than five complaints in relation to our fundraising activities. We remain committed to improving our practice and learning from supporter feedback.

Reserves & Liquidity Policy

The Foundation currently has 'free reserves' of £2,084,596 (31 December 2021: £2,097,116).

The Foundation's policy is to maintain reserves sufficient to continue to fund its objectives on a long term basis, and to ensure that the charity operates with an adequate level of liquidity to (i) minimise the risk associated with a temporary or unforeseen shortfall in liquidity; (ii) manage its cash and investments to meet its liabilities and remain a going concern for at least 1 year in the event of an unplanned drop in income. Liquidity is defined as cash and the investment portfolio held as unrestricted funds. The Policy establishes a minimum liquidity target of £500,000 ("Minimum Required Reserve") subject to future modification by the Finance Committee and Trustees' approval.

The Trustees consider that reserves held in excess of the amounts required to fund all future commitments together with the initial fund of £500,000, will be available to increase its visibility and expand its operations including funding for further research and a wider range of projects.

The Trustees plan levels of expenditure from unrestricted and restricted funds for the year ahead based upon the level of incoming resources for the current year as well as utilising restricted funds.

Statement of going concern

The Foundation's unrestricted net funds generated in 2022 are judged to be sufficient to meet the requirements of the charity for charitable giving in the coming year.

Investments Policy

The Foundation's investments are managed by Rothschild Bank (CI) Limited. The Treasurer and the Chief Executive are responsible for managing the relationship with Rothschild but changes in investment strategy are subject to approval by the board of trustees. The investment manager is asked to attend at least one board meeting annually.

The board follows a medium risk 'Balanced' investment strategy which is intended to achieve steady growth over the long term through a diversified approach to investment. Capital preservation in real terms over a long term horizon is the primary objective and some volatility is acceptable in order to achieve this. The charity's investments are held in the Exbury Fund, an ethical portfolio managed by Rothschild. The fund achieved near 15% returns over 2020 and 2021 but reported a decrease in value of 6.8% over the 12 months up to and including December 2022.

All other Foundation funds are held in accounts with the charity's bankers, National Westminster Bank plc.

Remuneration policy

In setting salary levels, The Urology Foundation follows the National Council for Voluntary Organisation's guidance that a charity's pay policy should be to offer fair pay to attract and keep appropriately-qualified staff to lead, manage, support and/or deliver the charity's aims. It also conducts online research of charity salaries and uses surveys to benchmark levels of pay. The Urology Foundation does not automatically award its staff with annual salary increases, either incremental or cost of living.

Pensions policy

The charity offers a stakeholder pension, operated by The People's Pension (B&CE Holdings), in line with statutory requirements. All new staff are automatically enrolled but can opt out if desired.

Equal opportunities and diversity policy

The charity is committed to being an Equal Opportunities employer and to respecting diversity, and is determined to ensure that no job applicant, employee, or Trustee receives less favourable treatment on the grounds of their age, disability, gender identity, marriage and civil partnership, pregnancy or maternity, race, religion or belief, sex or sexual orientation. The charity also seeks to ensure that its employees are not victimised or subjected to harassment.

The policy applies to recruitment and selection for jobs in the Foundation, career development and training, promotion, performance management, pay, redundancy, disciplinary and grievance procedures, the application of terms and conditions of employment and any other aspects of employment with the Foundation.

The policy also applies to third parties such as Trustees and committee volunteers, clients (ie grant applicants) and suppliers.

Principal risks and uncertainties

The Trustees take the management of risks seriously. The Chair of the Board of Trustees and the Chief Executive are charged with responsibility to ensure that the risks which have been identified are adequately assessed and properly mitigated on a regular basis. The potential risks have been discussed with the Chairman and the charity and a formal risk register is kept and brought before the Board on at least an annual basis.

Impact of Covid-19 and war in Ukraine

The pandemic continued to affect the urology workforce, which meant that applications to, and take up of, our travel and fellowship awards were lower than expected. Looking forward, the ongoing war in Ukraine has broader economic implications, some of which will be reflected in our investment fund holdings. Our Investment Manager keeps us regularly updated and there is no immediate cause for concern or action.

Risks to Data

The charity takes its responsibilities for data very seriously. We follow a Data Protection policy based on the GDPR and have a nominated Trustee (Mr Adrian Joyce) who has Board oversight for data compliance. We use a professional data base provider that stores all information in the cloud and this is secured using a two-step password verification. We review our records on an ongoing basis and delete old or historical records that are no longer relevant, and remove people who no longer wish to hear from us (provided that there is no financial information that we need to retain).

Other key risks are assessed as follows:

Governance /Environmental	Impact of the external environment on fundraising, in particular: public confidence in charities; new fundraising regulations; Data Protection Regulations.

Income Sources	TUF is wholly reliant upon voluntary income as an annual source of funding. It is the role of the Trustees to manage risk exposure on fundraising activities and in doing so to accept an appropriate level of risk in order to raise income from a wide range of sources.
Risk of data breach	The charity uses a professional database provider that stores all information in the cloud and this is secured using a two-step password verification. The charity's own day to day working documents are also stored on a cloud-based system. TUF staff are regularly made aware of possible phishing scams and to be alert to any potential email or system data breaches.
Key Person risk	The small staff base makes TUF heavily reliant on the Chief Executive and a few key Trustees so the unexpected loss or departure of the Chief Executive or certain Trustees is a risk. Succession planning processes are in place.
Investment Risk	TUF's success is directly related to the amount of resource it can devote to its objectives, so the key risk identified by trustees relates to the proper management of its funds. Imprudent or unprofessional decisions could majorly impact on the performance of those funds. In common with similar charities, TUF employs professional fund managers, whose performance is regularly reviewed by the Treasurer together with other trustees.
Risk to Employees	Employees are not subject to risks other than those likely to be associated with routine office work. Apart from obtaining statutory Employers Liability Insurance, TUF nonetheless treats the welfare of its staff as a priority. The Chief Executive is the Nominated Safety Officer for the purposes of the Health and Safety at Work Act. The premises are checked and maintained by the landlord and by the fire service to ensure appropriate mitigation of the risk of fire. Employees are aware of the location of fire extinguishers. The charity also has a number of policies in place covering Equal Opportunities, Lone Working, Working from Home and Safe Guarding Vulnerable People.
Risk that research fails to deliver results	Grants awarded are subject to rigorous review by the SEC and Reviewing Committee. Grantees are expected to submit progress reports and these are reviewed by the SEC and TUF. The charity maintains ongoing communication with grant holders.
Loss of Records	To protect against the loss of records, and to increase data security, files are stored in the cloud. The risk of any unsaved data being critical to TUF is regarded as insignificant. Other similar risks are dealt with by insurance.

Structure, Governance & Management

The Urology Foundation is a charity and a company limited by guarantee and was established on 12 February 2009 to incorporate the charitable activities of the British Urological Foundation (BUF), an unincorporated charitable trust, established in 1994 by the British Association of Urological Surgeons and BJU International, and a registered charity since 17 March 1995. The Urology Foundation itself became a registered charity on 19 March 2009.

Charity Governance Code

The Board and Executive of the charity abide by the standards set by the Charity Governance Code when executing their duties. The overall strategic direction of the charity is determined by the Trustees, who meet three times each year including an Annual General Meeting.

Trustee Recruitment, Training and Induction

The Foundation seeks to achieve a balance of lay and medical Trustees. Appointed Trustees are recruited on the basis of fulfilling the criteria to provide a balance of experience and knowledge. Members of the charity's Scientific and Education Committee (see below) are recruited through calls in industry publications.

All new Trustees are provided with an induction programme and an induction pack. They are provided with relevant Charity Commission publications and regularly briefed on developments and opportunities that will support their general understanding of the voluntary sector, healthcare and medical research issues.

Appointment & Election

The Trustees and Chairman are appointed for an initial period of three years that can be extended for a further three-year term. A further extension may be made if it is deemed to be in the best interests of the Charity. The governing document requires that there should be a minimum of seven Trustees.

Two of the Trustees are required to be representative Trustees, one nominated by The British Association of Urological Surgeons (BAUS) and one nominated by British Journal of Urology International (BJUI). All other Trustees, known as appointed Trustees, are appointed by unanimous written resolution of all the Trustees present and/or voting at a special meeting of Trustees called to take place immediately before or after an ordinary meeting of Trustees.

The representative Trustee nominated by BAUS is the President of BAUS and his / her appointment to the Board is concurrent with his/her post at BAUS, which is for a period of two years.

The Executive Team

The Chief Executive, is responsible for the day-to-day management of the charity.

The Chief Executive deals with the implementation of policy and strategic decisions taken by the Board of Trustees. She and the appropriate staff members attend the meetings of the Board of Trustees and sub-committees, and report on the day-to-day operations of the charity. The Foundation currently operates the following sub-committees:

Scientific and Education Committee (SEC)

The SEC is responsible for the development and assessment of The Foundation's research, education and training programmes and the review and administration of The Foundation's grant making policy. The Chairman of the SEC is also a member of the board of trustees, and reports back to the board on the work of the Committee. The SEC is made up of clinical and academic urologists and scientists with an interest in urology, and lay representatives.

Research Scholarship Review Panel
The Research Scholarship Review Panel is responsible for assessing applications for our major research grants and marking these according to the requisite criteria being met. In this task it assists the SEC in its final decision on who should receive grants. The Research Scholarship Review Panel is made up of clinical trustees and academic urologists and scientists with an interest in urology.

Membership of the SEC and Review Panel can be viewed on the charity's website: https://www.theurologyfoundation.org/about-us/who-we-are/our-team/committees. They provide their services as volunteers and we are enormously grateful to them.

Finance Committee
The charity Finance Committee is chaired by the Treasurer, Ms Angela Daniel. Membership includes The Chair of the Board and the Chair of the SEC, and two other Trustees and the Chief Executive. Any recommendations made by the Finance Committee are brought to the Board of Trustees for discussion and ratification. The Treasurer has oversight of the charity's bank and investment accounts. During the year the Terms of Reference were reviewed and updated.

Relationships with Related Parties
The Urology Foundation continues to maintain close links with its two founding charities, The British Association of Urological Surgeons (BAUS) and the BJU International, whose representatives are Trustees. The charity is also represented on BAUS Council by Mary Garthwaite.

Representation on Other Bodies
The charity is a member of the Association of Medical Research Charities (AMRC), which confers a quality mark for our peer review processes, as well as advocating for charity-funded research with government. The Urology Foundation is a National Institute for Health Research (NIHR) non-commercial Partner. This means the studies that the Foundation funds may be eligible to access the NIHR Study Support Service which is provided by the NIHR Clinical Research Network.

During the year, the charity became a member of Cancer 52, Charities Research Involvement Group and the National Council for Voluntary Organisations.

Reference and administrative details

The registered charity name is "The Urology Foundation" (sometimes referred to as "TUF"), a charity and a company limited by guarantee.

Trustees

Ms Mary Garthwaite *(Chair, appt 8 August 2022)*
Mr Paul Fletcher *(Chair, resigned 8 August 2022)*
Ms Angela Daniel (*Treasurer)*
Mr Mark Becker *(Secretary)*
Prof Grant Stewart (*Chair, SEC resigned 14 March 2023)*
Prof Rakesh Heer *(Chair SEC, appt 14 March 2023)*
Mr Ben Challacombe
Ms Jo Cresswell (BAUS rep appt 23 June 2022)
Mr Mike Griggs (*appt 1 January 2023*)
Mr Adrian Joyce
Prof Alan McNeill *(BJUI rep, appt 10 Feb 2022)*
Mr Roland Morley
Mr David Nicol (*resigned 31 December 2022*)
Mr Tim O'Brien *(BAUS rep, resigned 22 June 2022)*
Ms Hannah Warren

President

Prof Roger Kirby

Patrons

Mr Handel Evans
Sir Ranulph Fiennes OBE
Mrs Rosemary Macaire
Ms Jane Macquitty MBE
Mr Steven Norris

Ambassadors

Mr Alex Corbisiero
Mr Stephen Fry
Mrs Kate Holmes

Chief Executive

Ms Rebecca Porta

Registered Office

1-2 St Andrew's Hill
London
EC4V 5BY

Charity number

1128683 (England & Wales)

Company number

06817868

Auditors

Dunkley & Co Ltd
Woodlands Grange, Woodlands Lane
Bradley Stoke
Bristol BS32 4JY

Bankers

National Westminster Bank plc
PO Box 2021
10 Marylebone High Street
London W1A 1FH

Investment Manager

Rothschild Bank (CI) Limited
St. Julian's Court, St. Julian's Avenue
St. Peter Port
Guernsey GY1 3UA

Trustees' & Directors' Responsibilities in the Preparation of Financial Statements

The trustees (who are also the directors of The Urology Foundation for the purposes of company law) are responsible for preparing the trustees' Annual Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company as at the balance sheet date, and of the incoming resources and application of resources, including income and expenditure, for that period. In preparing those financial statements, the trustees and directors are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The trustees are responsible for keeping proper accounting records, which disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with Companies Acts 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from the legislation in other jurisdictions.

Auditor

Mr Matthew Dobbins (FCA), of Dunkley & Co Ltd. has agreed to act as Auditor.

Statement as to disclosure of information to the auditor

The trustees and directors at the date of approval of this trustees' annual report confirm that so far as each of them is aware, there is no relevant information of which the charity's auditor is unaware, and the trustees and directors have taken all steps that they ought to have taken to make themselves aware of any relevant information and to establish that the auditor is aware of that information.

M. Garthwaite

Mary Garthwaite (Sep 26, 2023 11:04 GMT+1)

Mary Garthwaite, Chair

Date: Sep 26, 2023

Report of the Independent Auditors to the Trustees of The Urology Foundation (Registered number: 06817868)

Opinion
We have audited the financial statements of The Urology Foundation (the 'charitable company') for the year ended 31 December 2022 which comprise the Statement of Financial Activities, the Balance Sheet, the Cash Flow Statement and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 December 2022 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern
In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate. Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information
The trustees are responsible for the other information. The other information comprises the information included in the Annual Report, other than the financial statements and our Report of the Independent Auditors thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Matters on which we are required to report by exception
We have nothing to report in respect of the following matters where the Charities (Accounts and Reports) Regulations 2008 requires us to report to you if, in our opinion:

- the information given in the Report of the Trustees is inconsistent in any material respect with the financial statements; or
- the charitable company has not kept adequate accounting records; or
- the financial statements are not in agreement with the accounting records and returns; or
- we have not received all the information and explanations we require for our audit.

Report of the Independent Auditors to the Trustees of
The Urology Foundation (Registered number: 06817868)

Responsibilities of trustees

As explained more fully in the Statement of Trustees' Responsibilities, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Report of the Independent Auditors to the Trustees of
The Urology Foundation (Registered number: 06817868)

Our responsibilities for the audit of the financial statements
We have been appointed as auditors under Section 144 of the Charities Act 2011 and report in accordance with the Act and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Independent Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Extent to which the audit was considered capable of detecting irregularities, including fraud

We identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and then design and perform audit procedures responsive to those risks, including obtaining audit evidence that is sufficient and appropriate to provide a basis for our opinion.

Identifying and assessing potential risks related to irregularities

In identifying and assessing risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, we considered the following:

- The nature of the charitable sector, control environment and performance including the design of the organisation's remuneration policies;

- Any matters we identified, having obtained and reviewed the organisation's documentation of their policies and procedures relating to:

o Identifying, evaluating and complying with laws and regulations and whether they were aware of any instances of non-compliance;

o Detecting and responding to the risks of fraud and whether they have knowledge of any actual, suspected or alleged fraud;

o The internal controls established to mitigate risks of fraud or non-compliance with laws and regulations;

o The matters discussed among the audit engagement team regarding how and where fraud might occur in the financial statements and any potential indicators of fraud.

As a result of these procedures, we considered the opportunities and incentives that may exist within the organisation for fraud and identified the greatest potential for fraud in the areas of management override of controls, going concern, income recognition, and the appropriateness of expenditure.

We also obtained an understanding of the legal and regulatory framework that the organisation operates in, focusing on provisions of those laws and regulations that had a direct effect on the determination of material amounts and disclosures in the financial statements.

Audit response to risks identified

Our procedures to respond to risks identified included the following:

- Enquiring of management, concerning actual and potential litigation and claims;

- Substantive testing to vouch source records to the financial statements;

- Performing analytical procedures to identify any unusual or unexpected relationships that may indicate risks of material misstatement due to fraud;

- Enquiring of management the internal controls in, evaluating each control for weakness and vouching to evidence of the control taking place;

- In addressing the risk of fraud through management override of controls, testing the appropriateness of journal entries and other adjustments; assessing whether the judgements made in making accounting estimates are indicative of a potential bias; and evaluating the business rationale of any significant transactions that are unusual or outside the normal course of business.

We also communicated relevant identified laws and regulations and potential fraud risks to all engagement team members, and remained alert to any indications of fraud or non-compliance with laws and regulations throughout the audit.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Independent Auditors.

Use of our report
This report is made solely to the charitable company's trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. Our audit work has been undertaken so that we might state to the charitable company's trustees those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's trustees as a body, for our audit work, for this report, or for the opinions we have formed.

Matthew Dobbins FCA
Dunkley's
Chartered Accountants
Registered Auditors
Eligible to act as an auditor in terms of Section 1212 of the Companies Act 2006
Woodlands Grange
Woodlands Lane
Bradley Stoke
Bristol
BS32 4JY

Date: Sep 26, 2023

THE UROLOGY FOUNDATION

STATEMENT OF FINANCIAL ACTIVITIES
for the year ended 31 December 2022

	Note	Unrestricted Funds £	Restricted Funds £	Total 2022 £	Total 2021 £
INCOME					
Donations and legacies	1	1,016,881	301,472	1,318,353	686,522
Other trading activities	2	30,980	-	30,980	83,389
Investments	3	6,380	-	6,380	41,020
TOTAL INCOME		1,054,241	301,472	1,355,713	810,931
EXPENDITURE					
Raising Funds					
Donations and legacies	4	38,978	4,330	43,308	46,687
Trading activities	5	38,547	4,283	42,830	23,620
Investment management costs		74	-	74	72
Expenditure on Charitable activities					
Raising Awareness	6	126,910	14,101	141,011	85,890
Grant making	7	606,675	73,461	680,136	742,928
Net losses/(Gains) on investment assets	11	255,577	320	255,897	(377,727)
TOTAL EXPENDITURE		1,066,761	96,495	1,163,256	521,470
NET INCOME/(EXPENDITURE)		(12,520)	204,977	192,457	289,461
RECONCILIATION OF FUNDS					
Fund balances brought forward at 1 January 2022		2,097,116	350,768	2,447,884	2,158,423
Transfer between funds		-	-	-	-
FUND BALANCES CARRIED FORWARD AT 31 DECEMBER 2022		2,084,596	555,745	2,640,341	2,447,884

The net movement in funds for the year arises from the charity's continuing operations.

No separate statement of total changes in equity has been presented as all such gains and losses have been dealt with in the statement of financial activities.

The notes on pages 29 to 39 form part of these accounts

THE UROLOGY FOUNDATION

STATEMENT OF FINANCIAL ACTIVITIES
for the year ended 31 December 2021 (Full fund comparative)

	Note	Unrestricted Funds £	Restricted Funds £	Total 2021 £
INCOME				
Donations and legacies	1	639,590	46,932	686,522
Other trading activities	2	83,389	-	83,389
Investments	3	41,020	-	41,020
TOTAL INCOME		763,999	46,932	810,931
EXPENDITURE				
Raising Funds				
Donations and legacies	4	42,022	4,665	46,687
Trading activities	5	21,262	2,358	23,620
Investment management costs		72	-	72
Expenditure on Charitable activities				
Raising Awareness	6	77,315	8,575	85,890
Grant making	7	614,398	128,530	742,928
Net (Gains) on investment assets	11	(377,255)	(472)	(377,727)
NET INCOME/(EXPENDITURE)		377,814	143,656	521,470
NET (EXPENDITURE)		386,185	(96,724)	289,461
RECONCILIATION OF FUNDS				
Fund balances brought forward at 1 January 2021		1,675,542	482,881	2,158,423
Transfer between funds		35,389	(35,389)	-
FUND BALANCES CARRIED FORWARD AT 31 DECEMBER 2021		2,097,116	350,768	2,447,884

The net movement in funds for the year arises from the charity's continuing operations.

No separate statement of total changes in equity has been presented as all such gains and losses have been dealt with in the statement of financial activities.

The notes on pages 29 to 39 form part of these accounts

THE UROLOGY FOUNDATION

BALANCE SHEET
as at 31 December 2022 Company Number 06817868

	Note	2022 £	2021 £
FIXED ASSETS			
Tangible assets	10	2,719	3,627
Investments	11	3,407,104	3,657,270
		3,409,823	3,660,897
CURRENT ASSETS			
Debtors	12	413,449	98,723
Cash at bank and in hand		322,606	238,420
		736,055	337,143
LIABILITIES: amounts falling due within one year	13	1,102,738	1,133,522
NET CURRENT LIABILITIES		(366,683)	(796,379)
LIABILITIES: amounts falling due in more than one year	13	402,799	416,634
NET ASSETS		2,640,341	2,447,884
THE FUNDS OF THE CHARITY			
Restricted income funds	15		
Robotic Surgery Training Fund		160,170	200,076
Prostate Cancer Research Fund		137,269	138,804
Bladder Cancer Fund		184,851	(31,425)
Travel Fellowship Fund		648	653
Team Corbs - Testicular		7,311	2,158
Charles Reynolds		65,497	40,503
Unrestricted income funds	15		
General Fund		1,584,597	1,597,116
Designated Fund (British Urology Foundation)		500,000	500,000
TOTAL CHARITY FUNDS	16	2,640,341	2,447,884

These financial statements have been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small charitable companies and with the Financial Reporting Standard 102.

The financial statements on pages 25 to 28 were approved by the trustees and authorised for issue on 25 September 2023, and are signed on their behalf by

M. Garthwaite
Mary Garthwaite (Sep 26, 2023 11:04 GMT+1)
..... Chair
Mary Garthwaite
Sep 26, 2023

Angela Daniel (Sep 26, 2023 11:09 GMT+1)
..... Treasurer
Angela Daniel
Sep 26, 2023

The notes on pages 29 to 39 form part of these accounts

THE UROLOGY FOUNDATION

STATEMENT OF CASHFLOWS
as at 31 December 2022

	Note	2022 £	2021 £
CASH FLOWS FROM OPERATING ACTIVITIES:	14		
Net cash used in operating activities		84,134	(333,651)
Cash flows from investing activities:			
Dividends and interest from investments		5,855	41,002
Management fees paid from investments		(72)	(72)
Purchase of equipment		-	(2,159)
Transfer from cash		-	-
Proceeds from sale of investments		150	852,452
Purchase of investments		(5,882)	(536,261)
Net cash used in investing activities:		51	354,962
Change in cash and cash equivalents in the reporting period		84,185	21,311
Cash equivalents at the beginning of the reporting period		238,420	217,109
Cash and cash equivalents at the end of the reporting period		322,605	238,420

The notes on pages 29 to 39 form part of these accounts

THE UROLOGY FOUNDATION

Financial statements for the year ended 31 December 2022

ACCOUNTING POLICIES

BASIS OF ACCOUNTING

The financial statements have been prepared under the historical cost convention with items recognised at cost or transaction value unless otherwise stated in the relevant notes to these accounts. The financial statements have been prepared in accordance with the Statement of Recommended Practice: Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) issued on 1 January 2019 and Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102) and Charities Act 2011. The trust constitutes a public benefit entity as defined by FRS 102.

INCOME

Grants, donations and other similar types of voluntary income are brought into account when it is probable that they will be received, except that donated income is included gross of any attributable tax recoverable, where relevant. Donations given for specific purposes are treated as restricted income. Tax recoverable is recognised when claims are submitted to HM Revenue and Customs. Legacy gifts are recognised in the period in which the Charity becomes entitled to receive the income.

Income receivable from activities for generating funds and from investment income is accounted for on an accruals basis. Deferred income represents revenues collected but not earned as of 31 December 2022. This is primarily composed of income collected in advance of a fundraising event taking place and deferred until the charity is entitled to that income as and when the event takes place.

EXPENDITURE

Resources expended are allocated to the costs of generating funds or to the charity's principal activity where the costs can be identified as being directly related. All other costs are categorised as either support costs or governance costs, and are allocated in proportions based upon a suitable ratio applicable to the nature of the cost involved.

Grants payable are recognised in full in the period in which the approved offer is conveyed to the recipient. Grants are recognised and deferred where there is a long term commitment for the Charity. Where grants are recognised and conditions for staged grant payments are not met in subsequent years, an adjustment to grants payable will be made in the relevant accounting period. Expenditure includes irrecoverable VAT which is reported as part of the expenditure to which it relates.

TANGIBLE FIXED ASSETS

All tangible assets purchased that have an expected useful economic life that exceeds one year are capitalised and classified as fixed assets. Tangible fixed assets are stated at historical cost less depreciation. Depreciation is provided on all tangible fixed assets at rates calculated to write each asset down to its estimated residual value evenly over its expected useful life, as follows:

Office equipment	25% reducing balance

OPERATING LEASES

Rentals under operating leases are charged to the Statement of financial activities on a straight line basis over the lease term.

ACCOUNTING POLICIES

INVESTMENTS

The charity's investments are included in the balance sheet at their market value. The gains or losses arising upon their annual revaluation are included in the statement of financial activities.

FUND ACCOUNTING

The general fund comprises the accumulated surpluses of unrestricted incoming resources over resources expended, which are available for use in the furtherance of the general objective of the charity.

Designated funds are a particular form of unrestricted funds consisting of amounts, which have been allocated or designated for specific purposes by the trustees. The use of designated funds remains at the discretion of the trustees.
Restricted funds are funds subject to specific conditions imposed by donors. The purpose and use of the restricted funds are set out in the notes to the accounts. Amounts unspent at the year end are carried forward in the balance sheet.

FOREIGN EXCHANGE

Receipts and payments which occur in foreign currencies are included in the accounts at the amount into which they are converted in sterling, using the exchange rate on the day in which the transaction occurs.

GOING CONCERN

The Trustees as Directors of the Charity believe that there are no material uncertainties that may cast significant doubt about the ability of the Charity to continue as a going concern, due to the significant unrestricted reserves as at 31st December and the forecast income expected in 2023. As we prepare this statement in early 2023, it is clear that the long tail of the COVID-19 pandemic, and its impact on the NHS workload, continues to have a bearing on the charity's operations, with applications for programmes such as fellowships and travel grants still low. It remains to be seen whether our events fundraising and income will be impacted by global issues such as the war in Ukraine and the current cost of living crisis, which may affect future budgets for research and training. The trustees believe, however, that given the level of available cash and reserves, the charity can continue as a going concern.

FINANCIAL INSTRUMENTS

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

		Unrestricted funds £	Restricted funds £	2022 £	2021 £
1.	**INCOME FROM DONATIONS AND LEGACIES**				
	Grants received from charitable trusts and corporate sponsors	628,363	301,472	929,835	477,362
	Donations	388,518	-	388,518	204,580
	Legacies	-	-	-	4,580
		1,016,881	301,472	1,318,353	686,522
2.	**INCOME FROM OTHER TRADING ACTIVITIES**				
	Income from fundraising events	30,980	-	30,980	83,389
3.	**INVESTMENT INCOME**				
	Bank interest receivable on short term cash deposits	525	-	525	18
	Income from investments listed on a recognised stock exchange:				
	UK investments	5,855	-	5,855	41,002
	Overseas investments	-	-	-	-
		6,380	-	6,380	41,020
4.	**COSTS OF RAISING FUNDS VOLUNTARY INCOME**				
	Direct costs	16,798	1,866	18,664	28,220
	Support costs (see note 8)	22,180	2,464	24,644	18,467
		38,978	4,330	43,308	46,687

		Unrestricted funds £	Restricted funds £	2022 £	2021 £
5.	**COSTS OF RAISING FUNDS TRADING ACTIVITIES**				
	Costs of fundraising events	16,367	1,819	18,186	5,153
	Support costs (see note 8)	22,180	2,464	24,644	18,467
		38,547	4,283	42,830	23,620
6.	**COSTS OF RAISING AWARENESS**				
	Costs of fundraising events	38,190	4,243	42,433	12,024
	Support costs (see note 8)	88,720	9,858	98,578	73,866
		126,910	14,101	141,011	85,890
7.	**GRANT MAKING**				
	Research Scholarships awarded to 5 (2021: 5) individuals	310,302	58,780	369,082	263,888
	PPI in Research/patient engagement	39,203	-	39,203	-
	Small Research Projects awarded to 5 (2021: 4) teams	38,914	-	38,914	29,738
	Keith Yeates medals awarded to 5 (2021: 2) individuals	10,000	-	10,000	(800)
	Urolink Fellowship	4,500	-	4,500	4,500
	BAUS	3,032	-	3,032	-
	Awareness campaigns (WCW & UAM)	1,350	-	1,350	-
	Travel Grants	500	-	500	-
	Robotic Centres of Training	-	(1,050)	(1,050)	-
	BAUN/TUF Nurse	(2,083)	-	(2,083)	2,156
	iROC Bladder Cancer Trial	-	(2,342)	(2,342)	-
	Patient Advocacy Research	(4,449)	-	(4,449)	-
	Cancer biomarker / wearable sensor study	-	-	-	195,000
	TUF Fulbright Research Fellowship Award	-	-	-	7,176
	TUF Trials Unit	-	-	-	180,000
	Other direct costs	-	-	-	169
	V Arumuham	-	-	-	(1,500)
	Movement in present value of grant accruals	42,752	-	42,752	(72,813)
		444,021	55,388	499,409	607,514
	Support costs (see note 8)	162,654	18,073	180,727	135,414
		606,675	73,461	680,136	742,928

	Costs of generating voluntary income 7.5% £	Fundraising trading: Cost of goods sold 7.5% £	Awareness raising 30% £	Giving grants 55% £	2022 £	2021 £
8. SUPPORT AND GOVERNANCE COSTS (UNRESTRICTED)						
Staff costs (see note 9)	14,606	14,606	58,422	107,107	194,741	130,653
Other staff costs including recruitment	234	234	935	1,715	3,118	24,909
Committee and other staff welfare expenses	301	301	1,203	2,205	4,010	333
Other office costs	4,418	4,418	17,674	32,402	58,912	41,189
Audit fee	22	22	90	164	298	2,900
Accountancy and advisory services	789	789	3,155	5,785	10,518	13,066
Other costs	1,749	1,749	6,996	12,826	23,320	8,097
Depreciation-owned assets	61	61	245	449	816	496
	22,180	22,180	88,720	162,653	295,733	221,643

8. SUPPORT AND GOVERNANCE COSTS (RESTRICTED)						
Staff costs (see note 9)	1,623	1,623	6,491	11,901	21,638	14,412
Other staff costs including recruitment	26	26	104	191	347	2,813
Committee and other staff welfare expenses	33	33	134	245	445	37
Other office costs	491	491	1,964	3,600	6,546	4,576
Audit fee	2	2	10	18	32	323
Accountancy and advisory services	88	88	351	643	1,170	1,453
Other costs	194	194	777	1,425	2,590	901
Depreciation-owned assets	7	7	27	50	91	55
	2,464	2,464	9,858	18,073	32,859	24,570

9. STAFF COSTS

		2022	2021
		No.	No.
The average monthly number of persons employed by the charity (excluding trustees) during the period was, as follows:			
Office and administration		3.3	2.7
		£	£
Staff costs for the above persons:			
Staff	Wages and salaries	137,779	51,800
Staff	Social security costs	13,374	3,743
Key management personnel	Wages and salaries	59,655	82,339
Key management personnel	Social security costs	5,571	7,183
		216,379	145,065

One employee received total emoluments in excess of £60,000 per annum during the period ended 31 December 2021. The total emoluments of this employee during the year were in the following ranges:

		2022	2021
£70,000 - £80,000	No.	0	1
£60,000 - £70,000	No.	1	0

The Charity considers its key management personnel comprise the Chief Executive, with remuneration as noted above. In setting salary levels, The Urology Foundation follows the National Council for Voluntary Organisation's advice that a charity's pay policy should be to offer fair pay to attract and keep appropriately-qualified staff to lead, manage, support and/or deliver the charity's aims. It also conducts online research of charity salaries and uses surveys to benchmark levels of pay. The Urology Foundation does not automatically award its staff with annual salary increases, either incremental or cost of living.

No Director received any remuneration from the Company during the year (2021: £nil).
No trustee received any remuneration for services provided to the charity during the current or previous period.
Trustees expenses reimbursed in respect of Trustee's meetings and travel for the year ended 31st December 2022 amounted to £0 paid to no Trustees (2021 £0 paid to no Trustees).

10. TANGIBLE ASSETS

	Office Equipment £
Cost:	
1 January 2022	22,494
Additions	0
31 December 2022	22,494
Depreciation:	
1 January 2022	18,867
Charge for year	908
31 December 2022	19,775
Net book value:	
31 December 2022	2,719
31 December 2021	3,627

		2022 £	2021 £
11.	**INVESTMENTS**		
	Investments listed on a recognised stock exchange at market value:		
	1 January 2022	3,657,270	3,595,733
	Transfers from cash		-
	Additions at cost	5,882	536,261
	Disposal proceeds	(150)	(852,452)
	Realised (losses)/gains	29	124,555
	Unrealised gains	(255,926)	253,173
	31 December 2022	3,407,105	3,657,270
	At the balance sheet date, the market value of the portfolio comprised:		
	UK investments	3,407,105	3,657,270
		3,407,105	3,657,270
	Fixed income securities	549,597	543,742
	Equities	-	-
	Multi-Asset & Hybrid Instruments	2,857,508	3,113,528
		3,407,105	3,657,270

At the balance sheet date, the historical cost of the investments was £2,944,132 (2021: £2,938,371).
The following holdings had a value of >5% of the market value of the investments:

Name	Holding	Value £ 2022	Value £ 2021
Rothschild & Co WM SICAV-SIF Exbury Fund GBP		2,857,508	3,113,528
Pentairs QIAIF PLC - Vanda Fund Shs -F- USD Shs			-
InstitutionalCash SeriesPLC - BlackRock ICS Sterling Liquidity Fund		549,597	543,742

		2022 £	2021 £
12.	**DEBTORS**		
	Amounts falling due within one year:		
	Other debtors	0	3,017
	Prepayments	14,086	21,450
	Accrued Income	399,363	74,256
		413,449	98,723

13. CREDITORS	2022 £	2021 £
Amounts falling due within one year:		
Deferred income	504	80,628
General accruals	45,971	11,270
Grant accruals	1,049,953	1,041,624
Other creditors	6,310	-
	1,102,738	1,133,522
Deferred income b/fwd at 1 January 2022	80,628	
Amounts released in the year	(80,628)	
New amounts deferred in the year	504	
Deferred income c/fwd at 31 December 2022	504	

CREDITORS	2022 £	2021 £
Amounts falling due in more than one year:		
Grant accruals	402,799	416,634
	402,799	416,634

14. RECONCILIATION OF NET INCOME/(EXPENDITURE) TO NET CASHFLOW FROM OPERATING ACTIVITIES

Net Income/(expenditure) for the reporting period per the statement of financial activities	192,458	289,461
Adjustments for:		
Depreciation charges	907	350
Losses/(gains) on investments	255,897	(377,727)
Dividends and interest from investments	(5,855)	(41,002)
Management fees paid from investments	72	72
(Increase) in debtors	(314,726)	(20,950)
(Decrease) in creditors	(44,619)	(183,855)
Net cash used in operating activities	84,134	(333,651)

15. THE FUNDS OF THE CHARITY

	1 January 2022 £	Transfer £	Income £	Expenditure £	Gains/(losses) on Investments £	31 December 2022 £
Restricted income funds:						
Robotic Surgery Training Fund	200,076	-	-	(39,737)	(169)	160,170
Prostate Cancer Research Fund	138,804	-	57,313	(58,780)	(68)	137,269
Bladder Cancer Fund	(31,425)	-	214,000	2,342	(66)	184,851
Travel Fellowship Fund	653	-	-	-	(5)	648
Team Corbs - Testicular	2,158	-	5,159	-	(6)	7,311
Charles Reynolds	40,503	-	25,000	-	(6)	65,497
	350,768	-	301,472	(96,175)	(321)	555,744
Unrestricted income funds:						
General Fund	1,597,116	-	1,054,241	(811,183)	(255,577)	1,584,597
Designated Fund (BUF)	500,000	-	-	-	-	500,000
	2,447,884	-	1,355,713	(907,358)	(255,898)	2,640,341

15. THE FUNDS OF THE CHARITY (Continued)

- The trustees have designated the original 1995 start-up funding for the BUF of £500,000 as the trustees feel strongly that The Foundation should seek to maintain reserves sufficient to continue to fund its objectives on a long term basis.
- The Robotic Surgery Training Fund was set up in 2009 following the receipt of restricted donation income from the British Urological Foundation and a generous private donation. The funds are mainly used to award grants towards robotically assisted surgery training, education, and research into robotic training techniques.
- Bladder cancer remains one of the most expensive cancers to treat and survival rates appear to have reached a plateau at 50%. In the UK, more than 10,000 new cases of bladder cancer are diagnosed every year. The Foundation is determined to improve the diagnosis, treatment and outcomes of people with bladder cancer and to allocate resources to vital research into the diagnosis and pathology of bladder cancer and to funding training and education to improve patient treatment and care. Through a generous donation from The Champniss Foundation, TUF has funded the iROC bladder cancer surgery trial, investigating the efficacy of Robot assisted radical cystectomy and intracorporeal urinary diversion compared with open radical cystectomy in patients with bladder cancer. The Champniss Foundation and the Champniss Charitable Trust are also funding a study into patient tracking post-surgery via fitness devices.
- Prostate Cancer Research – Thanks to the John Black Charitable Foundation (JBCF) TUF has been able to invest in a number of high profile research studies, such as the CLIMATE trial, which are ongoing. There were no new JBCF awards given in 2022.
- The Foundation started working with former England and Lions rugby champion, Alex Corbisiero, to raise funds for research into testicular cancer, following Alex's diagnosis. A Just Giving page has been set up and the charity will continue to fundraise with Alex.

16. ANALYSIS OF NET ASSETS BETWEEN FUNDS

	Fixed Assets £	Net Assets/(Liabilities) £	Total £
Restricted income funds:			
Robotic Surgery Training Fund	186,354	(26,184)	160,170
Prostate Cancer Research Fund	914,994	(777,725)	137,269
Bladder Cancer Fund	139,651	45,200	184,851
Travel Fellowship Fund	1,046	(398)	648
Team Corbs - Testicular	-	7,311	7,311
Charles Reynolds	-	65,497	65,497
Unrestricted income funds:			
General Fund	1,667,778	(83,181)	1,584,597
Designated Fund (British Urology Foundation)	500,000	-	500,000
NET ASSETS	3,409,823	(769,482)	2,640,341

17. ULTIMATE CONTROLLING PARTY

The Charity is controlled by the board of Trustees.

18. COMMITMENTS UNDER OPERATING LEASES

As at 31st December 2022, the Charity had annualised operating commitments under non-cancellable operating leases expiring as follows:

	2022 £	2021 £
Expiring within one year		
- Land and Buildings	10,937	28,700
- Others	-	1,566
	10,937	30,266
Expiring within two to five years		
- Land and Buildings	12,500	-
- Others	-	-
	12,500	-

19. CONTINGENT ASSETS

There were no contingent assets as at 31 December 2022.

20. RELATED PARTY TRANSACTIONS

There were no related party transactions during the current or prior year.

THE UROLOGY FOUNDATION

England & Wales - Charity number 1128683

Accounts

THE UROLOGY FOUNDATION

TRUSTEES' ANNUAL REPORT & FINANCIAL STATEMENTS

DECEMBER 2021




Contents

Chairman's statement 3
Overview of the year 3
Objectives and Activities 4
Our Vision and Mission 4
Our Aims 4
Our Values 4
What we do 4
Public Benefit 5
Grants policy 5
Comparison of 2020 v 2021 6
Achievements and Performance in 2021 7
1. Seeking better treatments and cures through research 7
2. Improving knowledge and skills through training 9
3. Improve public awareness of urological conditions and symptoms 10
4. Plans for the future 11
Financial Review 12
Financial Results of Activities & Events 12
Fundraising 12
Reserves & Liquidity Policy 12
Statement of going concern 13
Investments Policy 13
Remuneration policy 13
Pensions policy 13
Equal opportunities and diversity policy 13
Principal risks and uncertainties 14
Structure, Governance & Management 16
Charity Governance Code 16
Trustee Recruitment, Training and Induction 16
Appointment & Election 16
Relationships with Related Parties 17
Representation on Other Bodies 17
Reference and administrative details 18
Trustees 18
Registered Office 18
Auditors 18
Trustees' & Directors' Responsibilities in the Preparation of Financial Statements 19
Auditor 19
Statement as to disclosure of information to the auditor 19
Annex A 20

Front cover image courtesy Findlay MacAskill, urology trainee, completing the Hackney Half Marathon for TUF.

Chairman's statement

Overview of the year



It was pleasing to see the charity able to make more awards and to support more urologists and researchers in 2021, compared with the previous year, in spite of the continuing impact of Covid-19 on our operations. We are currently funding over 50 projects covering a range of urological diseases from prostate, kidney and bladder cancer to urinary tract infections and incontinence. This was largely due to our regular donors, and to Trusts & Foundations and companies, many of whom share our mission of improving quality of life and outcomes and saving lives. Without their ongoing commitment and support our ability to make awards, meet our objectives and support the urology community would have been more limited, particularly as opportunities to fundraise were still constrained due to Covid-19.

2021 saw The Urology Foundation making some significant investment into urological research and care, most notably the creation of our TUF Trials Unit. Following a competitive tendering process we signed a three year partnership with the Centre for Healthcare Randomised Trials centre in Aberdeen to encourage and enable more clinical research in urology. Trials are an important way of measuring a medical, surgical or behavioural intervention and successful trials are catalysts for change, provide potential for transformational discoveries and drive improvements in services. The role of the TUF Trials Unit is to identify promising and important research ideas from urology departments from all corners of the UK and provide a team of medical investigators to bring those ideas to fruition. This approach will enable more high-quality urology trials to take place, leading to better care, quicker recovery times and fewer long-term issues.

2021 also presaged some changes to the TUF team with our Chief Executive, Louise de Winter, saying she wished to step back into a part time role within the organization. We are hugely indebted to Louise for her leadership and commitment to TUF over the past decade. Since her tenure TUF has expanded its programmes and funding to provide many more opportunities for research and training, and also to include specific funding for urology nurses. So, we were thoroughly delighted that Louise expressed her wish to continue to contribute to TUF in a renewed capacity as Director of Research & Operations, as she remains deeply committed to the charity and looks forward to being a part of its ongoing future success.

We were very pleased to welcome Rebecca Porta as our new TUF CEO in January 2022. Rebecca has held senior roles within some of the UK's leading health and medical research charities, and was Chief Executive of Orchid Cancer Appeal, the male cancer charity for over 11 years, responsible for driving transformation and growth including the introduction of Nurse-led Services, training for healthcare professionals and national media campaigns. We are confident she will build upon the excellent work and foundations that Louise has created and help us take The Urology Foundation to the next level.

Finally, it was a pleasure to connect in person with some of our donors and supporters at the TUF dinner hosted by TUF Patron, Jane MacQuitty at Vintners' Hall last November. It provided a real boost to morale and a fantastic evening was had by all, with more funds raised to support our vital work. We will continue to put the needs of urology patients and the urology community of professionals at the heart of what we do.



Paul Fletcher, Chairman

Objectives and Activities

The Urology Foundation's objects are to:

"Advance, promote, encourage, develop and improve the study and knowledge of urology, urological surgery and the general knowledge of science and medicine and all matters relating to the progress and development of that branch of science and medicine and for that purpose to fund, aid, maintain and endow scholarships, fellowships, chairs and bursaries and generally to assist in the funding, instruction and support of persons and institutions engaged or involved in urological research work."

Our Vision and Mission

We see a world where people will not die early from urological cancers and diseases, and where people with bladder, kidney and prostate problems can still lead full, active and productive lives.

Our mission is to improve survival and quality of life for urology patients through research and training, so patients receive the best possible treatment and care and fewer lives are devastated.

Our Aims

The Urology Foundation is committed to reducing the suffering caused by urological diseases. We work with researchers, urology and health care professionals to improve the diagnosis, treatment and management of urological disease and the nation's urology care.

We rely on donations from individuals, trusts and foundations, and from companies to help fund our work. The money we raise is invested directly into research to find better treatments and cures, and in training for urology professionals to care for and help people affected by urology conditions.

The Foundation is governed by the rules and regulations set down in its company memorandum and articles of association originally dated 12 February 2009 and last updated by a special resolution on 29 June 2009.

Our Values

In undertaking our remit we are:

- *Ambitious* to see UK urology care, treatment and practice is the best in the world.
- *Dedicated* to beating all urology diseases through research and training.
- *Proud* of working in urology and committed to transforming the lives of people with a urology condition.
- *Collaborative*; working with researchers, urologists, nurses and health care professionals, influencers and decision makers, other charities, patients and their families we are improving the nation's urology care.

What we do

We seek to improve patient treatment and care through investing in research and training. We fund research that increases our understanding of urological diseases and that can bring about change in urology practice and guidelines to the benefit of patients. We are also looking for ways that can make treatments more effective and kinder. We are driving improvement in standards in urology practice through training and we are developing the next generation of urological experts who can meet the challenge of the increased burden of disease and who put excellence of care at their core.

Our website provides information on the signs and symptoms of urological diseases and sets out some of the treatment options available. Our campaigns such as Urology Awareness Month in September bring urology conditions to the public eye, and focus on breaking the stigma of these diseases.

Public Benefit

The trustees have taken The Charity Commission's general guidance on public benefit into consideration in preparing their statements on public benefit contained within this trustees' annual report. In accordance with its charitable objectives, The Foundation gives grants to individuals and not-for-profit organisations to:

- Promote the study of urological cancers and conditions by supporting and carrying out research into the causes, prevention, diagnosis and method of treatment of this disease and by publishing the useful results of such research;
- Provide opportunities for training and education of health professionals working in urology, in order to advance practice and improve patient treatment and care;
- Such other purposes for the benefit of the community as shall be exclusively charitable as the trustees from time to time shall decide.


In addition, TUF provides information on its website on urological cancers and conditions, and raises awareness through social media channels and media such as press and radio.


Grants policy


TUF advertises its programmes and awards on its website and through its professional e-newsletter. Applications for Research Scholarship funding are assessed by the SEC and the Reviewing Panel. Other applications for funding are assessed by the SEC.

TUF is a member of the Association of Medical Research Charities (AMRC) and abides by its standards and guidelines for peer review and funding. It is also a National Institute for Health Research (NIHR) non-commercial Partner. Research studies funded through TUF's NIHR approved funding streams are automatically eligible for consideration for NIHR Clinical Research Network (CRN) support subject to meeting the standard study eligibility criteria.


Comparison of 2020 v 2021
An Overview














Achievements and Performance in 2021

1. Seeking better treatments and cures through research

With over 750,000 urology hospital care episodes each year in the UK, urology is a specialty faced with a high demand, yet the field remains remarkably under researched. While there have been notable successes in prostate cancer, much of urological practice lacks level one evidence to guide practice. Surgery in general, and urology in particular, currently attracts a disproportionately small proportion of clinical trials funding compared with the massive burden of urological diseases on NHS expenditure. Two key factors that have led to lack of trials are the complexity of surgical trials and the potentially hazardous and invasive nature of interventions.

We set out to address these challenges by creating an infrastructure to develop fund worthy urological trials by securing sufficient methodological expertise and support for good research ideas. Successful trials that go on to develop evidence for best practice and guidance on treatment of urological diseases will result in huge patient benefits. Our competitive call to work with an established Trials unit within the UK attracted responses from one third of all the units throughout the UK, leading us to set up the TUF Trials Unit in partnership with the Centre for Healthcare Randomised Trials (CHaRT) in Aberdeen.

TUF Trials Unit (TTU): in 2021 following a Dragon's Den session to consider ideas for urological trials, two proposals have been taken forward by the TTU:



Urology trainee, Nikita Bhatt, wants to investigate the use of stents following stone surgery. Patients undergoing uncomplicated telescopic stone surgery routinely have a stent placed after their operation in majority of the cases, despite guidelines stating these may not be necessary.

Stents have a role in some cases but patients usually find them bothersome, interfering with their daily activities and affecting their quality of life. In some cases they can cause harm.

No previous trial has compared patients' quality of life with or without a stent after such a procedure, we hence want to find out if there is a difference in this that may change clinical practice.



Consultant urologist, Krishna Narahari, wants to assess the clinical and cost effectiveness of pelvic lymph node dissection (PLND) in high-risk prostate cancer surgery.
The role of PLND in prostate cancer surgery has been controversial for the last 3 decades. Perceived benefits include optimal staging, identifying candidates for additional therapies and possible better cancer control. Harms include higher op time and complications such as blood loss, lymph collections requiring interventions and injury to nerves and vessels. To date, there remains a distinct lack of evidence of benefit of PLND in prostate cancer.

The purpose of this clinically integrated pragmatic randomised multicentre UK trial is to address this evidence gap and inform surgical practice worldwide.

2021 also saw the introduction of our new funding stream, the **Innovation & Research Award**, replacing our previous Research Scholarships. The award funds projects up to a value of £60,000 that seek to use new, exciting, innovative approaches to address urological diseases and disorders. The projects must either (a) aim to create innovative treatments or devices, (b) aim to deliver innovative care pathways or (c) aim to use innovative research techniques or methods. It was gratifying that in its first year, the award attracted a high number of applications (19) from across the UK and a wide range of urological conditions.

Five projects were selected for funding:

Kidney tumours: There are approximately 13,000 new kidney cancer diagnoses in the UK each year, projected to rise by 26% by 2035. Due to increasing use of medical imaging, most kidney tumours are

now detected incidentally at an early stage i.e. picked up on a scan done for another reason. However, not all lumps that grow in the kidney are cancer. As many as two in every ten growths found in the kidney incidentally are a non-cancerous. This project aims to evaluate existing and novel diagnostic imaging techniques in the assessment of small renal tumours, with a view to reducing unnecessary invasive diagnostics and management in patients with benign disease.

Kidney stones: Kidney stone disease is a common problem that affects ~20% of men and ~10% of women by 70 years of age. Unfortunately, up to 50% of individuals who have formed a kidney stone will form a second stone within 10 years of their first. Furthermore, individuals who recurrently form kidney stones are at increased risk of chronic kidney disease. The reasons why some people form kidney stones recurrently are poorly understood and the need for improved treatments is widely recognised. This project aims to understand associated genetic variants and identify drugs that have the potential to be innovative therapies for kidney stone prevention.

Bladder Cancer: Bladder cancer (BC) is the seventh most common cancer in the UK and is associated with increasing age and smoking. As the population ages rates of incidence will likely increase. The current gold standard for diagnosing BC is cystoscopy under local anaesthesia but this invasive procedure is associated with complications. This study will look at alternative ways of diagnosing BC through electrical analysis of cells in urine, and identify methods of tumour grading, ahead of a subsequent clinical trial.

Incontinence: The prevalence of Stress Urinary Incontinence (SUI) in women aged over 21 years in the UK has been reported to be 24%, with 9% of those considering it bothersome enough to want surgical treatment. This project aims to develop and validate a system that can be used to measure pressure along the urethra (waterpipe/bladder outlet) during surgery to treat stress urinary incontinence (SUI, leakage of urine during exercise, cough, sneeze or strain).

Pelvic Mesh implants: In pelvic mesh surgery, a sheet of material is permanently implanted to support pelvic organs that have shifted downwards into the vagina, or to treat the involuntary leaking of urine. Research suggests up to 30% of women experience long-lasting pelvic pain after pelvic mesh surgery. However, the current tools used to assess pain related to pelvic mesh implants have not been developed specifically for these patients. Therefore, our current understanding of the problem might be incomplete. To address this issue, the aim of this project is to develop a questionnaire that can be used to assess pain associated with pelvic mesh implants. In particular, the questionnaire could be used to assess outcomes following mesh removal procedures.

In 2021 our **Small Research Projects fund**, which is geared towards improving treatment and care, once again received a high level of applications in the first round (11). We had increased our budget for these awards in 2021 to accommodate four projects. The variety and quality of the applications were such that we were able to make all four awards from this tranche but sadly had to close the fund for the rest of the year. Awards were for the following projects:

- Accurate and timely detection of testicular torsion by urology registrars in training.
- A pilot study into measuring urine flow remotely, to speed up diagnostic appointments and reduce waiting times.
- Research into BXO, a chronic and progressive inflammatory skin disease affecting the male external genitalia, causing deformities and considerable pain.
- Developing new measures for reporting male infertility trials, to ensure better treatments going forward.

In addition to the above grants and awards, we were also fortunate to receive funding from The Champniss Foundation and the Champniss Charitable Trust to fund a **Cancer biomarker / wearable sensor study**, to establish and test a repository for integrating genomic and wearable sensor data in order to explore a relation between the two and cancer outcomes. This study is being led by Professor John Kelly at University College London (see box).

Case study: Seeking better treatments and cures through research

Collecting and integrating genomic and wearable sensor data in order to explore a relation between the two and cancer outcomes.

Covid-19 has highlighted the need to be able to track post-operative cancer patients remotely for any signs of degradation in health or recurrence of cancer. Moving forwards, there will also be a desire to reduce unnecessary hospital appointments for the patient, if remote monitoring is effective and reliable.

There is a correlation between a patient's physical activity and recurrence of cancer. Loss of activity is strongly associated with cancer specific survival in patients after radical cystectomy. An initial study in post-operative cancer patients wearing fitness trackers (eg Fitbits or similar) showed that loss of activity was detected *prior to evidence of measurable disease on imaging*, and suggests that there may be changes in activity at a very early stage of cancer recurrence. We now wish to combine this data with genomic changes in patients' blood samples for evidence of cancer recurrence.

Taken together, the combined approach may well reveal markers for clinically relevant states such as disease recurrence and progression. Further, linkage between the genomic state and the activity state may highlight cases for additional therapies, and be a means to monitor response to therapy.

2. Improving knowledge and skills through training

The impact of the pandemic on formal training continued during 2021 while the NHS struggled to cope with backlogs and staff shortages. Nevertheless, we launched our TUF/Urolink Fellowships which provide UK trainees opportunities to teach and train in low to middle income countries, and saw a take up in applications for trainees to supplement their training.

Support for urology trainees

The **TUF/Urolink Fellowships** is open to those senior level trainees who have completed their FRCS (Urol) and it is expected that the successful applicants will accompany established workshop teams in the first instance, and stay to work in that centre (or those centres) for an unspecified time after the workshop team's departure. In 2021 three awards were made:

- Nishant Bedi from Barts Health NHS Trust
- Patrick Gordon from St James Hospital Leeds
- Su-Min Lee from Musgrove Park Hospital, Taunton

The destinations for each of the visits are still to be advised, and we hope they can take place in 2022.

The **Keith Yeates Medal/Ralph Shackman** prize is only conferred when candidates achieve over 90% in their Intercollegiate Specialty Examination in Urology. In 2021 two candidates made the grade: Ms Sophia Cashman and Mr Ben Starmer. They each receive a travelling fellowship worth £2,000. Due to ongoing travel restrictions at the time, they have yet to arrange their visits.

Support for urology nurses

Our planned **Communications and Leadership Skills** course for nurses, originally planned for 2020, had to be postponed yet again because of the pandemic. A date has now been set for 2022. Sadly, because of the ongoing pandemic and restrictions around travel, there were no applications for TUF travel grants for nurses in 2021. We hope this funding stream will pick up in 2022. TUF is liaising with

representatives of the British Association of Urological Nurses (BAUN) to support ongoing nurse training and education.


3. Improve public awareness of urological conditions and symptoms

The Urology Foundation has continued to build public awareness of urological cancers and conditions as well as raise the profile of urologists and urology nurses for better patient care. Our main channel for engaging with the public has been through our website, with visitor numbers spiking during Incontinence Week in June and during September Urology Awareness Month. The most visited pages continue to be those that provide health information on the male reproductive organs, Urinary Tract Infections (UTIs), kidney stones and bladder problems. The majority of website visitors are women (52%) but the highest number of users were in the 18 – 34 age range, comprising 44% of visitors to the site.

TUF's social media profile is also growing with Facebook and Instagram more popular among the general public. Our Facebook user numbers have historically risen most around World Continence Week in June and Urology Awareness Month in September. Twitter and Linked-In have higher numbers of urology professionals engaging. During 2021, our Twitter followers increased by 10 per cent bringing the total number of followers to 4,436. The average numbers of people seeing each tweet is just shy of 1,200.

Our Urology Awareness Month in September focused on the need for people to be open about concerns and to get checked if worried about any symptoms; provided key information on signs to look out for and tips and advice for maintaining good urological health (examples below). We featured in key press such as the *Journal of Clinical Nursing*, and a Guardian Media Planet supplement, as well as providing content for online health forums and lifestyle websites such as *ManDad Magazine*.







We continued to partner with TalkHealth, an online health website, to provide information blogs and expert-led medical advice forums about urological health matters to members of the public, and to provide articles on urological health matters for supplements in national newspapers.

4. Plans for the future

The incidence of urological cancers and conditions is increasing, as is the prevalence of bladder and incontinence problems, benign prostate problems and kidney stones. This is leading to major morbidity and quality of life issues for urology patients and places a growing burden on the healthcare service, and on those working within it. Allied to this, the way in which healthcare is delivered will need to change, with an emphasis on personalised medicine and community-based services which are designed to enhance both patient outcomes and experience.

In 2021 we introduced two major new grant programmes, the TUF Trials Unit and our Innovation & Research Awards, and we were gratified to see such a positive response and so many applicants to these. We aim to ensure that more urology professionals from around the UK regions can benefit from the opportunities we offer, and we intend to create some regionally specific awards to facilitate access to our programmes.

In May 2021 our CEO, Louise de Winter, announced her intention to stand down and move to a part time role within the charity. She now has responsibility for our programmes and grants, and has plans for introducing a new system to make it easier for people to apply online for grants and for peer reviewers to comment. With over 50 active open grants, TUF needs a robust system for managing our grants and grant holders, and for keeping track of where the research we have sponsored leads.


Rebecca Porta joined the charity as CEO on 4 January 2022. Her appointment provides us with an opportunity to revisit our strategic goals and to ensure our programmes and activities align with the needs of urology patients and urology community. A key focus will be to ensure that going forward, we work with a wide range of stakeholders to drive change and improve the outlook for those affected by or interested in urology.

Given the impact of the pandemic we will look to diversify our income streams – this will include expanding our events programme, developing partnerships with the wider business community alongside strengthening existing relationships and investing in our marketing and communications programme. To this end there are plans to hold a strategy session in early 2022.

The key to meeting the many challenges of urological disease is to develop a cadre of top-quality urological professionals who have access to the very latest research developments and technological innovations, and who put excellence of care and continuous professional development at their core. We will develop research and training programmes with these outcomes, and the wellbeing and quality of life of patients, in mind.

Financial Review

Financial Results of Activities & Events



The total value of net assets held by The Urology Foundation on 31 December 2021 was £2,447,884 (2020 £2,158,423). The Foundation's fundraising activities and other initiatives during the course of 2021 generated a total of £686,522 of voluntary income (2020 £1,366,619) and a further £83,389 (2020 £64,920) from specific fundraising event income.

Fundraising

TUF continues to be wholly reliant on fundraised and donated income to fulfil its remit. The charity operates a mix of its own fundraising activities and those organised and undertaken by third parties on its behalf.

The ongoing uncertainty of Covid-19 continued to impact our fundraising, with our charity trek to Machu Picchu having to be postponed once again. However, our annual Bike4TUF cycle ride took place with a 250 mile ride through the north Cotswolds and Warwickshire, raising over £30,000. We are also grateful to a number of individual patients, supporters, urologists and trainees who undertook various fundraising challenges for TUF, raising over £7,800.

In November we were fortunate to be able to finally go ahead with our Wine Tasting Dinner and auction at Vintners' Hall, with TUF Patron and *The Times* Wine Correspondent, Jane MacQuitty, as our host and guide to the wines. The evening raised £45,000 and it was clear that there was a real joy among guests at being able to be together in a room, rather than on a zoom screen.

However, once again a huge and special thanks must be paid to TUF's ongoing supporters who donated throughout the year. The Foundation also received a number of significant donations from Trusts and Foundations and individuals, which did so much to enable our programmes and operations to continue throughout this difficult year. *(See Annex A.)*

Reserves & Liquidity Policy

The Foundation currently has 'free reserves' of £2,097,116 (31 December 2020: £1,675,542).

The Foundation's policy is to maintain reserves sufficient to continue to fund its objectives on a long term basis, and to ensure that TUF operates with an adequate level of liquidity to (i) minimise the risk associated with a temporary or unforeseen shortfall in liquidity; (ii) manage its cash and

investments to meet its liabilities and remain a going concern for at least 1 year in the event of an unplanned drop in income. Liquidity is defined as cash and the investment portfolio held as Unrestricted funds. The Policy establishes a minimum liquidity target for TUF of £500,000 ("Minimum Required Reserve") subject to future modification by the Finance Committee and trustees' approval.

The trustees consider that reserves held in excess of the amounts required to fund all future commitments together with the initial fund of £500,000, will be available to increase its visibility and expand its operations including funding for further research and a wider range of projects.
The trustees plan levels of expenditure from unrestricted and restricted funds for the year ahead based upon the level of incoming resources for the current year as well as utilising restricted funds.

Statement of going concern

The Foundation's unrestricted net funds generated in 2021 are judged to be sufficient to meet the requirements of the charity for charitable giving in the coming year.

Investments Policy

The Foundation's investments are managed by Rothschild Bank (CI) Limited. The Treasurer and the Chief Executive are responsible for managing the relationship with Rothschild but changes in investment strategy are subject to approval by the board of trustees. The investment manager is asked to attend at least one board meeting annually.

The board follows a medium risk 'Balanced' investment strategy which is intended to achieve steady growth over the long term through a diversified approach to investment. Capital preservation in real terms over a long term horizon is the primary objective and some volatility is acceptable in order to achieve this. TUF's investments are held in the Exbury Fund, an ethical portfolio managed by Rothschild. The fund achieved a 14.5% return over 2021.

All other Foundation funds are held in accounts with the charity's bankers, National Westminster Bank plc. In 2021 the charity closed its account with CCLA Investment Management Limited, and the balance of funds (c. £11,000) were transferred to the charity's NatWest bank account.

Remuneration policy

In setting salary levels, The Urology Foundation follows the National Council for Voluntary Organisation's advice that a charity's pay policy should be to offer fair pay to attract and keep appropriately-qualified staff to lead, manage, support and/or deliver the charity's aims. It also conducts online research of charity salaries and uses surveys to benchmark levels of pay. The Urology Foundation does not automatically award its staff with annual salary increases, either incremental or cost of living.

Pensions policy

The charity offers a stakeholder pension, operated by The People's Pension (B&CE Holdings), in line with statutory requirements. All new staff are automatically enrolled but can opt out if desired.

Equal opportunities and diversity policy

TUF is committed to being an Equal Opportunities employer and to respecting diversity, and is determined to ensure that no job applicant, employee, or trustee receives less favourable treatment on the grounds of their age, disability, gender reassignment, marriage and civil partnership, pregnancy or maternity, race, religion or belief, sex or sexual orientation. TUF also seeks to ensure that its employees are not victimised or subjected to harassment.

The policy applies to recruitment and selection for jobs in the Foundation, career development and training, promotion and transfer, performance management, pay, redundancy, disciplinary and grievance procedures, the application of terms and conditions of employment and any other aspects of employment with the Foundation.

The policy also applies to third parties such as trustees and committee volunteers, clients (ie grant applicants) and suppliers.

Principal risks and uncertainties

The trustees take the management of risks seriously. The Chairman of the board of trustees and the Chief Executive are charged with responsibility to ensure that the risks which have been identified are adequately assessed and properly mitigated on a regular basis. The potential risks have been discussed with the Chairman and the charity and a formal risk register is kept and brought before the board on at least an annual basis.

Impact of Covid-19 and war in Ukraine

The pandemic continued to affect the urology workforce, which meant that applications to some of our programmes – mainly travel and fellowship grants – remained low. However, our applications for research grants were not impacted, and we also saw some pickup in activity with researchers returning to labs. Looking forward, the ongoing war in Ukraine has broader economic implications, some of which will be reflected in our investment fund holdings. Our Investment Manager keeps us regularly updated and there is no immediate cause for concern or action.

Risks to Data

The charity takes its responsibilities for data very seriously. We follow a Data Protection policy based on the GDPR and have a nominated trustee (Mr Adrian Joyce) who has Board oversight for data compliance. We use a professional data base provider that stores all information in the cloud and this is secured using a two-step password verification. We review our records on an ongoing basis and delete old or historical records that are no longer relevant, and remove people who no longer wish to hear from us (provided that there is no financial information that we need to retain).

Other key risks are assessed as follows:

Governance /Environmental	Impact of the external environment on fundraising, in particular: public confidence in charities; new fundraising regulations; Data Protection Regulations.
Income Sources	TUF is wholly reliant upon voluntary income as an annual source of funding. It is the role of the trustees to manage risk exposure on fundraising activities and in doing so to accept an appropriate level of risk in order to raise income from a wide range of sources.
Risk of data breach	The charity uses a professional database provider that stores all information in the cloud and this is secured using a two-step password verification. TUF also regularly deletes any old or historical records that are no longer relevant. The charity's own day to day working documents are also stored on a cloud-based system. We believe that keeping data in the cloud is still safer than keeping it on our own servers. TUF staff are regularly made aware of possible phishing scams and to be alert to any potential email or system data breaches.
Key Person risk	The small staff base makes TUF heavily reliant on the Chief Executive and a few key trustees so the unexpected loss or departure of the Chief Executive or certain trustees is a risk. Succession planning processes have been identified as necessary going forward.
Investment Risk	TUF's success is directly related to the amount of resource it can devote to its objectives, so the key risk identified by trustees relates to the proper management of its funds. Imprudent or unprofessional decisions could majorly impact on the performance of those funds. In common with similar charities, TUF employs professional fund managers, whose performance is regularly reviewed by the Treasurer together with other trustees.
Risk to Employees	Employees are not subject to risks other than those likely to be associated with routine office work. Apart from obtaining statutory Employers Liability

	Insurance, TUF nonetheless treats the welfare of its staff as a priority. The Chief Executive is the Nominated Safety Officer for the purposes of the Health and Safety at Work Act. The premises are checked and maintained by the landlord and by the fire service to ensure appropriate mitigation of the risk of fire. Employees are aware of the location of fire extinguishers. The charity also has a number of policies in place covering Equal Opportunities, Lone Working, Working from Home and Safe Guarding Vulnerable People.
Risk that research fails to deliver results	Grants awarded are subject to rigorous review by the SEC and Reviewing Committee. Grantees are expected to submit progress reports and these are reviewed by the SEC and TUF. The charity maintains ongoing communication with grant holders.
Loss of Records	To protect against the loss of records, and to increase data security, files are stored in the cloud. The risk of any unsaved data being critical to TUF is regarded as insignificant. Other similar risks are dealt with by insurance.

Structure, Governance & Management

The Urology Foundation is a charity and a company limited by guarantee and was established on 12 February 2009 to incorporate the charitable activities of the British Urological Foundation (BUF), an unincorporated charitable trust established in 1994 by the British Association of Urological Surgeons and BJU International, and a registered charity since 17 March 1995. The Urology Foundation itself became a registered charity on 19 March 2009.

Charity Governance Code

The Board and Executive of the charity abide by the standards set by the Charity Governance Code when executing their duties. The overall strategic direction of the charity is determined by the trustees, who meet three times each year including an Annual General Meeting.

Trustee Recruitment, Training and Induction

The Foundation seeks to achieve a balance of lay and medical trustees. Appointed trustees are recruited on the basis of fulfilling the criteria to provide a balance of experience and knowledge. Members of the charity's Scientific and Education Committee (see below) are recruited through calls in industry publications.

All new trustees are provided with a face-to-face induction meeting and an induction pack. They are provided with relevant Charity Commission publications and regularly briefed on developments and opportunities that will support their general understanding of the voluntary sector, healthcare and medical research issues.

Appointment & Election

The Trustees and Chairman are appointed for an initial period of three years that can be extended for a further three-year term. A further extension may be made if it is deemed to be in the best interests of the Charity. The governing document requires that there should be a minimum of seven trustees.

Two of the trustees are required to be representative trustees, one nominated by The British Association of Urological Surgeons ("BAUS") and one nominated by British Journal of Urology International ("BJUI"). All other trustees, known as appointed trustees, are appointed by unanimous written resolution of all the trustees present and/or voting at a special meeting of trustees called to take place immediately before or after an ordinary meeting of trustees.

The representative trustee nominated by BAUS is the President of BAUS and his appointment to the board is concurrent with his post at BAUS, which is for a period of two years.

The Executive Team

The Chief Executive, is responsible for the day-to-day management of the charity. She is assisted by a Director of Research & Operations and a Fundraising & Events Manager.

The Chief Executive deals with the implementation of policy and strategic decisions taken by the board of trustees. She and the appropriate staff members attend the meetings of the board of trustees and of all sub-committees, and report on the day-to-day operations of the charity. The Foundation currently operates the following sub-committees:

Scientific and Education Committee (SEC)

The SEC is responsible for the development and assessment of The Foundation's research, education and training programmes and the review and administration of The Foundation's grant making policy. The Chairman of the SEC, Professor Grant Stewart, is a member of the board of trustees, and reports back to the board on the work of the Committee. The SEC is made up of clinical and academic urologists and scientists with an interest in urology, and lay representatives. The BAUS Surgical

Specialty Lead also sits on the SEC, *ex officio,* to provide further insight into the research and training needs of the profession.

Research Scholarship Review Panel
The Research Scholarship Review Panel is responsible for assessing applications for TUF's major research grants and marking these according to the requisite criteria being met. In this task it assists the SEC in its final decision on who should receive grants. The Research Scholarship Review Panel is made up of clinical trustees and academic urologists and scientists with an interest in urology.

Membership of the SEC and Review Panel can be viewed on the charity's website: https://www.theurologyfoundation.org/about-us/who-we-are/our-team/committees. They provide their services as volunteers and TUF is enormously grateful to them.

Finance Committee
The charity Finance Committee is chaired by the Treasurer, Ms Angela Daniel. Membership includes The Chairman of the Board and the Chairman of the SEC, and two other trustees: Mr Becker & Mr Nicol, the Chief Executive and the Director of Research & Operations. Any recommendations made by the Finance Committee are brought to the board of trustees for discussion and ratification. The Treasurer has oversight of the charity's bank and investment accounts.

Relationships with Related Parties
The Urology Foundation continues to maintain close links with its two founding charities, The British Association of Urological Surgeons (BAUS) and the BJU International, whose representatives are trustees. TUF is also represented on BAUS Council by trustee, Mr Ben Challacombe.

Representation on Other Bodies
The charity is a member of the Association of Medical Research Charities (AMRC), which confers a quality mark for TUF's peer review processes, as well as advocating for charity-funded research with government. The Urology Foundation is a National Institute for Health Research (NIHR) non-commercial Partner. This means the studies that we fund may be eligible to access the NIHR Study Support Service which is provided by the NIHR Clinical Research Network. In 2022, TUF became a member of Cancer 52, a collaborative voice for rare and less common cancers and a member of the National Council for Voluntary Organisations.

Reference and administrative details

The registered charity name is "The Urology Foundation" (sometimes referred to as "TUF"), a charity and a company limited by guarantee.

Trustees

Mr Paul Fletcher *(Chair)*
Ms Angela Daniel (*Treasurer)*
Mr Mark Becker *(Secretary)*
Prof Grant Stewart (*Chair, SEC)*
Mr Ben Challacombe
Ms Mary Garthwaite
Mr Adrian Joyce
Prof Alan McNeill *(BJUI rep, appt Feb 2022)*
Mr Roland Morley
Mr David Nicol
Mr Tim O'Brien *(BAUS rep)*
Prof Krishna Sethia *(BJUI rep, retd Oct 2021)*
Ms Hannah Warren

President

Prof Roger Kirby

Patrons

Mr Handel Evans
Sir Ranulph Fiennes OBE
Mrs Rosemary Macaire
Ms Jane Macquitty MBE
Mr Steven Norris

Ambassadors

Mr Alex Corbisiero
Mr Stephen Fry
Mrs Kate Holmes

Chief Executive

Ms Rebecca Porta *(appt 4 January 2022)*

Registered Office

1-2 St Andrew's Hill
London
EC4V 5BY

Charity number

1128683 (England & Wales)

Company number

06817868

Auditors

Dunkley & Co Ltd
Woodlands Grange, Woodlands Lane
Bradley Stoke
Bristol BS32 4JY

Bankers

National Westminster Bank plc
PO Box 2021
10 Marylebone High Street
London W1A 1FH

Investment Manager

Rothschild Bank (CI) Limited
St. Julian's Court, St. Julian's Avenue
St. Peter Port
Guernsey GY1 3UA

Trustees' & Directors' Responsibilities in the Preparation of Financial Statements

The trustees (who are also the directors of The Urology Foundation for the purposes of company law) are responsible for preparing the trustees' Annual Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company as at the balance sheet date, and of the incoming resources and application of resources, including income and expenditure, for that period. In preparing those financial statements, the trustees and directors are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The trustees are responsible for keeping proper accounting records, which disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with Companies Acts 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from the legislation in other jurisdictions.

Auditor

Mr Matthew Dobbins (FCA), of Dunkley & Co Ltd. has agreed to act as Auditor.

Statement as to disclosure of information to the auditor

The trustees and directors at the date of approval of this trustees' annual report confirm that so far as each of them is aware, there is no relevant information of which the charity's auditor is unaware, and the trustees and directors have taken all steps that they ought to have taken to make themselves aware of any relevant information and to establish that the auditor is aware of that information.

Paul Fletcher
Paul Fletcher (Sep 20, 2022 12:36 GMT+1)

Paul Fletcher, Chairman

Date: Sep 20, 2022

Annex A

The Urology Foundation is extremely grateful to the following Trusts & Foundations and organisations who kindly supported our work in 2021:

Amelia Chadwick Trust
Arbuthnott Charitable Trust
Berni Charitable Trust
Charles Reynolds Fund
Dennis Byrne Charitable Trust
Florence Shute Millennium Trust
Girdlers' Company
Heathside Charitable Trust
Hudson Charitable Trust
Irving Memorial Trust
Lord Belstead Charitable Trust
Masonic Charitable Foundation
Penguins Against Cancer
Peter Stebbings Charitable Trust
PF Charitable Trust
Sidney Jason Charitable Trust
The Hadley Trust
The Manet Trust
The Rosetrees Trust
The Thompson Family Charitable Trust
Yardley SBH Trust

We are also grateful to the following companies and their staff who donated in 2020:

Bank of England Court Award
CJ Medical
Ginmeister Ltd
Intuitive Surgical
Pelicans Manufacturing Co Ltd
Santander
Solutions PT
WPA Health
Yandell Publishing

Thank you to all our donors, fundraisers, supporters and volunteers who have made The Urology Foundation's work possible.

Report of the Independent Auditors to the Trustees of The Urology Foundation (Registered number: 06817868)

Opinion
We have audited the financial statements of The Urology Foundation (the 'charitable company') for the year ended 31 December 2021 which comprise the Statement of Financial Activities, the Balance Sheet, the Cash Flow Statement and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 December 2021 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern
In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate. Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information
The trustees are responsible for the other information. The other information comprises the information included in the Annual Report, other than the financial statements and our Report of the Independent Auditors thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Matters on which we are required to report by exception
We have nothing to report in respect of the following matters where the Charities (Accounts and Reports) Regulations 2008 requires us to report to you if, in our opinion:

- the information given in the Report of the Trustees is inconsistent in any material respect with the financial statements; or
- the charitable company has not kept adequate accounting records; or
- the financial statements are not in agreement with the accounting records and returns; or
- we have not received all the information and explanations we require for our audit.

Report of the Independent Auditors to the Trustees of
The Urology Foundation (Registered number: 06817868)

Responsibilities of trustees

As explained more fully in the Statement of Trustees' Responsibilities, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Report of the Independent Auditors to the Trustees of
The Urology Foundation (Registered number: 06817868)

Our responsibilities for the audit of the financial statements
We have been appointed as auditors under Section 144 of the Charities Act 2011 and report in accordance with the Act and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Independent Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Extent to which the audit was considered capable of detecting irregularities, including fraud

We identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and then design and perform audit procedures responsive to those risks, including obtaining audit evidence that is sufficient and appropriate to provide a basis for our opinion.

Identifying and assessing potential risks related to irregularities

In identifying and assessing risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, we considered the following:

- The nature of the charitable sector, control environment and performance including the design of the organisation's remuneration policies;

- Any matters we identified, having obtained and reviewed the organisation's documentation of their policies and procedures relating to:

o Identifying, evaluating and complying with laws and regulations and whether they were aware of any instances of non-compliance;

o Detecting and responding to the risks of fraud and whether they have knowledge of any actual, suspected or alleged fraud;

o The internal controls established to mitigate risks of fraud or non-compliance with laws and regulations;

o The matters discussed among the audit engagement team regarding how and where fraud might occur in the financial statements and any potential indicators of fraud.

As a result of these procedures, we considered the opportunities and incentives that may exist within the organisation for fraud and identified the greatest potential for fraud in the areas of management override of controls, going concern, income recognition, and the appropriateness of expenditure.

We also obtained an understanding of the legal and regulatory framework that the organisation operates in, focusing on provisions of those laws and regulations that had a direct effect on the determination of material amounts and disclosures in the financial statements.

Audit response to risks identified

Our procedures to respond to risks identified included the following:

- Enquiring of management, concerning actual and potential litigation and claims;

- Substantive testing to vouch source records to the financial statements;

- Performing analytical procedures to identify any unusual or unexpected relationships that may indicate risks of material misstatement due to fraud;

- Enquiring of management the internal controls in, evaluating each control for weakness and vouching to evidence of the control taking place;

- In addressing the risk of fraud through management override of controls, testing the appropriateness of journal entries and other adjustments; assessing whether the judgements made in making accounting estimates are indicative of a potential bias; and evaluating the business rationale of any significant transactions that are unusual or outside the normal course of business.

We also communicated relevant identified laws and regulations and potential fraud risks to all engagement team members, and remained alert to any indications of fraud or non-compliance with laws and regulations throughout the audit.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Independent Auditors.

Use of our report
This report is made solely to the charitable company's trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. Our audit work has been undertaken so that we might state to the charitable company's trustees those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's trustees as a body, for our audit work, for this report, or for the opinions we have formed.

Matthew Dobbins (Sep 21, 2022 08:56 GMT+1)

Dunkley's
Chartered Accountants
Registered Auditors
Eligible to act as an auditor in terms of Section 1212 of the Companies Act 2006
Woodlands Grange
Woodlands Lane
Bradley Stoke
Bristol
BS32 4JY

Date: Sep 21, 2022

THE UROLOGY FOUNDATION

STATEMENT OF FINANCIAL ACTIVITIES
for the year ended 31 December 2021

	Note	Unrestricted Funds £	Restricted Funds £	Total 2021 £	Total 2020 £
INCOME					
Donations and legacies	1	639,590	46,932	686,522	1,366,619
Other trading activities	2	83,389	-	83,389	64,920
Investments	3	41,020	-	41,020	653
TOTAL INCOME		763,999	46,932	810,931	1,432,192
EXPENDITURE					
Raising Funds					
Donations and legacies	4	42,022	4,665	46,687	51,864
Trading activities	5	21,262	2,358	23,620	22,612
Investment management costs		72	-	72	365
Expenditure on Charitable activities					
Raising Awareness	6	77,315	8,575	85,890	88,885
Grant making	7	614,398	128,530	742,928	1,068,277
Net (Gains) on investment assets	11	(377,255)	(472)	(377,727)	(360,241)
TOTAL EXPENDITURE		377,814	143,656	521,470	871,761
NET INCOME/(EXPENDITURE)		386,185	(96,724)	289,461	560,431
RECONCILIATION OF FUNDS					
Fund balances brought forward at 1 January 2021		1,675,542	482,881	2,158,423	1,597,992
Transfer between funds		35,389	(35,389)	-	-
FUND BALANCES CARRIED FORWARD AT 31 DECEMBER 2021		2,097,116	350,768	2,447,884	2,158,423

The net movement in funds for the year arises from the charity's continuing operations.

No separate statement of total changes in equity has been presented as all such gains and losses have been dealt with in the statement of financial activities.

The notes on pages 29 to 39 form part of these accounts

THE UROLOGY FOUNDATION

STATEMENT OF FINANCIAL ACTIVITIES
for the year ended 31 December 2020 (Full fund comparative)

	Note	Unrestricted Funds £	Restricted Funds £	Total 2020 £
INCOME				
Donations and legacies	1	515,235	851,384	1,366,619
Other trading activities	2	64,920	-	64,920
Investments	3	653	-	653
TOTAL INCOME		580,808	851,384	1,432,192
EXPENDITURE				
Raising Funds				
Donations and legacies	4	35,877	15,987	51,864
Trading activities	5	20,350	2,262	22,612
Investment management costs		365	-	365
Expenditure on Charitable activities				
Raising Awareness	6	79,994	8,890	88,884
Grant making	7	378,014	690,263	1,068,277
Net (Gains) on investment assets	11	(359,687)	(554)	(360,241)
NET INCOME/(EXPENDITURE)		154,913	716,848	871,761
NET (EXPENDITURE)		425,895	134,536	560,431
RECONCILIATION OF FUNDS				
Fund balances brought forward at 1 January 2020		1,249,647	348,345	1,597,992
Transfer between funds		-	-	-
FUND BALANCES CARRIED FORWARD AT 31 DECEMBER 2020		1,675,542	482,881	2,158,423

The net movement in funds for the year arises from the charity's continuing operations.

No separate statement of total changes in equity has been presented as all such gains and losses have been dealt with in the statement of financial activities.

The notes on pages 29 to 39 form part of these accounts

THE UROLOGY FOUNDATION

BALANCE SHEET
as at 31 December 2021 Company Number 06817868

	Note	2021 £	2020 £
FIXED ASSETS			
Tangible assets	10	3,627	1,818
Investments	11	3,657,270	3,595,733
		3,660,897	3,597,551
CURRENT ASSETS			
Debtors	12	98,723	77,773
Cash at bank and in hand		238,420	217,109
		337,143	294,882
LIABILITIES: amounts falling due within one year	13	1,133,522	1,238,761
NET CURRENT LIABILITIES		(796,379)	(943,879)
LIABILITIES: amounts falling due in more than one year	13	416,634	495,249
NET ASSETS		2,447,884	2,158,423
THE FUNDS OF THE CHARITY			
Restricted income funds	15		
Robotic Surgery Training Fund		200,076	196,287
Prostate Cancer Research Fund		138,804	103,370
Bladder Cancer Fund		(31,425)	149,860
Travel Fellowship Fund		653	652
'EQUIP' Quality & Safety Pilot		-	30,889
Team Corbs - Testicular		2,158	1,823
Charles Reynolds		40,503	-
Unrestricted income funds	15		
General Fund		1,597,116	1,139,859
Designated Fund (Ralph Shackman)		-	35,683
Designated Fund (British Urology Foundation)		500,000	500,000
TOTAL CHARITY FUNDS	16	2,447,884	2,158,423

These financial statements have been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small charitable companies and with the Financial Reporting Standard 102.

The financial statements on pages 25 to 28 were approved by the trustees and authorised for issue on Sep 20, 2022 and are signed on their behalf by

Paul Fletcher
Paul Fletcher (Sep 20, 2022 12:36 GMT+1)
..... **Chairman**
Paul Fletcher
Sep 20, 2022
.....

Angela Daniel (Sep 20, 2022 13:07 GMT+1)
..... **Treasurer**
Angela Daniel
Sep 20, 2022
.....

The notes on pages 29 to 39 form part of these accounts

THE UROLOGY FOUNDATION

STATEMENT OF CASHFLOWS
as at 31 December 2021

	Note	2021 £	2020 £
CASH FLOWS FROM OPERATING ACTIVITIES:	14		
Net cash used in operating activities		(333,651)	973,271
Cash flows from investing activities:			
Dividends and interest from investments		41,002	291
Management fees paid from investments		(72)	(365)
Purchase of equipment		(2,159)	-
Transfer from cash		-	(1,045,830)
Proceeds from sale of investments		852,452	1,162,282
Purchase of investments		(536,261)	(1,161,969)
Net cash used in investing activities:		354,962	(1,045,591)
Change in cash and cash equivalents in the reporting period		21,311	(72,320)
Cash equivalents at the beginning of the reporting period		217,109	289,429
Cash and cash equivalents at the end of the reporting period		238,420	217,109

The notes on pages 29 to 39 form part of these accounts

ACCOUNTING POLICIES

BASIS OF ACCOUNTING

The financial statements have been prepared under the historical cost convention with items recognised at cost or transaction value unless otherwise stated in the relevant notes to these accounts. The financial statements have been prepared in accordance with the Statement of Recommended Practice: Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) issued on 1 January 2019 and Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102) and Charities Act 2011. The trust constitutes a public benefit entity as defined by FRS 102.

INCOME

Grants, donations and other similar types of voluntary income are brought into account when it is probable that they will be received, except that donated income is included gross of any attributable tax recoverable, where relevant. Donations given for specific purposes are treated as restricted income. Tax recoverable is recognised when claims are submitted to HM Revenue and Customs. Legacy gifts are recognised in the period in which the Charity becomes entitled to receive the income.

Income receivable from activities for generating funds and from investment income is accounted for on an accruals basis. Deferred income represents revenues collected but not earned as of 31 December 2021. This is primarily composed of income collected in advance of a fundraising event taking place and deferred until the charity is entitled to that income as and when the event takes place.

EXPENDITURE

Resources expended are allocated to the costs of generating funds or to the charity's principal activity where the costs can be identified as being directly related. All other costs are categorised as either support costs or governance costs, and are allocated in proportions based upon a suitable ratio applicable to the nature of the cost involved.

Grants payable are recognised in full in the period in which the approved offer is conveyed to the recipient. Grants are recognised and deferred where there is a long term commitment for the Charity. Where grants are recognised and conditions for staged grant payments are not met in subsequent years, an adjustment to grants payable will be made in the relevant accounting period. Expenditure includes irrecoverable VAT which is reported as part of the expenditure to which it relates.

TANGIBLE FIXED ASSETS

All tangible assets purchased that have an expected useful economic life that exceeds one year are capitalised and classified as fixed assets. Tangible fixed assets are stated at historical cost less depreciation. Depreciation is provided on all tangible fixed assets at rates calculated to write each asset down to its estimated residual value evenly over its expected useful life, as follows:

Office equipment	25% reducing balance

OPERATING LEASES

Rentals under operating leases are charged to the Statement of financial activities on a straight line basis over the lease term.

ACCOUNTING POLICIES

INVESTMENTS

The charity's investments are included in the balance sheet at their market value. The gains or losses arising upon their annual revaluation are included in the statement of financial activities.

FUND ACCOUNTING

The general fund comprises the accumulated surpluses of unrestricted incoming resources over resources expended, which are available for use in the furtherance of the general objective of the charity.

Designated funds are a particular form of unrestricted funds consisting of amounts, which have been allocated or designated for specific purposes by the trustees. The use of designated funds remains at the discretion of the trustees.
Restricted funds are funds subject to specific conditions imposed by donors. The purpose and use of the restricted funds are set out in the notes to the accounts. Amounts unspent at the year end are carried forward in the balance sheet.

FOREIGN EXCHANGE

Receipts and payments which occur in foreign currencies are included in the accounts at the amount into which they are converted in sterling, using the exchange rate on the day in which the transaction occurs.

GOING CONCERN

The Trustees as Directors of the Charity believe that there are no material uncertainties that may cast significant doubt about the ability of the Charity to continue as a going concern, due to the significant unrestricted reserves as at 31st December and the forecast income expected in 2022. As we prepare this statement in early 2022, it is clear that the long tail of the COVID-19 pandemic, and its impact on the NHS workload, continues to have a bearing on the charity's operations, with applications for programmes such as fellowships and travel grants still low. It remains to be seen whether our events fundraising and income will be impacted by global issues such as the war in Ukraine and the current cost of living crisis, which may affect future budgets for research and training. The trustees believe, however, that given the level of available cash and reserves, the charity can continue as a going concern.

FINANCIAL INSTRUMENTS

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

NOTES TO THE FINANCIAL STATEMENTS
for the year ended 31 December 2021

		Unrestricted funds £	Restricted funds £	2021 £	2020 £
1.	**INCOME FROM DONATIONS AND LEGACIES**				
	Grants received from charitable trusts and corporate sponsors	430,662	46,700	477,362	1,190,163
	Donations	204,348	232	204,580	162,456
	Legacies	4,580	-	4,580	14,000
		639,590	46,932	686,522	1,366,619
2.	**INCOME FROM OTHER TRADING ACTIVITIES**				
	Income from fundraising events	83,389	-	83,389	64,920
3.	**INVESTMENT INCOME**				
	Bank interest receivable on short term cash deposits	18	-	18	362
	Income from investments listed on a recognised stock exchange:				
	UK investments	41,002	-	41,002	291
	Overseas investments	-	-	-	-
		41,020	-	41,020	653
4.	**COSTS OF RAISING FUNDS VOLUNTARY INCOME**				
	Direct costs	25,398	2,822	28,220	30,191
	Support costs (see note 8)	16,624	1,843	18,467	21,673
		42,022	4,665	46,687	51,864

		Unrestricted funds £	Restricted funds £	2021 £	2020 £
5.	**COSTS OF RAISING FUNDS TRADING ACTIVITIES**				
	Costs of fundraising events	4,638	515	5,153	939
	Support costs (see note 8)	16,624	1,843	18,467	21,673
		21,262	2,358	23,620	22,612
6.	**COSTS OF RAISING AWARENESS**				
	Costs of fundraising events	10,821	1,203	12,024	2,190
	Support costs (see note 8)	66,494	7,372	73,866	86,695
		77,315	8,575	85,890	88,885
7.	**GRANT MAKING**				
	Research Scholarships awarded to 5 (2020: 3) individuals	295,939	(32,051)	263,888	120,950
	Cancer biomarker / wearable sensor study	-	195,000	195,000	750,830
	TUF Trials Unit	180,000	-	180,000	-
	Small Research Projects awarded to 4 (2020: 3) teams	29,738	-	29,738	29,800
	TUF Fulbright Research Fellowship Award	7,176	-	7,176	15,000
	Urolink Fellowship	4,500	-	4,500	-
	BAUN/TUF Nurse	2,156	-	2,156	6,200
	Other direct costs	169	-	169	-
	Keith Yeates medals awarded to 2 (2020: 1) individuals	(800)	-	(800)	2,000
	V Arumuham	(1,500)	-	(1,500)	-
	BAUS	-	-	-	477
	RSM Urology Section	-	-	-	6,000
	COVID-surg Urology Study	-	-	-	10,000
	Travel Grants	-	-	-	(1,289)
	UTI Research	-	-	-	(22,667)
	Movement in present value of grant accruals	(24,882)	(47,931)	(72,813)	(7,961)
		492,496	115,018	607,514	909,340
	Support costs (see note 8)	121,902	13,512	135,414	158,937
		614,398	128,530	742,928	1,068,277

7. GRANT MAKING (Continued)

The Charity's policy, in line with the Charities SORP 2019 is to recognise an expense and related liability for a research grant, at the point when the unconditional offer is conveyed to the recipient (see the accounting policy on page xx for further details). However, recipients do not always take up their research grants in full. Where this happens, in subsequent years, in order that the correct movement in the Charity's liability is recognised, the expense as shown in the Statement of Financial Activities may not reflect the level of grant giving in the current year. A reconciliation to assist with users' understanding of the grants awarded in the year, to the expense in the Statement of Financial Activities is provided below:

	Grants awarded in the year ended 31 December 2021	Effects of outstanding grant payments	Expense recognised in the accounts for the year ended 31 December 2021
Research Scholarships awarded to 5 (2020: 3) individuals	296,594	(32,706)	263,888
Small Research Projects awarded to 4 (2020: 3) teams	39,738	(10,000)	29,738
TUF Fulbright Research Fellowship Award	22,176	(15,000)	7,176
UTI Research	-	-	-
BAUS	-	-	-
RSM Urology Section	-	-	-
Keith Yeates medals awarded to 2 (2020: 1) individuals	4,000	(4,800)	(800)
Travel Grants	-	-	-
Educational Course	-		
Cancer biomarker / wearable sensor study	195,000	-	195,000
BAUN/TUF Nurse	2,000	156	2,156
COVID-surg Urology Study	-	-	-
Urolink Fellowship	4,500	-	4,500
TUF Trials Unit	180,000	-	180,000
Other direct costs	-	169	169
V Arumuham		(1,500)	(1,500)
Movement in present value of grant accruals	-	(72,813)	(72,813)
	744,008	**(136,494)**	**607,514**
Support costs (see note 8)	135,414	-	135,414
	879,422	**(136,494)**	**742,928**

	Costs of generating voluntary income 7.5% £	Fundraising trading: Cost of goods sold 7.5% £	Awareness raising 30% £	Giving grants 55% £	2021 £	2020 £
8. SUPPORT AND GOVERNANCE COSTS (UNRESTRICTED)						
Staff costs (see note 9)	9,799	9,799	39,197	71,859	130,653	162,978
Other staff costs including recruitment	1,868	1,868	7,473	13,700	24,909	2,565
Committee and other staff welfare expenses	25	25	100	183	333	574
Other office costs	3,089	3,089	12,357	22,654	41,189	59,878
Audit fee	218	218	870	1,594	2,900	2,901
Accountancy and advisory services	980	980	3,920	7,186	13,066	15,192
Other costs	607	607	2,429	4,453	8,097	15,442
Depreciation-owned assets	37	37	149	273	496	546
	16,624	16,624	66,494	121,902	221,644	260,076

8. SUPPORT AND GOVERNANCE COSTS (RESTRICTED)						
Staff costs (see note 9)	1,081	1,081	4,324	7,927	14,412	18,109
Other staff costs including recruitment	211	211	844	1,547	2,813	285
Committee and other staff welfare expenses	3	3	11	20	37	64
Other office costs	343	343	1,373	2,517	4,576	6,653
Audit fee	24	24	97	178	323	322
Accountancy and advisory services	109	109	436	799	1,453	1,688
Other costs	68	68	270	496	901	1,717
Depreciation-owned assets	4	4	17	30	55	64
	1,843	1,843	7,372	13,512	24,570	28,902

9. STAFF COSTS

		2021	2020
		No.	No.
The average monthly number of persons employed by the charity (excluding trustees) during the period was, as follows:			
Office and administration		2.7	3.5
		£	£
Staff costs for the above persons:			
Staff	Wages and salaries	51,800	84,690
Staff	Social security costs	3,743	6,411
Key management personnel	Wages and salaries	82,339	82,338
Key management personnel	Social security costs	7,183	7,648
		145,065	181,087

One employee received total emoluments in excess of £60,000 per annum during the period ended 31 December 2021. The total emoluments of this employee during the year were in the following ranges:

		2021	2020
£70,000 - £80,000	No.	1	1

The Charity considers its key management personnel comprise the Chief Executive, with remuneration as noted above. In setting salary levels, The Urology Foundation follows the National Council for Voluntary Organisation's advice that a charity's pay policy should be to offer fair pay to attract and keep appropriately-qualified staff to lead, manage, support and/or deliver the charity's aims. It also conducts online research of charity salaries and uses surveys to benchmark levels of pay. The Urology Foundation does not automatically award its staff with annual salary increases, either incremental or cost of living.

No Director received any remuneration from the Company during the year (2020: £nil).
No trustee received any remuneration for services provided to the charity during the current or previous period.
Trustees expenses reimbursed in respect of Trustee's meetings and travel for the year ended 31st December 2021 amounted to £0 paid to no Trustees (2020 £0 paid to no Trustees).

10. TANGIBLE ASSETS

	Office Equipment £
Cost:	
1 January 2021	20,335
Additions	2,159
31 December 2021	22,494
Depreciation:	
1 January 2021	18,517
Charge for year	350
31 December 2021	18,867
Net book value:	
31 December 2021	3,627
31 December 2020	1,818

11. INVESTMENTS

	2021 £	2020 £
Investments listed on a recognised stock exchange at market value:		
1 January 2021	3,595,733	2,189,975
Transfers from cash	-	1,045,830
Additions at cost	536,261	1,161,969
Disposal proceeds	(852,452)	(1,162,282)
Realised (losses)/gains	124,555	(49,621)
Unrealised gains	253,173	409,862
31 December 2021	3,657,270	3,595,733
At the balance sheet date, the market value of the portfolio comprised:		
UK investments	3,657,270	3,595,733
	3,657,270	3,595,733
Fixed income securities	543,742	750,830
Equities	-	-
Multi-Asset & Hybrid Instruments	3,113,528	2,844,903
	3,657,270	3,595,733

At the balance sheet date, the historical cost of the investments was £2,938,371 (2020: £3,185,794).
The following holdings had a value of >5% of the market value of the investments:

Name	Holding	Value £ 2021	Value £ 2020
Rothschild & Co WM SICAV-SIF Exbury Fund GBP	116,874	3,113,528	2,844,903
Pentairs QIAIF PLC - Vanda Fund Shs -F- USD Shs	-	-	-
InstitutionalCash SeriesPLC - BlackRock ICS Sterling Liquidity Fur	543,715	543,742	750,830

12. DEBTORS

	2021 £	2020 £
Amounts falling due within one year:		
Other debtors	3,017	2,761
Prepayments	21,450	19,574
Accrued Income	74,256	55,438
	98,723	77,773

13. CREDITORS	2021 £	2020 £
Amounts falling due within one year:		
Deferred income	80,628	34,778
General accruals	11,270	10,895
Grant accruals	1,041,624	1,193,088
	1,133,522	1,238,761
Deferred income b/fwd at 1 January 2021	34,778	
Amounts released in the year	(34,778)	
New amounts deferred in the year	80,628	
Deferred income c/fwd at 31 December 2021	80,628	

CREDITORS	2021 £	2020 £
Amounts falling due in more than one year:		
Grant accruals	416,634	495,249
	416,634	495,249

14. RECONCILIATION OF NET INCOME/(EXPENDITURE) TO NET CASHFLOW FROM OPERATING ACTIVITIES

Net Income/(expenditure) for the reporting period per the statement of financial activities	289,461	560,431
Adjustments for:		
Depreciation charges	350	606
(Gains) on investments	(377,727)	(360,241)
Dividends and interest from investments	(41,002)	(291)
Management fees paid from investments	72	365
(Increase)/Decrease in debtors	(20,950)	53,262
(Decrease)/Increase in creditors	(183,855)	719,139
Net cash used in operating activities	(333,651)	973,271

15. THE FUNDS OF THE CHARITY

	1 January 2021 £	Transfer £	Income £	Expenditure £	Gains/(losses) on Investments £	31 December 2021 £
Restricted income funds:						
Robotic Surgery Training Fund	196,287	-	(94)	3,641	242	200,076
Prostate Cancer Research Fund	103,370	-	-	35,340	94	138,804
Bladder Cancer Fund	149,860	-	-	(181,360)	75	(31,425)
Travel Fellowship Fund	652	-	-	-	1	653
'EQUIP' Quality & Safety Pilot	30,889	(35,389)	6,194	(1,748)	54	-
Team Corbs - Testicular	1,823	-	332	-	3	2,158
Charles Reynolds	-	-	40,500	-	3	40,503
	482,881	(35,389)	46,932	(144,128)	472	350,768
Unrestricted income funds:						
General Fund	1,139,859	35,768	763,999	(719,765)	377,255	1,597,116
Designated Fund (R. Shackman)	35,683	(379)	-	(35,304)	-	-
Designated Fund (BUF)	500,000	-	-	-	-	500,000
	2,158,423	-	810,931	(899,197)	377,727	2,447,884

15. THE FUNDS OF THE CHARITY (Continued)

- The trustees have designated the original 1995 start-up funding for the BUF of £500,000 as the trustees feel strongly that The Foundation should seek to maintain reserves sufficient to continue to fund its objectives on a long term basis.

- Ralph Shackman Trust - The Ralph Shackman Trust's aims were similar to TUF, being to advance the study of urology through grants and awards and funding clinical visits. In 2012 the Trust asked TUF to assist them in promoting and administering their clinical visit grants. In 2015 the Trust wound down and transferred its remaining assets to TUF. This included the responsibilities for administering the Keith Yeates Medal, an Award given to the Urology Trainee who receives the highest marks in the Intercollegiate Specialist Exams in Urology. This award comes with a prize of £2,000 for a TUF/Shackman travelling fellowship.

- The Robotic Surgery Training Fund was set up in 2009 following the receipt of restricted donation income from the British Urological Foundation and a generous private donation. The funds are mainly used to award grants towards robotically assisted surgery training, education, and research into robotic training techniques.

- Bladder cancer remains one of the most expensive cancers to treat and survival rates appear to have reached a plateau at 50%. In the UK, more than 10,000 new cases of bladder cancer are diagnosed every year. The Foundation is determined to improve the diagnosis, treatment and outcomes of people with bladder cancer and to allocate resources to vital research into the diagnosis and pathology of bladder cancer and to funding training and education to improve patient treatment and care. Through a generous donation from The Champniss Foundation, TUF has funded the iROC bladder cancer surgery trial, investigating the efficacy of Robot assisted radical cystectomy and intracorporeal urinary diversion compared with open radical cystectomy in patients with bladder cancer. The Champniss Foundation and the Champniss Charitable Trust are also funding a study into patient tracking post-surgery via fitness devices.

- Prostate Cancer Research - Thanks to the John Black Charitable Foundation (JBCF) TUF has been able to invest in a number of high profile research studies, such as the CLIMATE trial, which are ongoing. There were no new JBCF awards given in 2021.
- Education in Quality Improvement Programme (EQUIP) - The Urology Foundation is keen to deliver real improvements in patient care, while also developing urologists and equipping them to become leaders of the future. We supported the development of the EQUIP training programme, that equips urologists with the skills required to analyse current practise and to develop collaborative quality improvement work, and to share learning and best practices with their peers and urology departments regionally and nationally. This programme has now been incorporated into the urology curriculum and the anticipated benefits will be improved patient safety and care that will reflect a culture that fosters continuous improvement. We are grateful to the Schroder Foundation and a number of other funders for their generous support of the programme.

- The Foundation started working with former England and Lions rugby champion, Alex Corbisiero, to raise funds for research into testicular cancer, following Alex's diagnosis. A Just Giving page has been set up and the charity will continue to fundraise with Alex.

16. ANALYSIS OF NET ASSETS BETWEEN FUNDS

	Fixed Assets £	Net Assets/(Liabilities) £	Total £
Restricted income funds:			
Robotic Surgery Training Fund	200,076	-	200,076
Prostate Cancer Research Fund	982,367	(843,563)	138,804
Bladder Cancer Fund	149,934	(181,359)	(31,425)
Travel Fellowship Fund	1,123	(470)	653
Team Corbs - Testicular	-	2,158	2,158
Charles Reynolds	-	40,503	40,503
Unrestricted income funds:			
General Fund	1,827,397	(230,281)	1,597,116
Designated Fund (Ralph Shackman)	-	-	-
Designated Fund (British Urology Foundation)	500,000	-	500,000
NET ASSETS	3,660,897	(1,213,013)	2,447,884

17. ULTIMATE CONTROLLING PARTY

The Charity is controlled by the board of Trustees.

18. COMMITMENTS UNDER OPERATING LEASES

As at 31st December 2021, the Charity had annualised operating commitments under non-cancellable operating leases expiring as follows:

	2021 £	2020 £
Expiring within one year		
- Land and Buildings	28,700	49,200
- Others	1,566	3,132
	30,266	52,332
Expiring within two to five years		
- Land and Buildings	-	28,700
- Others	-	1,566
	-	29,366

19. CONTINGENT ASSETS

As at 31st December 2019, the Trustees were aware of a Legacy which is due to The Urology Foundation. The Legacy is the balance of the sale of a property, a 14% share of the estate was bequeathed to the Charity in 2013/2014. £9,000 was received in 2020 and a further £4,580 was expected and paid in 2022 and has been accrued into the 31st December 2021 accounts.

20. RELATED PARTY TRANSACTIONS

There were no related party transactions in the period under review or in the prior year.

THE UROLOGY FOUNDATION

England & Wales - Charity number 1128683

Accounts



THE UROLOGY FOUNDATION

TRUSTEES' ANNUAL REPORT & FINANCIAL STATEMENTS

DECEMBER 2020


Contents

Chairman's statement 3
Overview of the year 3
Objectives and Activities 4
Our Vision and Mission 4
Our Aims 4
Our Values 4
What we do 4
Public Benefit 4
Grants policy 5
Achievements and Performance in 2020 5
1. Seeking better treatments and cures through research 5
2. Improving knowledge and skills through training 7
3. Improve public awareness of urological conditions and symptoms 8
4. Plans for the future 9
Financial Review 10
Financial Results of Activities & Events 10
Fundraising 10
Reserves & Liquidity Policy 11
Statement of going concern 11
Investments Policy 11
Remuneration policy 11
Principal risks and uncertainties 12
Structure, Governance & Management 13
Trustee Recruitment 13
Appointment & Election 13
Relationships with Related Parties 14
Representation on Other Bodies 14
Reference and administrative details 15
Trustees 15
Registered Office 15
Auditors 15
Trustees' & Directors' Responsibilities in the Preparation of Financial Statements 16
Auditor 16
Statement as to disclosure of information to the auditor 16
Annex A 17

Front cover image courtesy Sophie Rintoul-Hoad, urology trainee

Chairman's statement

Overview of the year



2020 was without doubt a year with immense disruption, uncertainty and challenge. However, it is to science and vaccines that we have relied on for a way out of the grip of the pandemic. The work of TUF has never felt so important.


Thanks to the ongoing support of our donors, TUF was able to maintain its commitment to funding throughout the year and through the pandemic. At a time when our own planned fundraising events were cancelled we are so grateful to all the individual donors and fundraisers, Trusts & Foundations and companies who helped us to continue our work and make a difference under difficult circumstances. TUF is currently supporting over 40 research projects and awards into all areas of urology, and the development of urology trainees and nurses. We will continue to put the needs of urology patients and the community of urology professionals at the heart of what we do.

Our many researchers and urology professionals faced significant challenges during the year. Several of the former were placed on furlough or were forbidden from entering their labs, which meant that much of the research was paused, and in one case had to be abandoned altogether as the interruption meant that no meaningful data could continue to be collected. Urologists and urology nurses were deployed to Covid wards, while others endeavoured to keep the system working and operations Covid-secure for patients and ensure that urgent referrals continued to be seen. What we do know from this is that our experience of healthcare will change, as the pandemic has accelerated the use of video and telephone consultations which, in the right context, will save patients and doctors valuable time. TUF is also funding research that is trialling the use of fitness trackers on post-surgery patients, to see if it is possible to tell sooner (before there are any apparent symptoms) if a patient goes into decline.

But it is also important to learn how the pandemic might have affected the outcomes for the many urology cancer sufferers. We know that many people will have received late diagnoses, as they tried to avoid burdening the health service, others will have been placed under different regimes and given different types of treatment to avoid surgery and hospitalisation where possible. We need to understand how these changes in treatment and care will impact on patients and, indeed, whether there is any discernible difference in outcomes. TUF is therefore funding a two-year research study examining the impact of the pandemic on urology cancer sufferers, to see if there any lessons to be learned from the experience that may result in changes to treatment and care.

Thanks are due to our own team who managed to efficiently transfer to long months of home working. I am very grateful to them for keeping the charity working seamlessly.

We now look forward to taking the steps towards normality and you can be assured that TUF will strive to be at the centre of improving the outcome for all Urology patients.



Paul Fletcher, Chairman

Objectives and Activities

The Urology Foundation's objects are to:

"Advance, promote, encourage, develop and improve the study and knowledge of urology, urological surgery and the general knowledge of science and medicine and all matters relating to the progress and development of that branch of science and medicine and for that purpose to fund, aid, maintain and endow scholarships, fellowships, chairs and bursaries and generally to assist in the funding, instruction and support of persons and institutions engaged or involved in urological research work."

Our Vision and Mission

We see a world where people will not die early from urological cancers and diseases, and where people with bladder, kidney and prostate problems can still lead full, active and productive lives.

Our mission is to improve survival and quality of life for urology patients through research and training, so patients receive the best possible treatment and care and fewer lives are devastated.

Our Aims

The Urology Foundation is committed to reducing the suffering caused by urological diseases. We work with researchers, urology and health care professionals to improve the diagnosis, treatment and management of urological disease and the nation's urology care.

We rely on donations from individuals, trusts and foundations, and from companies to help fund our work. The money we raise is invested directly into research to find better treatments and cures, and in training for urology professionals to care for and help people affected by urology conditions.

The Foundation is governed by the rules and regulations set down in its company memorandum and articles of association originally dated 12 February 2009 and last updated by a special resolution on 29 June 2009.

Our Values

In undertaking our remit we are:

- *Ambitious* to see UK urology care, treatment and practice is the best in the world.
- *Dedicated* to beating all urology diseases through research and training.
- *Proud* of working in urology and committed to transforming the lives of people with a urology condition.
- *Collaborative*; working with researchers, urology and health care professionals and other charities we are improving the nation's urology care.

What we do

We seek to improve patient treatment and care through investing in research and training. We fund research that increases our understanding of urological diseases and that can bring about change in urology practice and guidelines to the benefit of patients. We are also looking for ways that can make treatments more effective and kinder. We are driving improvement in standards in urology practice through training and we are developing the next generation of urological experts who can meet the challenge of the increased burden of disease and who put excellence of care at their core.

Our website provides information on the signs and symptoms of urological diseases and sets out some of the treatment options available. Our campaigns such as Urology Awareness Month in September bring urology conditions to the public eye, and focus on breaking the stigma of these diseases.

Public Benefit

The trustees have taken The Charity Commission's general guidance on public benefit into consideration in preparing their statements on public benefit contained within this trustees' annual

report. In accordance with its charitable objectives, The Foundation gives grants to individuals and not-for-profit organisations to:

- Promote the study of urological cancers and conditions by supporting and carrying out research into the causes, prevention, diagnosis and method of treatment of this disease and by publishing the useful results of such research;
- Provide opportunities for training and education of health professionals working in urology, in order to advance practice and improve patient treatment and care;
- Such other purposes for the benefit of the community as shall be exclusively charitable as the trustees from time to time shall decide.

In addition, TUF provides information on its website on urological cancers and conditions, and raises awareness through social media channels and media such as press and radio.

Grants policy

TUF advertises its programmes and awards on its website and through its professional e-newsletter. Applications for Research Scholarship funding are assessed by the SEC and the Reviewing Panel. Other applications for funding are assessed by the SEC.

TUF is a member of the Association of Medical Research Charities (AMRC) and abides by its standards and guidelines for peer review and funding. It is also a National Institute for Health Research (NIHR) non-commercial Partner. Research studies funded through TUF's NIHR approved funding streams are automatically eligible for consideration for NIHR Clinical Research Network (CRN) support subject to meeting the standard study eligibility criteria.

Achievements and Performance in 2020

1. Seeking better treatments and cures through research

It would be hard to open a report on 2020 activity without a mention of Covid-19. Nearly all our research programmes were suspended owing to the lockdown measures, with labs either shut or repurposed towards Covid-19 research. We contacted our researchers at the time to ask about the potential impact on their work and whether they would be able to resume once labs reopened. The majority requested (and have been granted) no-cost extensions to their grants.

Sadly, one of our grants, a trial in Newcastle comparing treatments for Recurrent Urinary Tract Infections, had to be abandoned midway through the 2-year project as the interruption caused by the coronavirus meant that hospital visits had to be discontinued, so the trial was no longer viable. We are hoping that we may be able to support a similar study in this important topic in future.

In spite of the impact of the pandemic on our operations, we nevertheless felt it was important to continue to support research and promising researchers that could deliver better diagnosis, better patient outcomes and better treatments. In 2020 we invested over £1 million into funding urological research, education and training. We awarded three Research Scholarships in the following areas:

- ***Bladder Cancer*** - This study will explore the potential of ex-vivo high-throughput drug screening for precision oncology in bladder cancer and aim to increase the number of agents and personalise their use for this morbid disease.
- ***Pelvic floor materials*** - Polymer meshes can cause painful fibrosis when implanted for pelvic organ prolapse (POP) repair, as highlighted by the vaginal mesh scandal. We need better, safer, materials which do not cause pathological fibrosis and we need to find new tests, capable of predicting fibrosis risk for POP devices.
- ***Posterior Urethral Valves*** - PUV is a devastating developmental bladder disorder and is a leading cause of dialysis and kidney transplantation in children. PUV causes bladder scarring,

rendering it dysfunctional. This project aims to create a 'predictive tool' for outcomes based on biopsy and evaluate novel anti-scarring treatments. *(We understand this is the only research of its type in the world, making TUF support crucial.)*

Thanks to the John Black Charitable Foundation, we were able fund two potentially game-changing studies into prostate cancer. "CLIMATE", a three-year trial comparing a 35-40 minute multi-parametric MRI scan for prostate cancer with a novel, single 3-4 minute Luminal Index (LI) MRI scan. If proven to be as good, if not better than traditional MRI, this trial will transform prostate cancer care (see box).

Case study: Seeking better treatments and cures through research

'Comparison of diagnostic accuracy of Luminal Index and Multi-parametric MRI for Accelerated detection of significant prostate cancer (CLIMATE)'

In the UK, more than 47,500 men are diagnosed with prostate cancer every year, 129 men every day. Within the NHS prostate cancer is diagnosed with a blood test which measures the level of prostate specific antigen (PSA). If this exceeds the recommended threshold patients are referred for an MRI scan.

MRI scans have greatly improved prostate cancer diagnosis but there is a need to

- improve specificity (identifying a significant tumour);
- improve sensitivity (identifying significant cancer);
- improve image quality;
- reduce gadolinium contrast agent usage (to avoid potential toxicity).

Current scanning methods require the injection of a contrast agent, followed by a 35-40 minutes scan. The team at UCL have discovered a new scanning method which does not require a contrast agent and the scan itself takes only 3-4 minutes. The CLIMATE study tests this new technology against current standard of care scans. The aim of CLIMATE is to test whether this new scan is as good as, or better than, the current scans at detecting clinically significant prostate cancer.

The second is a Pilot study to "Identify Predictive and Prognostic Biomarkers of Response to Radiotherapy in Prostate Cancer", to show which patients are likely to respond to radiotherapy (RT) and which would be better following different treatments, enabling treatment plans to be personalised, and overcoming the limitations of current RT treatment regimens which can involve some harsh and unpleasant side effects. This novel research, if successful, is a crucial and transformative step towards obtaining personalised prostate cancer treatment.

In 2020 we received 17 applications in the first round of our Small Research Projects fund, the highest number ever. The variety and quality of the applications were such that we were able to make all three awards from this tranche but sadly had to close the fund for the rest of the year. Awards were for the following projects:

- Testicular Torsion 'Save the Ball' campaign.
- Investigating the effects of neo-adjuvant chemotherapy on the immune tumour microenvironment of bladder cancer (see box).
- Validation of a novel patient reported outcome measure (PROM) following gender affirming surgery.

Given that Covid-19 is expected to significantly affect people with urological cancers, we funded the UK urology arm of an international, two-year study into understanding the outcomes for patients having surgical treatment of urological cancers delayed, or having alternative treatment strategies not usually used. Such studies would not be possible (or ethical) in normal times, but the pandemic presented this opportunity to learn.

Case study: Seeking better treatments and cures through research

Investigating the effects of neo-adjuvant chemotherapy on the immune tumour microenvironment of bladder cancer

Patients with muscle-invasive bladder cancer are first treated with chemotherapy followed by either radiotherapy or surgery to remove the bladder. Both treatments are equally as effective with similar rates of cure but the bladder cancer returns in half of the patients. An understanding of which patients are more likely to relapse means they can be better informed when making decisions regarding primary treatment. This could also result in the identification of 'high-risk' patients who may benefit from intensification of treatment and entry into clinical trials if available.

Over the last few years, a significant body of evidence has emerged suggesting that outcomes after radiotherapy may be influenced by the immune tumour microenvironment. Patients with bladder tumours with high levels of immune infiltration had better survival outcomes after radical radiotherapy than those with less immune rich tumours. There is growing evidence that chemotherapy may enhance immune infiltration in several different types of cancer.

This study is looking at whether the immune system can be "switched on" to the bladder cancer by the chemotherapy before surgery or radiotherapy. Patients who have a "switched on" immune system might respond better to radiotherapy, which in the future can guide whether radiotherapy or surgery is best for them.

2. Improving knowledge and skills through training

In addition to the pandemic's impact on research activities was the massive disruption it caused to formal training, with teaching, training and exams suspended, and many trainees being reassigned to duties covering Covid-19 wards and intensive care units. Surgical training was disrupted as fewer operations were taking place, and meeting in conference or seminar teaching sessions was banned.

Support for urology trainees

TUF partnered with the Royal Society of Medicine to provide a series of 12 weekly webinars on urological diseases and practise that urologists and trainees could access online. Several of these were chaired by TUF trustee, Mr Ben Challacombe. We ensured that all urology trainees could attend these webinars free of charge and many trainees described these sessions as a lifeline for them, with attendance averaging 200 per session, and several more watching on catch-up.

Through our 'TUF Warrior' programme, we provided a series of peer-to-peer online webinars for trainees wishing to seek advice on career development and progression. We also introduced a mentorship programme for trainees to help them with their professional and personal development. Several TUF Trustees have volunteered to take part in the mentoring scheme, providing a pool of expertise in urology and business leadership from whom trainees can seek advice.



TUF WARRIOR PROGRAMME

The TUF Warrior programme creates opportunities for urology trainees to develop extracurricular interests and boost applications for specialty training. Applications for Core Surgical and Specialist Registrar training is a competitive process and credit is given for extra-curricular activities, outstanding charity achievements and commitment to specialty.

The programme gives trainees an opportunity to come together with like-minded colleagues to achieve something outstanding, while having fun in the process. Warriors have the opportunity to demonstrate leadership and team-working by taking on representative, regional roles; gain experience in organising or taking part in charity events; and review and update patient information, this contributing towards the work that TUF does whilst increasing their skills and credentials and demonstrating their commitment to Urology.

The training progression within the NHS is long and tough, with increasing numbers of doctors feeling 'burnt out' or choosing to take career breaks. Resilience is important and a healthy work/life balance is key to career longevity. Participating in such activities is a refreshing change from training which is an increasingly arduous process.

Support for urology nurses

Our planned communications and leadership skills course for nurses had to be postponed because of the pandemic. The interactive and role-playing nature of the course would not lend itself well to an online format, and many nurses consulted said they would prefer to meet in person. We hope to run this later in 2021.

The **Keith Yeates Medal/Ralph Shackman** prize is only conferred when candidates achieve over 90% in their Intercollegiate Specialty Examination in Urology. In 2020 it was awarded to Mr Sotonye Tolofari, a trainee urologist at the Royal Liverpool & Broadgreen Hospital, who receives a travelling fellowship worth £2,000. He hopes to gain experience in laparoscopic and robotic urology in Aalborg, Denmark.

3. Improve public awareness of urological conditions and symptoms

The Urology Foundation has continued to build public awareness of urological cancers and conditions as well as raise the profile of urologists and urology nurses for better patient care. Our main channel for engaging with the public has been through our website, with visitors more than doubling to over 320,000 compared with 160,000 in 2019. The most visited pages continue to be those that provide health information on Urinary Tract Infections (UTIs), kidney failure, bladder cancer, kidney stones and prostate cancer. After the health pages, the most visited pages are our news stories, the Need to Pee page and the Urology Awareness Month page.

TUF's social media profile is also growing with Facebook and Instagram more popular among the general public. Our Facebook user numbers have historically risen most around World Continence Week in June and Urology Awareness Month in September. Twitter and Linked-In have higher numbers of urology professionals engaging. During 2020, our Twitter followers increased by 16 per cent bringing the total number of followers to 4,069. The average numbers of people seeing each tweet is just shy of 1,200.

Our Urology Awareness Month in September focused on the signs and symptoms of the five urological cancers (prostate, bladder, kidney, testicular, penile) in weeks one and two, and then on chronic urological conditions such as incontinence, prostate problems, urinary tract infections and kidney stones, and impact they have on sufferers' quality of life and their mental health.

We continued to partner with TalkHealth, an online health website, to provide information blogs and expert-led medical advice forums about urological health matters to members of the public, and to provide articles on urological health matters for supplements in national newspapers.

4. Plans for the future

The incidence of urological cancers and conditions is increasing, as is the prevalence of bladder and incontinence problems, benign prostate problems and kidney stones. This is leading to major morbidity and quality of life issues for urology patients and places a growing burden on the healthcare service, and on the doctors and nurses working within it. Allied to this, the way in which healthcare is delivered will need to change, with an emphasis on personalised medicine and community-based services which are designed to enhance both patient outcomes and experience.

We want to ensure that urology is primed to lead this revolution in healthcare. The key to meeting these challenges is to develop a cadre of top-quality urological professionals who have access to the very latest research developments and technological innovations, and who put excellence of care and continuous professional development at their core, and we will develop research and training programmes with these outcomes in mind.

In 2020, with the input of the urology community, we conducted a review of our programmes and grants and have made two major innovations. The first is our intention to fund a TUF Urological Trials Unit.

With over 750,000 urology hospital care episodes each year in the UK, urology is a specialty faced with a high demand, yet the field remains remarkably under researched. While there have been notable successes in prostate cancer, much of urological practice lacks level one evidence to guide practice. Surgery in general, and urology in particular, currently attracts a disproportionately small proportion of clinical trials funding compared with the massive burden of urological diseases on NHS expenditure. Two key factors that have led to lack of trials are the complexity of surgical trials and the potentially hazardous and invasive nature of interventions.


We wish to address these challenges by creating an infrastructure to develop fund worthy urological trials by securing sufficient methodological expertise and support for good research ideas. Successful trials that go on to develop evidence for best practice and guidance on treatment of urological diseases will result in huge patient benefits. We know, from the experience of the British Orthopaedic Association who pioneered this, that they have been able to lever in a further £9 million of research funding through this initiative. Our competitive call to work with an established Trials unit within the UK attracted over 15 responses from units throughout the UK.

The second change is to reconfigure our Research Scholarship grants into an 'Innovation and Research' award that seeks to use new, exciting, innovative approaches to address urological diseases and disorders. The projects must either (a) aim to create innovative treatments or devices, (b) aim to deliver innovative care pathways, or (c) aim to use innovative research techniques or methods. It is hoped this way to capture a wider range of submissions and explore ideas that can make a material difference to people suffering with urological diseases.

We will continue to support the training and development of urology professionals through awards, travel grants and training fellowships.

Financial Review

Financial Results of Activities & Events



The total value of net assets held by The Urology Foundation on 31 December 2020 was £2,158,422 (2019 £1,597,992). The Foundation's fundraising activities and other initiatives during the course of 2020 generated a total of £1,366,619 of voluntary income (2019 £429,692) and a further £64,920 (2019 £427,976) from specific fundraising event income.

Impact of Covid-19

The pandemic impacted on the charity's operations, as many medics and researchers were pulled into Covid-related duties or in some cases furloughed. Many research projects stalled, while one UTI trial comparing treatment had to be abandoned altogether because patients were no longer permitted to travel to hospital for the comparative treatment arm. In addition, applications to some of our awards programmes fell as people were unsure whether they would be able to start their research or plan educational trips. Some grant holders have asked for and received no-cost extensions to their research projects.

Having a small staff count meant that none of the charity's staff were furloughed, although the Fundraising Manager left in March 2020 and has not been replaced. We also successfully negotiated with our landlords to reduce our office costs.

Fundraising

TUF continues to be wholly reliant on fundraised and donated income to fulfil its remit. The charity operates a mix of its own fundraising activities and those organised and undertaken by third parties on its behalf.

The Covid-19 pandemic seriously hindered the charity's plans for 2020, with events such as a wine tasting dinner and a charity trek having to be postponed. Our April appeal was repurposed to take into account the expected impact of Covid-19 on our fundraising and operations and we are grateful to all our donors and supporters.

At relatively short notice the charity instituted a number of 'virtual', online challenges or events and fundraisers and urology trainees rallied to the cause and raised over £10,000 through a fun run and individual challenges. The annual Bike 4 TUF, in which urologists and patients had planned to cycle

to Birmingham from the four corners of the country, adapted its plans so that the riders cycled in bubbles of six in their local regions. They managed to raise over £41,000, a remarkable amount in the circumstances.

Special thanks must be paid to TUF's ongoing supporters who donated throughout the year. The Foundation also received a number of significant donations from Trusts and Foundations and individuals, which did so much to enable our programmes and operations to continue throughout this difficult year. *(See Annex A.)*

Reserves & Liquidity Policy

The Foundation currently has 'free reserves' of £1,675,540 (31 December 2019: £1,249,647).

The Foundation's policy is to maintain reserves sufficient to continue to fund its objectives on a long term basis, and to ensure that TUF operates with an adequate level of liquidity to (i) minimise the risk associated with a temporary or unforeseen shortfall in liquidity; (ii) manage its cash and investments to meet its liabilities and remain a going concern for at least 1 year in the event of an unplanned drop in income. Liquidity is defined as cash and the investment portfolio held as Unrestricted funds. The Policy establishes a minimum liquidity target for TUF of £500,000 ("Minimum Required Reserve") subject to future modification by the Finance Committee and trustees' approval.

The trustees consider that reserves held in excess of the amounts required to fund all future commitments together with the initial fund of £500,000, will be available to increase its visibility and expand its operations including funding for further research and a wider range of projects.
The trustees plan levels of expenditure from unrestricted and restricted funds for the year ahead based upon the level of incoming resources for the current year as well as utilising restricted funds.

Statement of going concern

The Foundation's unrestricted net funds generated in 2020 are judged to be sufficient to meet the requirements of the charity for charitable giving in the coming year.

Investments Policy

The Foundation's investments are managed by Rothschild Bank (CI) Limited. The Treasurer and the Chief Executive are responsible for managing the relationship with Rothschild but changes in investment strategy are subject to approval by the board of trustees. The investment manager is asked to attend at least one board meeting annually.

The board follows a medium risk 'Balanced' investment strategy which is intended to achieve steady growth over the long term through a diversified approach to investment. Capital preservation in real terms over a long term horizon is the primary objective and some volatility is acceptable in order to achieve this. In 2020, continuing a move first started in 2019, the remainder of TUF's holdings were moved to an ethical investment portfolio managed by Rothschild, the Exbury Fund. The fund achieved a near 15% return over 2020.

All other Foundation funds are held in accounts with the charity's bankers, National Westminster Bank plc and CCLA Investment Management Limited.

Remuneration policy

In setting salary levels, The Urology Foundation follows the National Council for Voluntary Organisation's advice that a charity's pay policy should be to offer fair pay to attract and keep appropriately-qualified staff to lead, manage, support and/or deliver the charity's aims. It also conducts online research of charity salaries and uses surveys to benchmark levels of pay. The Urology Foundation does not automatically award its staff with annual salary increases, either incremental or cost of living.

Principal risks and uncertainties

The trustees take the management of risks seriously. The Chairman of the board of trustees and the Chief Executive are charged with responsibility to ensure that the risks which have been identified are adequately assessed and properly mitigated on a regular basis. The potential risks have been discussed with the Chairman and the charity and a formal risk register is kept and brought before the board on at least an annual basis.

Ongoing Impact of Covid-19

As stated above the pandemic impacted on the charity's operations. At time of preparing this report the country is still in lockdown and it is not clear when 'normal', unrestricted operations will resume. This means that fundraising event planning continues to be uncertain while the ongoing impact of Covid - and the expected attendant backlog of patient cases - on the workloads of medics and researchers may also continue to affect our research programmes and awards.

Data breach

In 2020 TUF's database provider, Blackbaud, fell victim to a cyber-security attack which affected a number of UK universities and charities, including The Urology Foundation. As soon as TUF was alerted in July by Blackbaud that our data were compromised we immediately informed our relevant Trustee for Data issues and lodged a Serious Incident Report with the Charity Commission and notified the Information Commissioner. We put a notice up on our website informing people of the breach with all the information we had at the time from Blackbaud, and we emailed and wrote to every person on our database for whom we had details advising them of the breach which, it is important to note, did not emanate from TUF's own actions.

The Charity Commission and Information Commissioner concluded that we had acted properly throughout, and the ICO wrote:

"There is evidence that demonstrates that you took appropriate due diligence in sourcing a reputable data processor. This means, although we have not yet determined whether security was processed in compliance with the GDPR, it would appear that your organisation acted in a reasonable attempt to meet compliance under your own obligations."

Other key risks are assessed as follows:

Governance /Environmental	Impact of the external environment on fundraising, in particular: public confidence in charities; new fundraising regulations; Data Protection Regulations.
Income Sources	TUF is wholly reliant upon voluntary income as an annual source of funding. It is the role of the trustees to manage risk exposure on fundraising activities and in doing so to accept an appropriate level of risk in order to raise income from a wide range of sources.
Risk of data breach	Following the incident TUF reviewed possible, alternative suppliers but concluded that all suppliers were potentially at risk of similar attacks. All security passwords for the database have been updated and any old or historical records no longer relevant were deleted. We believe that keeping data in the cloud is still safer rather than keeping it on our own servers. TUF staff are regularly made aware of possible phishing scams and to be alert to any potential email or system data breaches.
Key Person risk	The small staff base makes TUF heavily reliant on the Chief Executive and a few key trustees so the unexpected loss or departure of the Chief Executive or certain trustees is a risk. Succession planning processes have been identified as necessary going forward.
Investment Risk	TUF's success is directly related to the amount of resource it can devote to its objectives, so the key risk identified by trustees relates to the proper management of its funds. Imprudent or unprofessional decisions could

	majorly impact on the performance of those funds. In common with similar charities, TUF employs professional fund managers, whose performance is regularly reviewed by the Treasurer together with other trustees.
Risk to Employees	Employees are not subject to risks other than those likely to be associated with routine office work. Apart from obtaining statutory Employers Liability Insurance, TUF nonetheless treats the welfare of its staff as a priority. The Chief Executive is the Nominated Safety Officer for the purposes of the Health and Safety at Work Act. The premises are checked and maintained by the landlord and by the fire service to ensure appropriate mitigation of the risk of fire. Employees are aware of the location of fire extinguishers.
Loss of Records	To protect against the loss of records, and to increase data security, files are stored in the cloud. The risk of any unsaved data being critical to TUF is regarded as insignificant. Other similar risks are dealt with by insurance.

Structure, Governance & Management

The Urology Foundation is a charity and a company limited by guarantee and was established on 12 February 2009 to incorporate the charitable activities of the British Urological Foundation (BUF), an unincorporated charitable trust established in 1994 by the British Association of Urological Surgeons and BJU International, and a registered charity since 17 March 1995. The Urology Foundation itself became a registered charity on 19 March 2009.

The overall strategic direction of the charity is determined by the trustees, who meet three times each year including an Annual General Meeting.

Trustee Recruitment

The Foundation seeks to achieve a balance of lay and medical trustees. Appointed trustees are recruited on the basis of fulfilling the criteria to provide a balance of experience and knowledge. Members of the charity's Scientific and Education Committee (see below) are recruited through calls in industry publications.

All new trustees are provided with a face-to-face induction meeting and an induction pack. They are provided with relevant Charity Commission publications and regularly briefed on developments within the charity sector.

Appointment & Election

The Trustees and Chairman are appointed for an initial period of three years that can be extended for a further three-year term. A further extension may be made if it is deemed to be in the best interests of the Charity. The governing document requires that there should be a minimum of seven trustees.

Two of the trustees are required to be representative trustees, one nominated by The British Association of Urological Surgeons ("BAUS") and one nominated by British Journal of Urology International ("BJUI"). All other trustees, known as appointed trustees, are appointed by unanimous written resolution of all the trustees present and/or voting at a special meeting of trustees called to take place immediately before or after an ordinary meeting of trustees.

The representative trustee nominated by BAUS is the President of BAUS and his appointment to the board is concurrent with his post at BAUS, which is for a period of two years.

The Executive Team

The Chief Executive, is responsible for the day-to-day management of the charity. She is assisted by a Grants Manager and a Fundraising & Events Manager.

The Chief Executive deals with the implementation of policy and strategic decisions taken by the board of trustees. She and the appropriate staff members attend the meetings of the board of trustees and of all sub-committees, and report on the day-to-day operations of the charity. The Foundation currently operates the following sub-committees:

Scientific and Education Committee (SEC)
The SEC is responsible for the development and assessment of The Foundation's research, education and training programmes and the review and administration of The Foundation's grant making policy. The Chairman of the SEC, Professor Grant Stewart, is a member of the board of trustees, and reports back to the board on the work of the Committee. The SEC is made up of clinical and academic urologists and scientists with an interest in urology, and lay representatives. The BAUS Surgical Specialty Lead also sits on the SEC, *ex officio*, to provide further insight into the research and training needs of the profession.

Research Scholarship Review Panel
The Research Scholarship Review Panel is responsible for assessing applications for TUF's major research grants and marking these according to the requisite criteria being met. In this task it assists the SEC in its final decision on who should receive grants. The Research Scholarship Review Panel is made up of clinical trustees and academic urologists and scientists with an interest in urology.

Membership of the SEC and Review Panel can be viewed on the charity's website: https://www.theurologyfoundation.org/about-us/who-we-are/our-team/committees. They provide their services as volunteers and TUF is enormously grateful to them.

Finance Committee
The charity Finance Committee is chaired by the Treasurer, Ms Angela Daniel. Membership includes The Chairman of the Board and the Chairman of the SEC, and two other trustees: Mr Becker & Mr Nicol, and the Chief Executive. Any recommendations made by the Finance Committee are brought to the board of trustees for discussion and ratification. The Treasurer has oversight of the charity's bank and investment accounts.

Relationships with Related Parties

The Urology Foundation continues to maintain close links with its two founding charities, The British Association of Urological Surgeons and the BJU International, whose representatives are trustees.

Representation on Other Bodies

The charity is a member of the Association of Medical Research Charities and is also a member of Urology UK, which comprises: the British Association of Urological Surgeons (BAUS), British Association of Urological Nurses (BAUN) and BSoT (the BAUS Section of Trainees). The Urology Foundation is a National Institute for Health Research (NIHR) non-commercial Partner. This means the studies that we fund may be eligible to access the NIHR Study Support Service which is provided by the NIHR Clinical Research Network.

Reference and administrative details

The registered charity name is "The Urology Foundation" (sometimes referred to as "TUF"), a charity and a company limited by guarantee.

Trustees

Mr Paul Fletcher *(Chair)*
Ms Angela Daniel *(Treasurer)*
Mr Mark Becker *(Secretary)*
Prof Grant Stewart *(Chair, SEC)*
Mr Ben Challacombe
Ms Mary Garthwaite *(appointed Feb 2021)*
Mr Adrian Joyce
Mr Roland Morley
Mr Andrew Moss *(retired October 2020)*
Mr David Nicol
Mr Tim O'Brien *(appointed June 2020)*
Mr Duncan Summerton *(retired June 2020)*
Prof Krishna Sethia
Ms Hannah Warren *(appointed Feb 2021)*
Baroness (Laura) Wyld *(retired October 2020)*

President

Prof Roger Kirby

Patrons

Handel Evans
Sir Ranulph Fiennes OBE
Rosemary Macaire
Jane Macquitty MBE
Steven Norris

Ambassadors

Alex Corbisiero
Stephen Fry
Kate Holmes

Chief Executive

Louise de Winter

Registered Office

1-2 St Andrew's Hill
London
EC4V 5BY

Charity number

1128683 (England & Wales)

Company number

06817868

Auditors

Dunkley & Co Ltd
Woodlands Grange, Woodlands Lane
Bradley Stoke
Bristol BS32 4JY

Bankers

National Westminster Bank plc
PO Box 2021
10 Marylebone High Street
London W1A 1FH

CCLA Investment Management Limited
St. Alphage House
2 Fore Street
London EC2Y 5AQ

Investment Manager

Rothschild Bank (CI) Limited
St. Julian's Court, St. Julian's Avenue
St. Peter Port
Guernsey GY1 3UA

Trustees' & Directors' Responsibilities in the Preparation of Financial Statements

The trustees (who are also the directors of The Urology Foundation for the purposes of company law) are responsible for preparing the trustees' Annual Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company as at the balance sheet date, and of the incoming resources and application of resources, including income and expenditure, for that period. In preparing those financial statements, the trustees and directors are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The trustees are responsible for keeping proper accounting records, which disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with Companies Acts 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.


The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from the legislation in other jurisdictions.

Auditor

Mr Michael Dunkley (FCA), of Dunkley & Co Ltd. has agreed to act as Auditor.

Statement as to disclosure of information to the auditor

The trustees and directors at the date of approval of this trustees' annual report confirm that so far as each of them is aware, there is no relevant information of which the charity's auditor is unaware, and the trustees and directors have taken all steps that they ought to have taken to make themselves aware of any relevant information and to establish that the auditor is aware of that information.



Paul Fletcher, Chairman

01.07.2021

Annex A

The Urology Foundation is extremely grateful to the following Trusts & Foundations and organisations who kindly supported our work in 2020:

Blakemore Foundation
Brackloch Trust
Champniss Charitable Trust
Champniss Foundation
Girdlers' Company
Dennis Byrne Charitable Trust
Headley Trust
Hudson Charitable Trust
Jacqueline & Michael Gee Charitable Trust
John Black Charitable Foundation
JP Jacobs Charitable Trust
Michael Guest Charitable Foundation
Oliver Stanley Charitable Trust
Penguins Against Cancer
PF Charitable Trust
Sir John Eastwood Foundation
The Hadley Trust
The Joron Trust
The Rosetrees Trust
The Thompson Family Charitable Trust

We are also grateful to the following companies and their staff who donated in 2020:

Ashfield Healthcare
BXT Accelyon
Boston Scientific
Curb Records Ltd
Intuitive Surgical
Karl Storz
Peak Medical
Santander

Thank you to all our donors, fundraisers, supporters and volunteers who have made The Urology Foundation's work possible.

Report of the Independent Auditors to the Trustees of The Urology Foundation (Registered number: 06817868)

Opinion

We have audited the financial statements of The Urology Foundation (the 'charitable company') for the year ended 31 December 2020 which comprise the Statement of Financial Activities, the Balance Sheet, the Cash Flow Statement and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 December 2020 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate. Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The trustees are responsible for the other information. The other information comprises the information included in the Annual Report, other than the financial statements and our Report of the Independent Auditors thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters where the Charities (Accounts and Reports) Regulations 2008 requires us to report to you if, in our opinion:

- the information given in the Report of the Trustees is inconsistent in any material respect with the financial statements; or
- the charitable company has not kept adequate accounting records; or
- the financial statements are not in agreement with the accounting records and returns; or
- we have not received all the information and explanations we require for our audit.

Report of the Independent Auditors to the Trustees of The Urology Foundation (Registered number: 06817868)

Responsibilities of trustees

As explained more fully in the Statement of Trustees' Responsibilities, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Report of the Independent Auditors to the Trustees of The Urology Foundation (Registered number: 06817868)

Our responsibilities for the audit of the financial statements
We have been appointed as auditors under Section 144 of the Charities Act 2011 and report in accordance with the Act and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Independent Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Extent to which the audit was considered capable of detecting irregularities, including fraud

We identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and then design and perform audit procedures responsive to those risks, including obtaining audit evidence that is sufficient and appropriate to provide a basis for our opinion.

Identifying and assessing potential risks related to irregularities

In identifying and assessing risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, we considered the following:

- The nature of the charitable sector, control environment and performance including the design of the organisation's remuneration policies;

- Any matters we identified, having obtained and reviewed the organisation's documentation of their policies and procedures relating to:

o Identifying, evaluating and complying with laws and regulations and whether they were aware of any instances of non-compliance;

o Detecting and responding to the risks of fraud and whether they have knowledge of any actual, suspected or alleged fraud;

o The internal controls established to mitigate risks of fraud or non-compliance with laws and regulations;

o The matters discussed among the audit engagement team regarding how and where fraud might occur in the financial statements and any potential indicators of fraud.

As a result of these procedures, we considered the opportunities and incentives that may exist within the organisation for fraud and identified the greatest potential for fraud in the areas of management override of controls, going concern, income recognition, and the appropriateness of expenditure.

We also obtained an understanding of the legal and regulatory framework that the organisation operates in, focusing on provisions of those laws and regulations that had a direct effect on the determination of material amounts and disclosures in the financial statements.

Audit response to risks identified

Our procedures to respond to risks identified included the following:

- Enquiring of management, concerning actual and potential litigation and claims;

- Substantive testing to vouch source records to the financial statements;

- Performing analytical procedures to identify any unusual or unexpected relationships that may indicate risks of material misstatement due to fraud;

- Enquiring of management the internal controls in, evaluating each control for weakness and vouching to evidence of the control taking place;

- In addressing the risk of fraud through management override of controls, testing the appropriateness of journal entries and other adjustments; assessing whether the judgements made in making accounting estimates are indicative of a potential bias; and evaluating the business rationale of any significant transactions that are unusual or outside the normal course of business.

We also communicated relevant identified laws and regulations and potential fraud risks to all engagement team members, and remained alert to any indications of fraud or non-compliance with laws and regulations throughout the audit.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Independent Auditors.

Use of our report
This report is made solely to the charitable company's trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. Our audit work has been undertaken so that we might state to the charitable company's trustees those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's trustees as a body, for our audit work, for this report, or for the opinions we have formed.

Dunkley's
Chartered Accountants
Registered Auditors
Eligible to act as an auditor in terms of Section 1212 of the Companies Act 2006
Woodlands Grange
Woodlands Lane
Bradley Stoke
Bristol
BS32 4JY

Date: 01/07/21

THE UROLOGY FOUNDATION

STATEMENT OF FINANCIAL ACTIVITIES
for the year ended 31 December 2020

	Note	Unrestricted Funds £	Restricted Funds £	Total 2020 £	Total 2019 £
INCOME					
Donations and legacies	1	515,235	851,384	1,366,619	429,692
Other trading activities	2	64,920	-	64,920	427,976
Investments	3	653	-	653	19,378
TOTAL INCOME		580,808	851,384	1,432,192	877,046
EXPENDITURE					
Raising Funds					
Donations and legacies	4	35,877	15,987	51,864	67,350
Trading activities	5	20,350	2,262	22,612	62,874
Investment management costs		365	-	365	17,560
Expenditure on Charitable activities					
Raising Awareness	6	79,994	8,890	88,884	186,630
Grant making	7	378,014	690,263	1,068,277	583,126
Net (Gains) on investment assets	11	(359,687)	(554)	(360,241)	(231,251)
TOTAL EXPENDITURE		154,913	716,848	871,761	686,289
NET INCOME/(EXPENDITURE)		425,895	134,536	560,431	190,757
RECONCILIATION OF FUNDS					
Fund balances brought forward at 1 January 2020		1,249,647	348,345	1,597,992	1,407,235
Transfer between funds		-	-	-	-
FUND BALANCES CARRIED FORWARD AT 31 DECEMBER 2020		1,675,542	482,881	2,158,423	1,597,992

The net movement in funds for the year arises from the charity's continuing operations.

No separate statement of total changes in equity has been presented as all such gains and losses have been dealt with in the statement of financial activities.

The notes on pages 26 to 36 form part of these accounts

THE UROLOGY FOUNDATION

STATEMENT OF FINANCIAL ACTIVITIES
for the year ended 31 December 2019 (Full fund comparative)

	Note	Unrestricted Funds £	Restricted Funds £	Total 2019 £
INCOME				
Donations and legacies	1	162,125	267,567	429,692
Other trading activities	2	427,976	-	427,976
Investments	3	19,378	-	19,378
TOTAL INCOME		609,479	267,567	877,046
EXPENDITURE				
Raising Funds				
Donations and legacies	4	47,115	20,235	67,350
Trading activities	5	57,290	5,584	62,874
Investment management costs		17,560	-	17,560
Expenditure on Charitable activities				
Raising Awareness	6	169,609	17,021	186,630
Grant making	7	292,897	290,229	583,126
Net (Gains) on investment assets	11	(202,206)	(29,045)	(231,251)
NET INCOME/(EXPENDITURE)		382,265	304,024	686,289
NET (EXPENDITURE)		227,214	(36,457)	190,757
RECONCILIATION OF FUNDS				
Fund balances brought forward at 1 January 2019		1,022,433	384,802	1,407,235
Transfer between funds		-	-	-
FUND BALANCES CARRIED FORWARD AT 31 DECEMBER 2019		1,249,647	348,345	1,597,992

The net movement in funds for the year arises from the charity's continuing operations.

No separate statement of total changes in equity has been presented as all such gains and losses have been dealt with in the statement of financial activities.

The notes on pages 26 to 36 form part of these accounts

THE UROLOGY FOUNDATION

BALANCE SHEET
as at 31 December 2020

Company Number 06817868

	Note	2020 £	2019 £
FIXED ASSETS			
Tangible assets	10	1,818	2,424
Investments	11	3,595,733	2,189,975
		3,597,551	2,192,399
CURRENT ASSETS			
Debtors	12	77,773	131,035
Cash at bank and in hand		217,109	289,429
		294,882	420,464
LIABILITIES: amounts falling due within one year	13	1,238,761	836,246
NET CURRENT LIABILITIES		(943,879)	(415,782)
LIABILITIES: amounts falling due in more than one year	13	495,249	178,625
NET ASSETS		2,158,423	1,597,992
THE FUNDS OF THE CHARITY			
Restricted income funds	15		
Robotic Surgery Training Fund		196,287	225,176
Prostate Cancer Research Fund		103,370	46,370
UTI Research Fund		0	122
Bladder Cancer Fund		149,860	39,765
Travel Fellowship Fund		652	652
'EQUIP' Quality & Safety Pilot		30,889	35,307
Bladder Cancer Trial		0	953
Team Corbs - Testicular		1,823	-
Unrestricted income funds	15		
General Fund		1,139,859	666,632
Designated Fund (Ralph Shackman)		35,683	83,015
Designated Fund (British Urology Foundation)		500,000	500,000
TOTAL CHARITY FUNDS	16	2,158,423	1,597,992

These financial statements have been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small charitable companies and with the Financial Reporting Standard 102.

The financial statements on pages 22 to 25 were approved by the trustees and authorised for issue on 1 July **2021, and are signed on their behalf by**

Paul Fletcher

..... **Chairman**
Paul Fletcher
01/07/2021

..... Treasurer
Angela Daniel
01/07/2021

The notes on pages 26 to 36 form part of these accounts

THE UROLOGY FOUNDATION

STATEMENT OF CASHFLOWS
as at 31 December 2020

	Note	2020 £	2019 £
CASH FLOWS FROM OPERATING ACTIVITIES:	14		
Net cash used in operating activities		973,271	(129,656)
Cash flows from investing activities:			
Dividends and interest from investments		291	18,874
Management fees paid from investments		(365)	(17,560)
Purchase of equipment		-	-
Transfer from cash		(1,045,830)	-
Proceeds from sale of investments		1,162,282	1,971,467
Purchase of investments		(1,161,969)	(2,006,523)
Net cash used in investing activities:		(1,045,591)	(33,742)
Change in cash and cash equivalents in the reporting period		(72,320)	(163,398)
Cash equivalents at the beginning of the reporting period		289,429	452,827
Cash and cash equivalents at the end of the reporting period		217,109	289,429

The notes on pages 26 to 36 form part of these accounts

THE UROLOGY FOUNDATION

Financial statements for the year ended 31 December 2020

ACCOUNTING POLICIES

BASIS OF ACCOUNTING

The financial statements have been prepared under the historical cost convention with items recognised at cost or transaction value unless otherwise stated in the relevant notes to these accounts. The financial statements have been prepared in accordance with the Statement of Recommended Practice: Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) issued on 16 July 2014 and Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102) and Charities Act 2011.
The trust constitutes a public benefit entity as defined by FRS 102.

INCOME

Grants, donations and other similar types of voluntary income are brought into account when it is probable that they will be received, except that donated income is included gross of any attributable tax recoverable, where relevant. Donations given for specific purposes are treated as restricted income. Tax recoverable is recognised when claims are submitted to HM Revenue and Customs. Legacy gifts are recognised in the period in which the Charity becomes entitled to receive the income.

Income receivable from activities for generating funds and from investment income is accounted for on an accruals basis. Deferred income represents revenues collected but not earned as of 31 December 2020. This is primarily composed of income collected in advance of a fundraising event taking place and deferred until the charity is entitled to that income as and when the event takes place.

EXPENDITURE

Resources expended are allocated to the costs of generating funds or to the charity's principal activity where the costs can be identified as being directly related. All other costs are categorised as either support costs or governance costs, and are allocated in proportions based upon a suitable ratio applicable to the nature of the cost involved.

Grants payable are recognised in full in the period in which the approved offer is conveyed to the recipient. Grants are recognised and deferred where there is a long term commitment for the Charity. Where grants are recognised and conditions for staged grant payments are not met in subsequent years, an adjustment to grants payable will be made in the relevant accounting period.

Expenditure includes irrecoverable VAT which is reported as part of the expenditure to which it relates.

TANGIBLE FIXED ASSETS

All tangible assets purchased that have an expected useful economic life that exceeds one year are capitalised and classified as fixed assets. Tangible fixed assets are stated at historical cost less depreciation. Depreciation is provided on all tangible fixed assets at rates calculated to write each asset down to its estimated residual value evenly over its expected useful life, as follows:

Office equipment	25% reducing balance

OPERATING LEASES
Rentals under operating leases are charged to the Statement of financial activities on a straight line basis over the lease term.

ACCOUNTING POLICIES

INVESTMENTS

The charity's investments are included in the balance sheet at their market value. The gains or losses arising upon their annual revaluation are included in the statement of financial activities.

FUND ACCOUNTING

The general fund comprises the accumulated surpluses of unrestricted incoming resources over resources expended, which are available for use in the furtherance of the general objective of the charity.

Designated funds are a particular form of unrestricted funds consisting of amounts, which have been allocated or designated for specific purposes by the trustees. The use of designated funds remains at the discretion of the trustees.

Restricted funds are funds subject to specific conditions imposed by donors. The purpose and use of the restricted funds are set out in the notes to the accounts. Amounts unspent at the year end are carried forward in the balance sheet.

FOREIGN EXCHANGE

Receipts and payments which occur in foreign currencies are included in the accounts at the amount into which they are converted in sterling, using the exchange rate on the day in which the transaction occurs.

GOING CONCERN

The Trustees as Directors of the Charity believe that there are no material uncertainties that may cast significant doubt about the ability of the Charity to continue as a going concern, due to the significant unrestricted reserves as at 31st December and the forecast income expected in 2021. As we prepare this statement in early 2021, the impact of a second year of the COVID-19 pandemic and the attendant economic crisis on the charity's operations is still to be fully realised. However, there is a continued impact on our events fundraising and income, which may affect future budgets for research and training. The trustees believe, however, that given the level of available cash and reserves, the charity can continue as a going concern.

FINANCIAL INSTRUMENTS

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

		Unrestricted funds £	Restricted funds £	2020 £	2019 £
1.	**INCOME FROM DONATIONS AND LEGACIES**				
	Grants received from charitable trusts and corporate sponsors	350,000	840,163	1,190,163	360,330
	Donations	151,235	11,221	162,456	69,362
	Legacies	14,000	-	14,000	-
		515,235	851,384	1,366,619	429,692
2.	**INCOME FROM OTHER TRADING ACTIVITIES**				
	Income from fundraising events	64,920	-	64,920	427,976
3.	**INVESTMENT INCOME**				
	Bank interest receivable on short term cash deposits	362	-	362	504
	Income from investments listed on a recognised stock exchange:				
	UK investments	291	-	291	12,268
	Overseas investments	-	-	-	6,606
		653	-	653	19,378
4.	**COSTS OF RAISING FUNDS VOLUNTARY INCOME**				
	Direct costs	16,372	13,819	30,191	43,394
	Support costs (see note 8)	19,505	2,168	21,673	23,956
		35,877	15,987	51,864	67,350

		Unrestricted funds £	Restricted funds £	2020 £	2019 £
5.	**COSTS OF RAISING FUNDS TRADING ACTIVITIES**				
	Costs of fundraising events	845	94	939	38,918
	Support costs (see note 8)	19,505	2,168	21,673	23,956
		20,350	2,262	22,612	62,874
6.	**COSTS OF RAISING AWARENESS**				
	Costs of fundraising events	1,970	219	2,189	90,808
	Support costs (see note 8)	78,024	8,671	86,695	95,822
		79,994	8,890	88,884	186,630
7.	**GRANT MAKING**				
	Prostate Cancer Fund	-	750,830	750,830	-
	Research Scholarships awarded to awarded to 3 (2019: 3) teams	162,567	(41,617)	120,950	260,924
	Small Research Projects awarded to 3 (2019: 3) teams	29,800	-	29,800	17,101
	TUF Fulbright Research Fellowship Award	15,000	-	15,000	12,642
	COVID-surg Urology Study	10,000	-	10,000	-
	BAUN/TUF Nurse	6,200	-	6,200	3,127
	RSM Urology Section	6,000	-	6,000	-
	Keith Yeates medals awarded to 1 (2019: 1) individuals	2,000	-	2,000	2,000
	BAUS	477	-	477	5,801
	Travel Grants	(1,289)	-	(1,289)	-
	UTI Research	-	(22,667)	(22,667)	-
	EQUIP Programme	-	-	-	78,000
	Patient Advocacy Research	-	-	-	35,801
	iROC Bladder Cancer Trial	-	-	-	32,835
	Urology Awareness	-	-	-	4,566
	BAUN 19	-	-	-	993
	Educational Course	-	-	-	750
	Endourology Fellowships awarded to	-	-	-	(1,500)
	0 (2018: 0) individuals - programme now closed	-	-	-	-
	Fellowships	-	-	-	(2,000)
	ROBOT17	-	-	-	(44,527)
	Movement in present value of grant accruals	4,217	(12,178)	(7,961)	943
		234,972	674,368	909,340	407,456
	Support costs (see note 8)	143,042	15,895	158,937	175,670
		378,014	690,263	1,068,277	583,126

7. GRANT MAKING (Continued)

The Charity's policy, in line with the Charities SORP 2015 is to recognise an expense and related liability for a research grant, at the point when the unconditional offer is conveyed to the recipient (see the accounting policy on page 26 for further details). However, recipients do not always take up their research grants in full. Where this happens, in subsequent years, in order that the correct movement in the Charity's liability is recognised, the expense as shown in the Statement of Financial Activities may not reflect the level of grant giving in the current year. A reconciliation to assist with users' understanding of the grants awarded in the year, to the expense in the Statement of Financial Activities is provided below:

	Grants awarded in the year ended 31 December 2020	Effects of outstanding grant payments	Expense recognised in the accounts for the year ended 31 December 2020
Prostate Cancer Fund	796,257	(45,427)	750,830
Research Scholarships awarded to 3 (2019: 9) individuals	139,968	(19,018)	120,950
Small Research Projects awarded to 3 (2019: 3) teams	29,800	-	29,800
TUF Fulbright Research Fellowship Award	15,000	-	15,000
COVID-surg Urology Study	10,000	-	10,000
BAUN/TUF Nurse	6,000	200	6,200
RSM Urology Section	6,000	-	6,000
Keith Yeates medals awarded to 1 (2019: 1) individuals	2,000	-	2,000
BAUS	-	477	477
Educational Course	-	-	-
Travel Grants	-	(1,289)	(1,289)
UTI Research	-	(22,667)	(22,667)
Movement in present value of grant accruals	-	(7,961)	(7,961)
	1,005,025	(95,685)	909,340
Support costs (see note 8)	158,937	-	158,937
	1,163,962	(95,685)	1,068,277

	Costs of generating voluntary income 7.5% £	Fundraising trading: Cost of goods sold 7.5% £	Awareness raising 30% £	Giving grants 55% £	2020 £	2019 £
8. SUPPORT AND GOVERNANCE COSTS (UNRESTRICTED)						
Staff costs (see note 9)	12,223	12,223	48,894	89,638	162,978	190,629
Other staff costs including recruitment	192	192	770	1,411	2,565	3,828
Committee and other staff welfare expenses	43	43	172	316	574	2,308
Other office costs	4,491	4,491	17,963	32,933	59,878	60,621
Audit fee	218	218	870	1,595	2,901	4,309
Accountancy and advisory services	1,139	1,139	4,558	8,356	15,192	12,585
Other costs	1,158	1,158	4,633	8,493	15,442	12,457
Depreciation-owned assets	41	41	164	300	546	727
	19,505	19,505	78,024	143,042	260,076	287,464

8. SUPPORT AND GOVERNANCE COSTS (RESTRICTED)						
Staff costs (see note 9)	1,358	1,358	5,433	9,960	18,109	21,181
Other staff costs including recruitment	21	21	86	157	285	425
Committee and other staff welfare expenses	5	5	19	35	64	256
Other office costs	499	499	1,996	3,659	6,653	6,736
Audit fee	24	24	97	177	322	479
Accountancy and advisory services	127	127	506	928	1,688	1,398
Other costs	129	129	515	944	1,717	1,384
Depreciation-owned assets	5	5	19	35	64	81
	2,168	2,168	8,671	15,895	28,902	31,940

9. STAFF COSTS

		2020	2019
		No.	No.
The average monthly number of persons employed by the charity (excluding trustees) during the period was, as follows:			
Office and administration		3.5	5
		£	£
Staff costs for the above persons:			
Staff	Wages and salaries	84,690	113,525
Staff	Social security costs	6,411	9,508
Key management personnel	Wages and salaries	82,338	80,539
Key management personnel	Social security costs	7,648	8,238
		181,087	211,810

One employee received total emoluments in excess of £60,000 per annum during the period ended 31 December 2020. The total emoluments of this employee during the year were in the following ranges:

		2020	2019
£70,000 - £80,000	No.	1	1

The Charity considers its key management personnel comprise the Chief Executive, with remuneration as noted above. In setting salary levels, The Urology Foundation follows the National Council for Voluntary Organisation's advice that a charity's pay policy should be to offer fair pay to attract and keep appropriately-qualified staff to lead, manage, support and/or deliver the charity's aims. It also conducts online research of charity salaries and uses surveys to benchmark levels of pay. The Urology Foundation does not automatically award its staff with annual salary increases, either incremental or cost of living.

No Director received any remuneration from the Company during the year (2019: £nil).
No trustee received any remuneration for services provided to the charity during the current or previous period.
Trustees expenses reimbursed in respect of Trustee's meetings and travel for the year ended 31st December 2020 amounted to £0 paid to no Trustees (2019 £78 paid to 1 Trustee).

10. TANGIBLE ASSETS

	Office Equipment £
Cost:	
1 January 2020	20,335
Additions	-
31 December 2020	20,335
Depreciation:	
1 January 2020	17,911
Charge for year	606
31 December 2020	18,517
Net book value:	
31 December 2020	1,818
31 December 2019	2,424

		2020 £	2019 £
11.	**INVESTMENTS**		
	Investments listed on a recognised stock exchange at market value:		
	1 January 2019	2,189,975	1,923,668
	Transfers from cash	1,045,830	-
	Additions at cost	1,161,969	2,006,523
	Disposal proceeds	(1,162,282)	(1,971,467)
	Realised (losses)/gains	(49,621)	155,360
	Unrealised gains	409,862	75,891
	31 December 2020	3,595,733	2,189,975
	At the balance sheet date, the market value of the portfolio comprised:		
	UK investments	3,595,733	2,007,320
	Overseas investments	-	182,655
		3,595,733	2,189,975
	Fixed income securities	750,830	(4,490)
	Equities	-	182,655
	Multi-Asset & Hybrid Instruments	2,844,903	2,011,810
		3,595,733	2,189,975

At the balance sheet date, the historical cost of the investments was £3,185,794 (2019: £2,079,565).
The following holdings had a value of >5% of the market value of the investments:

Name	Holding	Value £ 2020	Value £ 2019
Rothschild & Co WM SICAV-SIF Exbury Fund GBP	120,761	2,844,904	2,011,810
Pentairs QIAIF PLC - Vanda Fund Shs -F- USD Shs	1,096	-	116,480
InstitutionalCash SeriesPLC - BlackRock ICS Sterling Liquidity Fu	750,830	750,830	-

		2020 £	2019 £
12.	**DEBTORS**		
	Amounts falling due within one year:		
	Other debtors	2,761	2,305
	Prepayments	19,574	25,215
	Accrued Income	55,438	103,515
		77,773	131,035

13. CREDITORS

	2020 £	2019 £
Amounts falling due within one year:		
Deferred income	34,778	-
General accruals	10,895	8,957
Grant accruals	1,193,088	827,289
	1,238,761	836,246
Deferred income b/fwd at 1 January 2019	-	
Amounts released in the year	-	
New amounts deferred in the year	34,778	
Deferred income c/fwd at 31 December 2020	34,778	

CREDITORS	2020 £	2019 £
Amounts falling due in more than one year:		
Grant accruals	495,249	178,625
	495,249	178,625

14. RECONCILIATION OF NET INCOME/(EXPENDITURE) TO NET CASHFLOW FROM OPERATING ACTIVITIES

Net Income/(expenditure) for the reporting period per the statement of financial activities	560,431	190,757
Adjustments for:		
Depreciation charges	606	808
(Gains)/Losses on investments	(360,241)	(231,251)
Dividends and interest from investments	(291)	(18,874)
Management fees paid from investments	365	17,560
Decrease in debtors	53,262	39,081
Increase/(Decrease) in creditors	719,139	(127,737)
Net cash used in operating activities	973,271	(129,656)

15. THE FUNDS OF THE CHARITY

	1 January 2020 £	Transfer £	Income £	Expenditure £	Gains/(losses) on Investments £	31 December 2020 £
Restricted income funds:						
Robotic Surgery Training Fund	225,176	-	-	(29,169)	280	196,287
Prostate Cancer Research Fund	46,370	-	750,830	(693,926)	96	103,370
UTI Research Fund	122	-	(22,666)	22,544	-	0
Bladder Cancer Fund	39,765	-	111,998	(2,035)	132	149,860
Travel Fellowship Fund	652	-	-	-	-	652
'EQUIP' Quality & Safety Pilot	35,307	-	9,400	(13,863)	45	30,889
Bladder Cancer Trial	953	-	-	(953)	0	0
Team Corbs - Testicular	-	-	1,822	-	1	1,823
	348,345		851,384	(717,402)	509	482,881
Unrestricted income funds:						
General Fund	666,632	-	580,808	(460,074)	352,493	1,139,859
Designated Fund (R. Shackman)	83,015	-	-	(54,526)	7,194	35,683
Designated Fund (BUF)	500,000	-	-	-	-	500,000
	1,597,992		1,432,192	(1,232,002)	360,196	2,158,423

15. THE FUNDS OF THE CHARITY (Continued)

- The trustees have designated the original 1995 start-up funding for the BUF of £500,000 as the trustees feel strongly that The Foundation should seek to maintain reserves sufficient to continue to fund its objectives on a long term basis.

- Ralph Shackman Trust - The Ralph Shackman Trust's aims were similar to TUF, being to advance the study of urology through grants and awards and funding clinical visits. In 2012 the Trust asked TUF to assist them in promoting and administering their clinical visit grants. In 2015 the Trust wound down and transferred its remaining assets to TUF. This included the responsibilities for administering the Keith Yeates Medal, an Award given to the Urology Trainee who receives the highest marks in the Intercollegiate Specialist Exams in Urology. This award comes with a prize of £2,000 for a TUF/Shackman travelling fellowship.

- The Robotic Surgery Training Fund was set up in 2009 following the receipt of restricted donation income from the British Urological Foundation and a generous private donation. The funds are mainly used to award grants towards robotically assisted surgery training, education, and research into robotic training techniques.

- Bladder cancer remains one of the most expensive cancers to treat and survival rates appear to have reached a plateau at 50%. In the UK, more than 10,000 new cases of bladder cancer are diagnosed every year and almost half that number die from it - nearly 14 people per day. The Foundation is determined to improve the diagnosis, treatment and outcomes of people with bladder cancer and to allocate resources to vital research into the diagnosis and pathology of bladder cancer and to funding training and education to improve patient treatment and care. Through a generous donation from The Champniss Foundation, TUF is funding the iROC bladder cancer surgery trial, investigating the efficacy of Robot assisted radical cystectomy and intracorporeal urinary diversion compared with open radical cystectomy in patients with bladder cancer.

- Prostate Cancer Research - Thanks to the John Black Charitable Foundation TUF was able to invest in two significant prostate cancer studies in 2020. The first, CLIMATE, is a 3-year trial looking to compare a faster, 3-4 minute MRI scan with the standard MRI. The second is a pilot study researching which patients might benefit more from radiotherapy.

- Education in Quality Improvement Programme (EQUIP) - The Urology Foundation is keen to deliver real improvements in patient care, while also developing urologists and equipping them to become leaders of the future. To that end TUF is supporting the development of the EQUIP training programme, that equips urologists with the skills required to analyse current practise and to develop collaborative quality improvement work, and to share learning and best practices with their peers and urology departments regionally and nationally. This programme has now been incorporated into the urology curriculum and the anticipated benefits will be improved patient safety and care that will reflect a culture that fosters continuous improvement. We are grateful to the Schroder Foundation and a number of other funders for their generous support of the programme.

- The Foundation started working with former England and Lions rugby champion, Alex Corbisiero, to raise funds for research into testicular cancer, following Alex's diagnosis. A Just Giving page has been set up and the charity will continue to fundraise with Alex.

16. ANALYSIS OF NET ASSETS BETWEEN FUNDS

	Fixed Assets £	Net Assets/(Liabilities) £	Total £
Restricted income funds:			
Robotic Surgery Training Fund	699,311	(503,024)	196,287
Prostate Cancer Research Fund	89,916	13,454	103,370
UTI Research Fund	0	0	0
Bladder Cancer Fund	114,485	35,375	149,860
Travel Fellowship Fund	1,876	(1,224)	652
'EQUIP' Quality & Safety Pilot	158,448	(127,559)	30,889
Bladder Cancer Trial	20,566	(20,566)	0
Team Corbs - Testicular	-	1,823	1,823
Unrestricted income funds:			
General Fund	1,597,404	(457,545)	1,139,859
Designated Fund (Ralph Shackman)	415,545	(379,862)	35,683
Designated Fund (British Urology Foundation)	500,000	-	500,000
NET ASSETS	3,597,551	(1,439,128)	2,158,423

17. ULTIMATE CONTROLLING PARTY

The Charity is controlled by the board of Trustees.

18. COMMITMENTS UNDER OPERATING LEASES

As at 31st December 2020, the Charity had annualised operating commitments under non-cancellable operating leases expiring as follows:

	2020 £	2019 £
Expiring within one year		
- Land and Buildings	49,200	49,200
- Others	3,132	3,132
	52,332	52,332
Expiring within two to five years		
- Land and Buildings	27,800	77,000
- Others	1,566	4,698
	29,366	81,698

19. CONTINGENT ASSETS

As at 31st December 2019, the Trustees were aware of a Legacy which is due to The Urology Foundation. The Legacy is the balance of the sale of a property, a 14% share of the estate was bequeathed to the Charity in 2013/2014. £9,000 was received in 2020 and a further £4,500 is expected but the timing of the receipt of this, is unknown at this stage.

20. RELATED PARTY TRANSACTIONS

There were no related party transactions in the period under review.